A Two-Pronged Approach to Preeclampsia: Understanding Gene Expression and Targeting sFlt1 using RNAi by Ashar-Patel, Ami
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2017-07-10 
A Two-Pronged Approach to Preeclampsia: Understanding Gene 
Expression and Targeting sFlt1 using RNAi 
Ami Ashar-Patel 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Biology Commons, Female Urogenital Diseases and Pregnancy Complications Commons, 
and the Genetics and Genomics Commons 
Repository Citation 
Ashar-Patel A. (2017). A Two-Pronged Approach to Preeclampsia: Understanding Gene Expression and 
Targeting sFlt1 using RNAi. GSBS Dissertations and Theses. https://doi.org/10.13028/M2RH4N. 
Retrieved from https://escholarship.umassmed.edu/gsbs_diss/909 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 i 
A TWO-PRONGED APPROACH TO PREECLAMPSIA: 
UNDERSTANDING GENE EXPRESSION AND TARGETING sFlt1 using 
RNAi 
 
A Dissertation Presented  
 
By 
 
Ami Ashar-Patel 
 
 
Submitted to the Faculty of the 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of  
 
 
DOCTOR OF PHILOSOPHY 
 
July 10, 2017 
 
INTERDISCIPLINARY GRADUATE PROGRAM
 ii 
A TWO-PRONGED APPROACH TO PREECLAMPSIA: 
UNDERSTANDING GENE EXPRESSION AND TARGETING sFlt1 using 
RNAi 
 
A Dissertation Presented  
By 
AMI ASHAR-PATEL 
This work was undertaken in the Graduate School of Biomedical Sciences 
Interdisciplinary graduate program 
 
The signature of the thesis advisor signifies 
validation of the Dissertation content 
 
____________________________________________ 
Melissa J. Moore, Ph.D., Thesis Advisor 
 
The signatures of the Dissertation Defense Committee signifies  
completion and approval as to style and content of the Dissertation 
 
____________________________________________ 
Jane E. Freedman, M.D., Member of Committee 
 
____________________________________________ 
Manuel Garber, Ph.D., Member of Committee 
 
____________________________________________ 
Tiffany A. Moore Simas, M.D., Member of Committee 
 
____________________________________________ 
Manoj Bhasin, Ph.D., External Member of Committee 
 
 
The signature of the Chair of the Committee signifies that the written dissertation meets 
the requirements of the Dissertation Committee 
 
___________________________________________ 
Jeremy Luban, M.D., Chair of Committee 
 
The signature of the Dean of the Graduate School of Biomedical Sciences signifies that 
the student has met all graduation requirements of the School 
 
Anthony Carruthers, Ph.D., 
Dean of the Graduate School of Biomedical Sciences 
 
Interdisciplinary Graduate Program  
July 10, 2017 
 iii 
DEDICATION 
 
This thesis is dedicated to all the women, their babies and their families who 
suffered due to preeclampsia.  
 
I also want to dedicate my thesis to my maternal grandfather and paternal 
grandmother, who are not amongst us today. They always believed that one day 
I would come to the United States of America, and fulfill my academic dreams. I 
am forever grateful to them for their confidence in me, and my abilities. I would 
also like to dedicate this thesis to my maternal grandmother, who cannot wait to 
call me Dr. Ami Ashar-Patel. 
 
This thesis would have been impossible without the love and never-ending 
support of my family. My parents, Jagdish and Priti Ashar, and my brother Mihir 
Ashar; they have been my side through thick and thin. My in-laws Nayana and 
Nalin Patel and my brother-in-law Biajun Patel have been a constant source of 
positivity, for which I am very grateful. 
 
Finally, this thesis is dedicated to my husband, Hemal Patel, who has been my 
guiding star throughout graduate school. Thank you for being by my side every 
day, and through the ups and downs of my PhD. Thank you for loving me, for 
believing in me, cooking for me, and staying positive no matter what.  
 iv 
ACKNOWLEDGEMENTS 
 
It takes a village to get a PhD, and I want to thank my village for not giving up on 
me through my PhD!  
 
I want to thank my roommates, and now my dearest friends, Jillian Lindblad and 
Ozge Yildiz, who held my hands in the valley of PhD qualifying darkness with 
their steadfast support and kind words. I am forever grateful for our friendship. I 
would also like to acknowledge the never-ending support of my best friends, 
Ashka Patel and Dr. Harjeet Johal.  I would not have survived my PhD without 
you two, and our crazy innumerable weekend get together.  
 
I want to thank all the past and present Moore lab members who have provided 
friendship and a friendly shoulder to cry upon, and with whom I have shared 
elation, frustration, tears and companionship. Thank you Harleen Saini, our 
friendship and afternoon coffee and singing will not be forgotten after we 
graduate. Mihir Metkar thanks for your help with bioinformatics, pushing me to 
think beyond my comfort zone, and all the bad jokes! I have to give special 
thanks to Dr. Alicia Bicknell who over the years has tirelessly provided feedback 
on my scientific writing. Thank you Alicia for willing to provide a shoulder to cry 
on whenever I needed it. Thank you Dr. Erin Heyer for countless scientific 
discussions and improving my presentation skills. 
 v 
A special thanks to Dr. Guramrit Singh who got me started with my PhD and is 
now a faculty at OSU. I miss our science and philosophical discussions. I also 
want to thank Dr. Blandine Mercier for taking over charge of my PhD career after 
Guramrit left. She was a tough and fantastic mentor, who always pushed me to 
advocate my scientific knowledge. Thank you Dr. Emiliano Ricci for patiently 
teaching me several scientific techniques, and always being positive despite the 
pressure of handling multiple projects. Thank you Dr. Akiko Noma for sharing the 
lab afternoons with cups of coffee and giggles. Thank you to Dr. Jennifer 
Broderick for the long walks in the park and warning me about the perils of 
attempting PhD. She was always willing to listen to my frustrations without 
judgment. I also want to thank Laureen Murtha and Rina Paladino for keeping the 
Moore lab running and handling logistics (meetings, QE, TRAC) over the years.  
 
In 2010, I started graduate school with two amazing scientists - Dr. Meetu Seth 
and Dr. Vahbiz Jokhi. Meetu, your friendship has been a blessing and I could not 
have asked for a better friend to survive graduate school. Vahbiz, your kindness 
and strength never cease to amaze me. Thank you both for your friendship 
through the PhD years and beyond. Thank you Dr. Shreya Kulkarni for your 
friendship, weekends filled with board games and singing songs. Many thanks to 
Shiuli Agrawal for the friendship, laughter, delicious food, and always having my 
back.  
 
 vi 
I would like to acknowledge the support and interest of my thesis research 
advisor committee members, Dr. Jeremy Luban, Dr. Tiffany Moore Simas, Dr. 
Jane Freedman and Dr. Manuel Garber. They have given me helpful scientific 
advise over the years. I would also like to thank my external committee member 
Dr. Manoj Bhasin, who has taken the time to come to Worcester for my defense.  
 
I would like to give special thanks to our collaborators, Dr. Ananth Karumanchi 
and Dr. Augustine Rajakumar without whom my thesis project would have not 
been possible. I would also like to acknowledge the tremendous support of Dr. 
Karumanchi over the last several years and also coming to Worcester to attend 
my defense seminar.  
 
Finally, I want to thank Dr. Melissa J. Moore, in whose lab I have conducted 
research for the last nine years (two years as a Research Associate, and seven 
years as a PhD student). I am very grateful for her mentoring, scientific training, 
freedom and the encouragement she has given me to pursue my scientific and 
non-scientific interests. It was a privilege to work with her on the preeclampsia 
project, which is close to her heart, both professionally and personally. Melissa, I 
am a better scientist today than when I had first entered your lab, and it has been 
an honor to be your student. 
 
 vii 
ABSTRACT 
Preeclampsia (PE) is a disorder affecting 2-10% of pregnancies worldwide. 
Clinical signs include high blood pressure (HBP) and proteinuria in the mother 
after the 20th week of pregnancy. Currently, the only cure for PE is delivery of the 
fetus, which is often necessary preterm and thus dangerous for both mother and 
fetus. Maternal symptoms of PE are caused by excess anti-angiogenic proteins 
of placental origin called soluble Flt1s (sFlt1s). sFlt1 mRNA isoforms are 
produced by alternative polyadenylation (APA) of full-length Flt1 (fl-Flt1) pre-
mRNA. While fl-Flt1 encodes a transmembrane protein, sFlt1s encode truncated 
proteins that are soluble. Multiple sFlt1 isoforms exist, and their respective 
contribution to the pathophysiology of PE is unclear. Furthermore, it is unknown 
whether there is a genome-wide role for APA in PE.  
 
In my thesis research, I developed a polyadenylation site sequencing method, 
and used this method to simultaneously quantify transcriptome-wide 
polyadenylation site usage and gene expression levels in normal, early-onset PE, 
and late-onset PE human placentae. I observed distinct expression profiles 
amongst the three groups, with differential expression of genes in several 
functional categories, including angiogenesis. I found that three sFlt1 isoforms 
account for >94% of all placental FLT1 transcripts, and that increased 
transcription of the entire FLT1 locus drives upregulation of both fl-Flt1 and sFlt1 
in PE. I found that APA does not contribute substantially to PE pathophysiology. I 
 viii 
also identified siRNAs that knock down sFlt1 mRNA efficiently in cell lines that 
pave the way for further development of novel RNAi based therapeutics to 
alleviate PE. 
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often termed as placental cells 
VEGF Vascular Endothelial Growth Factor 
WT Wild Type 
Yac Yeast Artificial Chromosome 
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1. CHAPTER I: INTRODUCTION 
1.1 Pregnancy and pregnancy complications 
 
Pregnancy in humans begins with conception when the sperm fertilizes the 
ovum creating a zygote (this stage is called conception). The zygote then 
implants itself in the uterus of the woman. Pregnancy typically lasts for forty-
two weeks and is divided into three trimesters as follows. Week’s 1-12 form 
the first trimester (conception and implantation), weeks 13 to 28 form the 
second trimester and weeks 29 to 40 make up the last trimester. Full term 
pregnancy refers to the pregnancy that lasts 37-42 weeks and preterm 
pregnancy is typically earlier than 37 week of pregnancy. In 2015, it was 
estimated that around 303,000 women (WHO, 2011) worldwide died due to 
complications during pregnancy. Ninety nine percent of these deaths 
occurred in developing countries.  
 
A few of the common pregnancy complications include but are not limited to 
severe bleeding, infections, gestational diabetes mellitus (GDM) and. PIH 
affects around 10% of pregnancies worldwide (American College of 
Obstetricians and GynecologistsTask Force on Hypertension in Pregnancy, 
2013) (ACOG Committee on Practice Bulletins--Obstetrics, 2002; WHO, 
2011). Hypertensive disorders of pregnancy encompass gestational 
hypertension, preeclampsia [PE] and HELLP (Hemolysis, Elevated Liver 
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enzymes and Low Platelet count) syndrome. Gestational hypertension in 
pregnant women is diagnosed as de novo blood pressure elevations above 
140/90 after 20 weeks, with the absence of excessive protein in the urine. PE 
is diagnosed as gestational hypertension or pregnancy-onset hypertension 
with the presence of excessive protein in the urine (termed as 
proteinuria)(ACOG Committee on Practice Bulletins--Obstetrics, 2002) or 
evidence of end-organ damage. Symptoms that are associated with PE are 
headaches; right upper quadrant abdominal pain and visual disturbances. A 
severe form of PE is called HELLP syndrome (Buchbinder et al., 2002; Haram 
et al., 2009). It is estimated that 10-20% of women who are diagnosed with 
PE, will develop HELLP syndrome during pregnancy and  even after delivery 
of the baby (https://www.preeclampsia.org/health-information/hellp-
syndrome)(Sibai, 2004). There is a 25% chance that a woman with a history 
of HELLP pregnancy will develop HELLP syndrome in future pregnancies. As 
both PE and the HELLP syndrome are very dangerous to the mother and the 
fetus, delivery of the placenta is the only treatment.  
 
1.2  Preeclampsia: a silent killer 
 
Amongst the hypertensive disorders associated with pregnancy, PE is the 
number one cause of severe morbidity and mortality worldwide in pregnant 
women(WHO, 2011). If not diagnosed correctly PE can be fatal for the mother 
and the developing baby. By definition, it can only be diagnosed after the 20th 
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week (fifth month) of pregnancy. PE that occurs within 48 hours post-partum 
(after delivering of the baby) is termed postpartum PE. It is also known to 
occur up to six weeks after delivery. PE is a heterogeneous disorder and can 
be classified as mild or severe PE depending on factors like severity of 
hypertension, symptoms and various laboratory criteria indicating end organ 
damage. It can further be classified into early-onset PE (EO-PE) versus late-
onset PE (LO-PE), depending on the gestational delivery week (GDW) of the 
baby. In cases of EO-PE, the premature fetus is usually delivered before 34 
weeks (GDW<34) and after 34 weeks in case of LO-PE (GDW>34). 
Furthermore, EO-PE is sometimes termed as “placental” PE wherein there is 
abnormal placentation leading to oxidative stress and hypoxia(Ness and 
Roberts, 1996). The LO-PE is referred as “maternal” PE wherein there is 
normal placentation but there is an inflammatory response(Ness and Roberts, 
1996) later in gestation.  
 
PE is one of the major causes of maternal and neonatal morbidity and 
mortality(Dadelszen et al., 2011). PE leads to a wide spread organ damage in 
the mother.  Depending on the severity of the symptoms PE is managed by 
fetal monitoring (amniotic fluid volume, ultrasound to determine fetal growth 
and non-stress testing of fetal well-being) and assessing mother’s health 
(monitoring symptoms, blood pressure, proteinuria, complete blood count, 
liver enzyme levels and renal function). In case of deteriorating condition of 
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the mother or evidence of fetal growth restriction, the only treatment available 
currently is to deliver the placenta i.e. the premature fetus irrespective of the 
gestational age. Premature delivery, thus, is one of the main mediators of 
neonatal morbidity and mortality(Larroque, 2004). In cases of EO-PE, the 
fetus is subject to nutritional insufficiency and asphyxia and the administration 
of corticosteroids for fetal lung development may have to be administered.   
 
1.3 History of preeclampsia 
 
According to the current standard, PE is defined as a hypertensive disorder. 
However, this modern day definition did not come into play until 1881. In 
1881, the world’s first blood pressure measuring device called 
sphygmomanometer was invented by Samuel Siegfried Karl Ritter von Basch. 
Prior to 1880s, PE was defined by observing the symptoms of the pregnant 
woman, though it was not classified as a pregnancy disorder. For example, 
symptoms like convulsions are common between PE and epilepsy and in fact, 
eclampsia in a pregnant woman was considered to be one of the four types of 
epilepsy in the 15th century(Bell, 2010; Chesley, 1985). It was Bossier de 
Sauvages who in 1739 distinguished between the seizures of epilepsy and 
PE(Bell, 2010; Chesley, 1985). It was only in the 16th century that the word 
“eclampsia” was termed. (Ong, 2004). In the ancient times (16th-18th century), 
the treatments available were bloodletting, using opiates, using cold water on 
the face and hurrying the delivery(Bell, 2010).  
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The definition of preeclampsia continued evolving in the 18th and 19th century and  
 
several pioneering physicians and scientists identified the other symptoms of PE. 
In 1797, Demanet recognized edema in PE women(Bell, 2010; Chesley, 1985). 
In 1840, Pierre Rayer observed high levels of protein in PE women and in 
1843{Thoms:hYXmnQiJ}; John Lever demonstrated that proteinuria was 
particular to PE women and not a distinct kidney disorder(Johns, 1843). 
Eventually, Vaquez and Nobecourt recognized high blood pressure as a 
symptom of PE in 1897(Bell, 2010; Chesley, 1985). The link between pregnancy 
and symptoms like swelling and edema were finally recognized as a distinct 
pregnancy syndrome called preeclampsia (Chesley, 1984).  
 
During the 20th century, the post-delivery examination of placenta was becoming 
common and further aided in understanding the pathophysiology of PE. In 1903, 
Seitz compared the uterus of two women who died of PE and observed the 
tissue under a microscope and reported lesions and infarctions on both the 
uteri(Robertson et al., 1967). Several other groups reported that women with 
hypertension develop vascular lesions on the placenta and the placental blood 
vessels(Williams, 1915) (Hertig, 1945). The foundations of classifying PE as a 
hypertensive disorder is credited to Dixon and Robertson, who in 
1958(Robertson et al., 1967) (Dixon and Robertson, 1958). 
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It is disheartening that, in spite of the advances in understanding the molecular 
basis of PE, the treatment and cure options for women with PE has unchanged. 
Even in the 21st century, the cure is delivery of the placenta. PE is a clinically 
unmet challenge, both in USA and around the world.  
 
1.4 Pathophysiology of preeclampsia 
 
In the past, PE was often termed the “disease of theories(Ness and Roberts, 
1996). The current theory is that it is a two-staged process that starts in early 
pregnancy even though the clinical manifestation do not arise until much later in 
gestation.(Borzychowski et al., 2006; Ness and Roberts, 1996; Roberts and 
Hubel, 2009)Some of the most common causes are summarized below.  
  
In the first stage, the cytotrophoblasts fail to invade the maternal arteries leading 
to shallow placentation followed by the second stage, which is the clinical 
manifestation of endothelial dysfunction or maternal syndrome (Figure 1.2).  As 
seen in the Figure 1.3 schematic, during the normal pregnancy, the 
cytotrophoblasts from the fetus invade the maternal decidua/uterus and bring 
about vasodilation of the maternal spiral arteries(Lyall et al., 2001). This 
vasodilation leads to an increased flow of maternal blood to the placenta. The 
cytotrophoblasts undergo Epithelial-Mesenchymal Transformation (EMT)(E 
Davies et al., 2016) and acquire endothelial characteristics which are needed for 
invading the mother’s uterine wall. In PE pregnancies, the EMT is incomplete 
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causing shallow placentation leading to reduced flow of blood and oxygen to the 
placenta. This reduced flow of blood/oxygen is believed to cause a hypoxic and 
anti-angiogenic environment in the placenta, where in there is oxidative damage 
and inflammation(Munaut et al., 2008; Pennington et al., 2011; Powe et al., 2011; 
Saito and Nakashima, 2014; Tsatsaris et al., 2003; Webster and Myatt, 2007; 
Young et al., 2010). The endothelial syndrome has a multi-system affect and if 
the symptoms are unchecked can lead to HELLP syndrome.  
1.4.1 Angiogenic Factors and their receptors 
Formation of new blood vessels from existing blood vessels, a process 
termed angiogenesis is absolutely essential for pregnancy(Ferrara et al., 
1996). Several studies have reported that malfunctioning angiogenesis is a 
hallmark feature of PE(Maynard and Karumanchi, 2011; Maynard et al., 2003; 
Torry et al., 1998).  
 
VEGF mediated FLT1 signaling pathway 
Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor 
(PGF) ligands bind to their receptors called Vascular endothelial growth factor 
receptor-1 (VEGFR-1) or “fms like tyrosine kinase” (Flt1) and sFlt1. Flt1 is an 
example of an receptor tyrosine kinase protein family(Vorlová et al., 2011) 
that plays an important role in the angiogenesis pathway. Binding of VEGF 
and PGF to membrane-bound Flt1 (mFlt1) leads to receptor dimerization 
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followed by autophosphorylation and signal transduction pathways like 
angiogenesis and cell proliferation and migration (Figure 1.4).  
 
Flt1 is expressed in several human tissues(Jebbink et al., 2011) as well as 
cells including endothelial cells, trophoblasts and macrophages(Clark et al., 
1996; Dumont et al., 1995).  Flt1 is reported to be transcriptionally 
upregulated by Hypoxia inducible factor 1-a (HIF1a)(Gerber et al., 1997). In 
mice embryos, Flt1 is needed for vasculogenesis but not for endothelial cell 
differentiation(Fong et al., 1995). Additionally in mice, Flt1 is not an essential 
gene and on Flt1 knockdown the mice survives(Hirashima et al., 2003).  
 
Role of sFlt1 under normal physiological and preeclamptic conditions 
 
sFlt1 is an anti-angiogenic protein and natural inhibitor of VEGF mediated 
angiogenesis pathway as an antagonist to m-Flt1.  sFlt1 arises because of  
alternative polyadenylation of the Flt1 pre-mRNA transcript.  sFlt1 mRNAs 
include unique 3’ sequence not present in m-Flt1 mRNA.  
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 Figure 1.1 VEGF mediated FLT1 signaling pathway 
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Under normal physiological condition, sFlt1 is expressed in cells like 
endothelial cells, in body fluids like the amniotic fluid (Hornig et al., 2000) and  
tissues where vascularization is not needed. For example, the corneal tissue 
expresses sFlt1 that maintains a avascular state which is needed for a clear 
eyesight(Ambati et al., 2006). It has also been reported to be expressed in the 
endometrium of women undergoing menstruation(Graubert et al., 2001). 
Graubert et al demonstrate that sFlt1 regulates the bioavailability of VEGF 
aiding to pause the VEGF-mediated vascular repair (angiogenesis) during the 
menstrual phase in the endometrium.  
sFlt1 contributes to the pathology of preeclampsia as high levels of sFlt1 of 
placental origin and reduced levels of its ligands VEGF and PGF are seen in 
the serum of pregnant women with preeclampsia.  It is interesting to note that 
patients receiving anti-VEGF therapies for inflammatory disorders such as 
rheumatoid arthritis and other diseases develop PE like symptoms of high 
blood pressure and proteinuria.  
1.4.2 Oxidative stress 
The placenta plays a central role in establishing the exchange of nutrients 
between the maternal and fetal blood pools. It is well understood that the 
generation of Reactive Oxygen Species (ROS) is a normal physiological 
response during pregnancy, however, increased levels prove damaging to 
the lipids and proteins(Tiwari et al., 2010). 
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Figure 1.2 FLT1 RNA and its isoforms 
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It has been reported that the increase in oxygen tension from 8 week to 12 
week of gestation is synchronized perfectly to the time of maternal spiral 
artery remodeling(Jauniaux et al., 2010). The lack or slow rate of maternal 
spiral artery remodeling leads to a high pressure and the maternal blood 
enters the intervillous space at a faster rate. This sudden change in 
pressure and oxygen concentrations leads to a hypoxic environment, 
which in turn causes severe oxidative stress(Huppertz et al., 2003). 
Oxidative stress generates ROS through various mechanisms causing 
ischemia, inflammation and damage to the placenta(MYATT and 
WEBSTER, 2009). 
 
Several studies have reported increase in glutathione peroxidase, 
superoxide dismutase, thioredoxin reductase, thioredoxin that are markers 
of oxidative stress(Jauniaux et al., 2010; Vanderlelie et al., 2005; 
Zusterzeel et al., 2001). Additionally, the PE placentae shows evidence of 
lipid and protein oxidation(Llurba et al., 2004; Vanderlelie et al., 2005).  
 
Oxidative stress also leads to necrosis in placenta causing trophoblast 
shedding(Huppertz et al., 2003). Using immunolocalization techniques, the 
authors studied trophoblast turnover and showed that placental hypoxia 
leads to necrotic shedding in PE as opposed to apoptotic shedding in 
normal placenta(Huppertz et al., 2003). These circulating trophoblast 
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debris also lead to inflammation and transfer of oxidative damage in the 
placenta to widespread endothelial organs of the mother.  
1.4.3  Immune response 
The maternal-fetal interface plays an important role in adapting mother’s 
immune response to the fetus, which is a mix of both maternal and 
paternal antigens. These paternal antigens are seen as foreign by the 
mother’s immune system. The placenta is broadly composed of two types 
of trophoblasts – villous trophoblasts which lacks the MHC class I and 
MHC class II molecules and hence does not cause a major immune 
response and extra villous trophoblasts which express a mix of MHC class 
I molecules. These molecules interact with their receptors present on 
uterine natural killer (NK) cells. NK cells secrete multiple cytokines like IL-
8 and Interferon gamma-induced protein 10 and angiogenic growth factors 
like VEGF, PGF and Transforming Growth Factor –β (TGF- β) that 
influence extravillous trophoblasts for vascular remodeling(Fukui et al., 
2012; Yagel, 2009).  
 
NK cells present at the maternal-fetal interface play an important role in 
building an immune tolerance to the paternal antigens and ensuring 
favorable pregnancy conditions(Yagel, 2009). It has been shown that the 
uterine or decidual NK cells play an important role of in regulating 
trophoblast invasion and remodeling of mother’s spiral arteries(Hanna et 
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al., 2006). Thus, perturbations in the NK cell signaling contribute to 
abnormal placentation causing PE.  
 
Interestingly, lack of immune tolerance plays a significant role in causing 
PE. The paternal antigen contribution is involved in abnormal placentation 
and PE(Dekker, 2002).Women who have been exposed to paternal sperm 
have a lower risk of developing PE as opposed to women who have never 
been exposed to paternal sperm due to use of barrier 
contraceptives(Klonoff-Cohen et al., 1989). The risk of developing PE is 
high in first pregnancies or in a pregnancy after a change in sexual 
partner(Tubbergen et al., 1999). The exposure to paternal semen during 
the first pregnancy seems to have a protective role during the second 
pregnancy with the same partner. Similarly the risk of developing PE is 
higher after a long interpregnancy interval(Skjærven et al., 2002). Women 
who undergo artificial insemination using donated semen have also been 
reported to have a higher risk of developing PE(Need et al., 1983; Smith 
et al., 1997), though it has not been reported in cases of women 
undergoing in vitro fertilization(Watanabe et al., 2014). 
 
1.4.4 Other factors that cause PE 
Other factors like upregulated levels of angiotensin-II receptor and soluble 
Endoglin(Levine et al., 2006; Venkatesha et al., 2006) have been linked to 
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PE. There is some evidence to support the familial increase of 
susceptibility to develop PE. However, studies have not resulted in any 
unanimous single gene or a loci, which indicates that multiple genetic 
factors are involved in the development of PE(Arngrimsson et al., 1990; 
Chappell and Morgan, 2006).  
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Table 1.1 Symptoms of PE 
Adapted from (American College of Obstetricians and GynecologistsTask Force 
on Hypertension in Pregnancy, 2013) 
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1.5 Risk Factors of preeclampsia 
 
Duckitt et al summarized the risk that predict that the woman will develop 
PE(Duckitt, 2005) which is meant as a guideline to be used at prenatal 
visits for both the physician and the pregnant woman. However, there are 
not many studies that predict the risk specifically of EO-PE. Some of the 
factors are age, previous history of PE, family history of PE, multiple 
pregnancies, pre-existing medical conditions, high BMI. A caveat of all 
these studies that only one factor was studied at a time. Therefore, the 
impact of the association between risk factors on pregnancy is unknown. 
Perhaps, future studies can be designed keeping this point in mind. Here I 
list more details on risk factors that pertain to this thesis research.  
 
BMI, High Blood Pressure and sFlt1 : PlGF ratio 
In general, women with high BMI before pregnancy have double the risk of 
developing PE (Bianco et al., 1998; Fields et al., 1996; Thadhani et al., 
1999). Another study predicts this risk to be as high as 4-fold(Thadhani et 
al., 1999).  Several reasons exist to explain this phenomenon such as 
these women are advanced in age (age>34 years) or suffer from chronic 
hypertension. It is interesting to note that older women also suffer from 
decreased ovarian reserves(Tanbo et al., 1995), which is also a risk factor 
for developing cardiovascular diseases later in life(Chu, 2003; 
Kalantaridou et al., 2004). Another study demonstrates that women who 
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have IVF pregnancies generally suffer from low ovarian reserves and have 
a 2.7-fold risk of developing PE(Shevell et al., 2005; Woldringh et al., 
2006). Additionally IVF babies are also at a risk of being born Small-for-
Gestational-Age (SGA)(Koudstaal, 2000). High blood pressure 
Hypertension in PE is defined as systolic blood pressure greater than or 
equal to 140 mmHg and diastolic blood pressure greater that or equal to 
90 mmHg. There are two distinct types of hypertension scenarios– chronic 
hypertension (high blood pressure existing before pregnancy) and 
gestational hypertension (high blood pressure that did not exist before 
getting pregnant). Studies suggest that when both systolic blood pressure 
and diastolic blood pressure are higher in the first trimester, the women go 
on to develop PE later during pregnancy(Reiss et al., 1987; Sibai et al., 
1997). A gene wide association study on Norwegian population report that 
women with cardiovascular risk factors are disposed to developing 
PE(Magnussen et al., 2007).  
 
Another important criteria which is now getting common in diagnosing 
women at risk of PE, is the ratio of sFlt to it’s ligand PlGF(Rana et al., 
2012; Verlohren et al., 2010; 2012a; 2012b). This ratio is particularly 
important, because not all women who develop PE show symptoms of 
proteinuria. This ratio is thus inclusive of women who present PE, but do 
not show signs of proteinuria. PlGF unlike VEGF binds exclusively to Flt1 
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receptor. It has been also reported that when sFlt1 levels rise, the levels of 
free PlGF falls suggesting that the ratio of the sFlt1 to its ligand PlGF 
correlates with the severity of PE (Karumanchi, 2016) (Levine et al., 2005; 
Noori et al., 2010). In several large multi-center studies, this ratio has 
shown accurate prediction rate(Malshe and Sibai, 2017; Rana et al., 2012) 
(Chappell et al., 2013) (Duckworth et al., 2016) (Andersen et al., 2016). 
 
In spite of these known risk factors, the fact is that majority of the women 
are symptom free. For example, a woman with a high BMI will not show 
symptoms like high blood pressure or proteinuria. This often causes 
delayed diagnosis.   
 
We were very stringent in our patient selection criteria and only women 
with no pre-existing diabetes or hypertension. We further used two main 
selection criteria- systolic blood pressures ≥ 140 mm Hg and circulating 
sFlt1:PlGF ratios ≥ 85, an accepted diagnostic measure of PE.   
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Table 1.2 Risk Factors for PE 
Adapted from (American College of Obstetricians and GynecologistsTask Force 
on Hypertension in Pregnancy, 2013) 
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1.6  Long term effects of preeclampsia on mother and baby 
 
PE has been shown to have several long-term problems for both the mother 
and the fetus. Even after delivering the placenta and in turn the fetus, these 
mother with preeclamptic pregnancies and their babies suffer for many years 
after.   
1.6.1 Long-term effects on mother 
Women who have preeclamptic pregnancy double their risk of developing 
long-term cardiovascular diseases(McDonald et al., 2008). Other reports that 
these women have a seven-fold risk of developing future cardiovascular 
diseases(Rodie et al., 2004; Valdiviezo et al., 2012). Additionally, their risk of 
developing cardiovascular diseases in the short term also increases(Edlow et 
al., 2009). Another study has shown that 20% of women with PE pregnancies 
develop hypertension or microalbuminuria within seven years of a PE 
pregnancy(Nisell et al., 1995). These women also develop kidney disorders 
but no association was found between women with PE and developing cancer 
in the future(Bellamy et al., 2007).  
1.6.2 Long-term effects on fetus 
The fetus in a PE pregnancy is at a risk of being born small for its gestational 
age when compared to a fetus from a CTRL pregnancy. The fetus is often 
delivered prematurely which has long term effects on the neurodevelopment 
of these infants(Moster et al., 2008; Saigal and Doyle, 2008). Children born to 
PE women have been shown to develop psychiatric disorders and depression 
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related disorders(Tuovinen et al., 2010; 2012). It was also found that the 
children of PE mother have cognitive problems. For example, in a Western 
Australian Pregnancy Cohort, it was found that the verbal ability of a 10-year 
old born to be PE mother had a lower mean score than compared to a 10-
year old born to off a CTRL pregnancy(Whitehouse et al., 2012).  
1.7 FLT1 and PE 
 
1.7.1     Role of Flt1 in PE 
Over the last decade, several publications (Ahmed, 1997; Heydarian et al., 
2009; Kendall and Thomas, 1993; Kita and Mitsushita, 2008; Kleinrouweler et 
al., 2013; Maynard et al., 2003; Sela et al., 2008; Thomas et al., 2010; 2009a) 
have shown that PE patients show elevated levels of Fms-related tyrosine 
kinase 1  (FLT1)  gene expression than in CTRL pregnant patients.  Maternal 
symptoms of PE are a primary consequence of excessive levels of sFlt1 
protein in the maternal blood supply. FLT1 gene located on chromosome 13 
gives rise to truncated mRNA isoforms (sFlt1s) in addition to the full-length or 
membrane Flt1 (mFlt1) (Figure1.5). Both mFlt1 and sFlt1 mRNAs share a 
common transcription site. There have been at least five sFlt1 mRNAs 
reported that arise from usage of alternative splicing and alternative 
polyadenylation (APA)(Heydarian et al., 2009; Maynard et al., 2003; Sela et 
al., 2008; Thomas et al., 2010; 2009a; 2007). All the sFlt1 mRNAs have 
distinct 3’ prime ends and give rise to distinct sFlt1 proteins due to coding 
region APA.  mFlt1 consists of 30 exons and the sFlt1-i13 S or L isoform 
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shares the first 13 exons and lacks the downstream exons. sFlt1-e15a, sFlt1-
e15b and sFlt1-i14 share the first 14 exons and lack the downstream exons.  
 
Thus, APA leads to formation of multiple protein isoforms: (a) transmembrane 
bound Flt1 (mFlt1), a tyrosine kinase receptor participating in vascular 
endothelial growth factor (VEGF) signaling; and (b) truncated and blood 
circulating (soluble) forms, sFlt1s, which lack the transmembrane anchoring 
domain and act as antagonists to mFlt1 (Figure 1.6). Relative production of 
these isoforms results from polyadenylation sites within exon 30 (mFlt1) or 
within introns 13 and 14 (sFlt1s) (Figure 1.5).  
 
1.7.2 sFlt1: Anti-angiogenic effect on mFlt1 and its signaling pathways 
sFlt1 protein can interfere with the VEGF signaling in the following ways. As 
the ligand binding domains are shared between the sFlt1 and mFlt1, sFlt2 
sequesters the VEGF and PGF ligands away from the mFlt1.  Additionally, it 
has also been reported that sFlt1 protein binds to VEGF with a higher affinity 
than the mFlt1(Thomas et al., 2007). On ligand binding the dimerization 
domain comes together to form a dimer that leads to downstream tyrosine 
kinase signaling. This dimerization domain is also shared and therefore sFlt1 
can form inactive receptor dimers or dominant-negative receptor with no 
downstream signaling.  
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There is rich evidence demonstrating that there is a down regulation of free 
VEGF and free PGF ligand levels when the sFlt1 receptor is upregulated in 
serum of PE patients(Ahmad and Ahmed, 2004; Kendall and Thomas, 1993; 
Maynard et al., 2003; McKeeman et al., 2004).  
 
Overexpression of sFlt1 in rats leads to hypertension, proteinuria and 
glomerular endotheliosis (Maynard et al., 2003; 2005) the classic symptoms 
of preeclampsia. Maynard et al used serum from CTRL and PE patients to 
induce endothelial tube formation (in vitro model of angiogenesis) in HUVEC 
cells. They found that there was impaired angiogenesis in HUVECs treated 
with serum of PE patients(Maynard et al., 2003).  
1.8 Current treatments for preeclampsia 
 
There is no current cure for PE, except delivery of the baby. Depending on 
the gestational delivery week of PE diagnosis, i.e. either EO-PE (GDW<34) or 
LO-PE (GDW>34), different strategies can be used. In case of EO-PE, before 
the onset of labor, maternal and fetal health is monitored closely. In case of 
the EO-PE women, who have to deliver the baby pre-maturely (<34 weeks), 
steroid is commonly administered to ensure fetal lung development. For 
women with LO-PE, monitoring the mother and fetus is usually 
recommended. In case of an adverse event, delivery is recommended. 
Traditionally, women with severe PE have been treated with magnesium 
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sulfate, an anticonvulsant that prevents seizures in women with PE(Magpie 
Trial Follow-Up Study Collaborative Group, 2006). 
An encouraging report by Thadhani et al have shown that reducing sFlt1 
levels in PE women is possible using dextran sulfate columns(Thadhani, 
2010; Thadhani et al., 2011). sFlt1 has a negative isoelectric point and the 
maternal blood is circulated through the positively charged dextran cellulose 
columns, where the negatively charged proteins bind to the positively charged 
column, and then circulated back in the mother. They treated five severe PE 
women and all of them showed reduced sFlt1 levels for a range of 14 to 21 
days. Additionally they observed reduced proteinuria and blood pressure, 
both classic symptoms of PE. These women could extend the pregnancy by 2 
to 4 weeks. Most importantly, the fetus was normal and showed no 
abnormality.   However, this was a pilot study and is an expensive treatment 
option, especially for the developing countries.  
 
Thus, instead of managing PE, I see a potential to treat PE. In this thesis I 
propose that down regulating sFlt1 is an ideal target. One way of down 
regulating sFlt1 protein is by targeting the mRNA encoding it.  
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1.9 siRNA therapeutics 
 
Short interfering RiboNucleic Acid (siRNA) is a type of RNA molecule, which 
is 20-25 nt in length. siRNAs are part of the naturally occurring RNAi (RNA 
interference) pathway(Lam et al., 2015) in eukaryotic cells. RNAi is a process 
by which gene can be silenced by knocking down mRNAs. RNAi has been 
shown to be an effective and safe as a therapeutic in several disease areas 
(Burnett et al., 2011). Clinical trials for siRNAs in kidney disorders and solid 
tumor are currently in process (Burnett et al., 2011) (Davis, 2009) (Zuckerman 
and Davis, 2015) 
 
Endogenously occurring siRNAs or siRNA expression vector can both be 
used to silence mRNAs (gene). siRNAs are associated with the RNA-induced 
silencing complex (RISC complex) and guide the complex to bind with the 
target mRNA. On binding of the siRNA-RISC to the mRNA, it leads to 
cleavage of the mRNA by the complex. siRNAs need complete sequence 
complementarity to the target mRNA or gene. The silencing effect usually 
lasts for a few days and is easier to deliver compared to other types of RNAi 
molecules like shRNA and miRNA (Lam et al., 2015).  
 
Some of the issues with siRNAs as therapeutic agent are activation of 
interferon pathway, stability in tissues, delivery to targeted cells and the 
routes of administration. However, in the last several years, there has been 
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tremendous research that tackles all the above-mentioned issues. The two 
main ways to avoid the immune response activation is to directly injecting 
synthetic siRNAs or replace the natural RNA moiety by non-natural moiety. 
Using the synthetic siRNAs instead of the traditional long double stranded 
RNA skips the Dicer processing part, thus avoiding activation of interferon 
pathway. In order to increase the stability of siRNAs in the human body, the 
backbone of the siRNA is replaced by 2’-O-Methyl RNA or 2’-O- Fluoro RNA, 
thus increasing the half-life of the siRNAs. Several modifications can be made 
to the sugar, base and backbone of the siRNA to increase stability. Addition 
of conjugates to the siRNAs aids in the delivery of siRNA to various tissues.  
siRNAs can be manufactured at low cost, are long-lived with high heat 
stability(Haussecker, 2012), and can be administered via subcutaneous (SC) 
injection.   
 
Thus, given the above-mentioned advances in the siRNA therapeutic world, I 
propose that siRNAs have strong potential to be developed as a therapy for 
women suffering from PE. In Chapter III and Chapter IV, I demonstrate that 
siRNAs can knockdown sFlt1, which leads to improvement of PE symptoms 
in an animal model.  
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SUMMARY  
 
In summary, PE is a disorder that affects 2-16% pregnancies worldwide with high 
mortality rates for both mother and fetus, especially in developing countries. 
Clinical signs like high blood pressure and proteinuria develop in the mother after 
the 20th week of pregnancy. Maternal complications include seizures, HELLP 
syndrome and even death, while the fetuses of mothers with preeclampsia are 
prone to be SGA, suffer from hypoxia induced injury and death. 
As seen in Chapter I, one major contributing factor in the pathogenesis of 
preeclampsia is increased level of proteins called soluble Fms-related tyrosine 
kinase 1 (sFlt1). sFlt1 is encoded by the gene Fms-related tyrosine kinase 1 
(FLT1), which produces two major protein isoforms: (1) a transmembrane bound 
full–length Flt1 (mFlt1), which relays angiogenic signals through the vascular 
endothelial growth factor (VEGF) signaling cascade; and (2) multiple truncated 
and blood circulating forms, sFlt1, which lacks the transmembrane domain and 
acts as an antagonist to mFlt1 protein. The production of these Flt1 isoforms are 
the result of alternative polyadenylation, either in the 3′-UTR to create the mRNA 
encoding mFlt1 or within upstream introns (intron 13 and intron 14) to create the 
mRNAs encoding sFlt1. Many studies have reported high circulating sFlt1 
expression levels in patients with preeclampsia compared to women who have a 
normal pregnancy. Furthermore, rats injected with an exogenous vector 
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expressing sFlt1, they developed signs of preeclampsia–high blood pressure and 
proteinuria. In preeclamptic women, the levels of sFlt1 drop to normal once the 
placenta is removed, indicating that placenta is the main source of sFlt1s. The 
only cure for preeclampsia currently is delivery of the placenta, irrespective of the 
gestational age of the fetus. Significant resources and health care expenditure 
are dedicated to the identification and management of preeclampsia.  The costs 
related to preterm delivery from early-onset preeclampsia (<34 weeks) are 40-
100 times when compared to uncomplicated term delivery. 
 
In spite of tremendous progress in the last few years, the mechanism by which 
sFlt1 is upregulated is unclear. Additionally, despite the knowledge that sFlt1s 
are generated by alternative polyadenylation, the genome-wide role of alternative 
polyadenylation is unclear. I address the following unanswered questions in this 
thesis: 
 
(1) Why do sFlt1 levels increase during preeclamptic pregnancies? (2) What 
other genes are differentially expressed during preeclamptic pregnancy as 
opposed to normal pregnancies? (3) Can a reduction in the levels of circulating 
sFlt1 protein through RNAi alleviate the clinical manifestations of preeclampsia?  
Furthermore, this thesis delves into (4) is there an overall increase in FLT1 gene 
expression? and/or (5) is there a preferential switch in polyadenylation sites from 
those in the 3′-UTR to those in the upstream introns? 
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In my thesis research, I developed and made polyadenylation site sequencing 
(PAS-Seq) libraries from RNA of normal and PE human placentae to measure 
gene expression in a transcriptome-wide manner and investigate alternative 
polyadenylation signatures associated with early-onset PE (EO-PE; symptom 
onset <34 weeks) and late-onset PE (LO-PE; symptom onset >34 weeks) 
cohorts. 
 
To investigate if sFlt1 levels increase by alternative polyadenylation or splicing 
and to identify other differentially expressed genes in PE, I analyzed the 
bioinformatics data generated from PAS-Seq (Chapter II) and RNA-Seq 
(Appendix A) on human placental RNA samples. I found no general shift in 
alternative polyadenylation associated with PE. However, I observe three main 
sFlt1 mRNA isoforms that account for >94% of all transcripts, with increased 
transcription of the entire locus driving FLT1 upregulation in both EO-PE and LO-
PE (Chapter II). I find that EO-PE and LO-PE cohorts do exhibit gene expression 
profiles distinct from both each other and from normal placentae (Chapter II). I 
observed only two genes upregulated across all transcriptome-wide PE analyses 
to date; namely NRIP1 (RIP140), a transcriptional co-regulator linked to 
metabolic syndromes associated with obesity, and FLT1 (Chapter II).  
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The sFlt1 isoforms identified in Chapter II represent potential targets for 
therapeutic anti-sFlt1 siRNAs in EO-PE and LO-PE. In a proof-of-concept study, I 
identified anti-sFlt1 siRNAs that efficiently knockdown sFlt1 (both mammalian 
and mice sFlt1 isoforms) in NIH-3T3 cells (Chapter III). These anti-sFlt1 siRNAs 
are further chemically modified for efficient uptake and injected in mice to test for 
pharmacodynamics and pharmacokinetics studies and test if the siRNAs can 
reach the placenta and reach the fetus (Chapter IV). Furthermore, in 
collaboration with Dr. Anastasia’s Khvorova, Dr. Ananth Karumanchi and Dr. 
Annemarie Hennessey, we test these siRNAs in a baboon-model of 
preeclampsia and demonstrate that these siRNA injected baboons show 
improvement in preeclamptic symptoms like high blood pressure and proteinuria 
(Chapter IV). 
 
The results of this thesis have advanced our understanding of the molecular 
changes occurring in preeclampsia (Chapter II) as well as demonstrated the 
value of sFlt1 as a therapeutic target to treat this disease (Chapter III and 
Chapter IV). 
 
Both appendices B and C represent other contributions I have made in terms of 
experiments, method development and bioinformatics data analysis during the 
duration of my PhD thesis.  
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2. CHAPTER II: FLT1 and transcriptome-wide polyadenylation site (PAS) 
analysis in preeclampsia 
 
 
 
 
Chapter II was taken verbatim from:  
Patel A.A., Kaymaz Y., Rajakumar A., Bailey J.A., Karumanchi S.A., Moore M.J.  
FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in 
preeclampsia (Manuscript under review at Nature Scientific Reports) 
 
 
Author contributions statement:  
 
M.J.M conceived of the project, A.R. collected the samples and prepared total 
RNA, and A.A.P made PAS-Seq libraries and performed data analysis. Y.K. 
wrote custom pipelines for analyzing PAS-Seq data. M.J.M. and A.A.P wrote the 
main manuscript text and A.A.P prepared figures. J.A.B and S.A.K provided 
material support, expert advice and participated in manuscript editing. All authors 
reviewed the manuscript. 
 
For information not contained in this chapter (i.e. supplemental tables), please 
refer online after the paper is published.  
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2.1 Introduction 
 
Preeclampsia (PE) is one of the three leading causes of premature birth (Ananth 
et al., 2013).  Characterized by hypertension and proteinuria in the third 
trimester, PE complicates up to 10% of pregnancies, and is estimated to result in 
more than 76,000 maternal and 500,000 infant deaths each year worldwide 
(www.preeclampsia.org).  In the developed world, significant resources are 
dedicated to the identification and management of preeclampsia, with US health 
care costs estimated to be 40-100 times higher for early-onset preeclamptic 
deliveries than for uncomplicated term deliveries(Shih et al., 2016). PE is a highly 
heterogeneous disease that initiates in the placenta and is likely driven by 
multiple mechanisms (Chaiworapongsa et al., 2004; Kang et al., 2011).  In 
particular, early onset PE (EO-PE; defined by symptom onset <34 weeks) is 
thought to be clinically distinct from late onset PE (LO-PE; defined by symptom 
onset >34 weeks) (Dadelszen et al., 2003; Kusanovic et al., 2009; Romero et al., 
2009; Soto et al., 2011; Várkonyi et al., 2011).  EO-PE is thought to be driven by 
poor placentation during early development, whereas LO-PE is considered to be 
a more maternal syndrome(Junus et al., 2012a). 
 
Although the root causes of PE are not fully understood, it is now well 
established that the clinical manifestations are due to excess anti-angiogenic 
proteins, primarily "soluble fms-like tyrosine kinase 1" proteins (sFlt1s) in the 
mother’s bloodstream (Rana et al., 2012). sFlt1s are truncated forms of the 
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membrane-bound vascular endothelial growth factor (VEGF) receptor FLT1 (aka, 
VEGFR1) that normally function to buffer placental growth factor (PlGF) and 
VEGF signaling.  sFlt1s contain the extracellular binding domain present in full 
length or membrane-bound FLT1 (mFlt1), but are secreted because they lack the 
transmembrane and intracellular tyrosine kinase domains.  When sFlt1s are 
abnormally high in the mother's circulatory system, they interfere with her body's 
ability to respond to VEGF. Among other functions, VEGF is required for 
maintenance of the hepatic sinusoidal vasculature and other fenestrated vascular 
beds in the body (Kamba et al., 2006). Breakdown of these structures impairs 
maternal kidney function, leading to hypertension, proteinuria and cerebral 
edema (Eremina et al., 2008; 2003; Young et al., 2010) – classic features of PE 
and eclampsia.   
 
In mammals, FLT1 is predominantly expressed in the placenta, with human 
placental Flt1 mRNA levels being 40-50 times higher than those observed in any 
other adult tissue (Jebbink et al., 2011) (Figure 2.1 a).  Whereas the full-length 
isoform predominates in most adult tissues, placental and liver expression are 
dominated by truncated isoforms due to alternative polyadenylation (Figure 2.1 
b).  These alternative polyadenylation sites occur within introns downstream of 
the exons encoding the extracellular binding domain but upstream of those 
encoding the transmembrane and intracellular signaling domains (Thomas et al., 
2010; 2007; Vorlová et al., 2011).  Five different sFlt1 mRNA isoforms have been  
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Figure 2.1 FLT1 expression and patient selection 
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a. Mean RNA-Seq FLT1 gene expression in various human tissues.  Expression values 
are given as Fragments Per Kilobase of transcript per Million reads (FPKM) (whisker: 
standard deviation). b. RNA-Seq data for FLT1 gene illustrating isoform differences 
across various tissues.  All data in a. and b. are from 
http://v14.proteinatlas.org./ENSG00000102755-FLT1/tissue.  c. Patient segmentation 
into three groups by maternal systolic blood pressure and serum sFlt1: PlGF:  Normal 
(CTRL, green, n=6), Early-Onset PE (EO-PE, red, n=8), and Late-Onset PE (LO-PE, 
blue, n=3). 
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reported to date(Heydarian et al., 2009). Two (sFlt1-i13-short and sFLT-i13-long) 
result from alternative polyadenylation at different sites in intron 13 to yield 
mRNAs encoding the same 687 amino acid sFlt1 protein isoform, but with either 
a 17 or 4146 nt 3'-UTR, respectively.  Three others (sFlt1-i14, sFlt1-e15a and 
sFlt1-e15b) are due to alternative polyadenylation within intron 14. sFlt1-e15a 
and sFlt1-e15b result from activation of two different cryptic splice acceptors 
(cryptic 3' splice sites) upon use of alternative polyadenylation sites in the latter 
half of intron 14. In all, these five sFlt1 mRNAs encode four different sFlt1 
proteins with different C-termini. 
 
In women with PE, circulating sFlt1 protein levels are 5 to 7 times higher than 
those observed in normal pregnancies.  One potential therapeutic approach 
would be to selectively knock down sFlt1 expression by RNA silencing (RNA 
interference, RNAi) using short interfering RNAs (siRNAs) targeting sequences 
unique to the sFlt1 mRNA isoforms and not contained in mFlt1 mRNA (Turanov 
et al.).  Success of this strategy requires knowing exactly which sFlt1 mRNA 
isoforms to target.  Further, while circulating sFlt1 levels increase in both EO-PE 
and LO-PE, this increase starts earlier in EO-PE and often with a more 
aggressive trajectory (Noori et al., 2010).  This raises the question of whether 
EO-PE placentae express a different pattern of sFlt1 mRNA isoforms than LO-PE 
placentae.  That is, is it possible to define a common set of sFlt1 mRNA isoforms 
suitable for therapeutic intervention in both EO-PE and LO-PE patients?  
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Here we applied polyadenylation site sequencing (PAS-Seq) method on RNA 
isolated from normal (CTRL) and PE human placentas to identify the most 
abundant sFlt1 mRNA isoforms.  Because PAS-Seq specifically interrogates 
polyadenylation sites it provides a much more accurate assessment of transcript 
3' ends than RNA-Seq(Derti et al., 2012; Shepard et al., 2011), which is generally 
biased toward transcript 5' ends and is a better for investigating alternative 
splicing pattern(Zheng et al., 2011).  Like RNA-Seq, PAS-Seq can be used for 
differential gene expression analysis by combining all isoforms detected at an 
individual gene locus into a single gene expression number(Derti et al., 2012).  
Therefore, in addition to quantifying alternative polyadenylation both at the Flt1 
locus and transcriptome-wide, we also used our PAS-Seq data to investigate 
overall gene expression changes between our patient groups. 
2.2  Results 
2.2.1 Placental PAS-Seq datasets 
Several risk factors are associated with PE(WHO, 2011).  In an attempt to 
minimize confounding variables by other associated conditions, we used highly 
selective criteria for patient inclusion.  First, we limited our sample set to 
singleton pregnancies, and excluded any patients with preexisting hypertension 
or diabetes mellitus.  Second, all of our control set (CTRL; n = 6) delivered at 
term with no other pregnancy complications (such as preterm labor or premature 
rupture of membranes). Finally, we limited our PE set (n=11) to patients with 
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systolic blood pressures ≥ 140 mm Hg and circulating sFlt1:PlGF ratios ≥ 85, an 
accepted diagnostic measure of PE associated with adverse PE related 
maternal/fetal outcome(Verlohren et al., 2010; 2012b) (Figure 2.1 c and Table 
2.1). Gestational delivery week (GDW), ranged from 37 to 40 weeks in the CTRL 
set and from 28 to 39 weeks in the PE set.  Based on the GDW, we further 
divided the PE patients into Early-Onset (EO-PE; GDW <34; n=8) and Late-
Onset (LO-PE; GDW >34; n=3) subgroups.  In all cases, placental tissue was 
collected within 30 minutes of delivery and flash frozen in liquid nitrogen. Using 
these frozen samples, we isolated polyA tailed RNA from the villous tissue, which 
is the spongy layer in between the decidua (maternal side) and the chorion (fetal 
side), and the main source of sFlt1(Rajakumar, 2011; Rajakumar et al., 2012) 
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Mean statistic ± standard deviation. Patient set comparisons were performed using the 
Mann-Whitney test; *P=0.05, **P=0.001, ***P=0.0002 
Table 2.1 Clinical characteristics of patients 
 
 
 
 
 
 
 
 
 
 
 
PAS-Seq patient characteristics  
Variables CTRL (n=6) EO-PE (n=8) LO-PE (n=3) 
Systolic BP (mmHg) 125 ± 10 183 ± 14 *** 154 ± 4 ** 
Diastolic BP (mmHg) 79 ± 8 109 ± 11** 98 ± 15 
Maternal plasma sFlt1 (pg/mL) 9238 ± 4257 29672 ± 10420*** 26243 ± 13805* 
Maternal plasma PGF (ng/mL) 331 ± 262 98  ± 55* 158  ± 77 
sFlt1 : PlGF ratio 40 ± 24 405 ± 256*** 166 ± 14* 
Maternal age (years) 35 ± 8 31 ± 5 27 ± 6 
Maternal pre-pregnancy BMI (kg/m2) 26 ± 5 34 ± 5* 18 ± 8 
Gestational delivery week 39 ± 1 31 ±2*** 37 ± 2 
Proteinuria NA 100% 100% 
Newborn gender (F/M) 3/3 4/4 2/1 
Mode of delivery (C-sec/Vaginal) 6/0 8/0 3/0 
Induction of labor (yes/no) 0/6 1/7 2/1 
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To analyze APA transcriptome-wide, we developed a simple, kit-free method by 
combining elements of a published PAS-Seq protocol(Shepard et al., 2011) with 
a circularization strategy used in our lab for making short RNA fragment 
libraries(Heyer et al., 2015b) (Figure 2.2 a, see Methods). Single-end sequencing 
on the Illumina HiSeq 2000 platform yielded 30-70 million (in average) high 
quality reads per library, of which 70-85% mapped uniquely to the human 
genome (hg19) (Table 2.2).  Using a custom pipeline (Figure 2.2 b and Methods), 
peaks were identified as clusters of ≥15 reads (all libraries combined) whose 3' 
ends mapped within a 40 nt window (to allow for microheterogeneity in PAS 
use)(Tian et al., 2005).  Peaks representing true PAS (i.e., those at which a 
polyA tail was added post-transcriptionally) were distinguished from peaks due to 
oligoT internal priming of transcripts at genomically-encoded adenosine-rich 
regions using a Naives Bayes classifier based probabilistic method (Shepard et 
al., 2011). True PAS were then assigned to genes using GENCODE (v19) 
annotations and quantified as counts per million (CPM).  Custom UCSC genome 
browser tracks enabled visualization of read clusters and true PAS sites (Figure 
2.2 c). In all, we detected 31,615 PAS on or within 5 kb downstream of annotated 
transcripts representing 13,328 genes and 3,482 PAS in intergenic regions. The 
majority of the annotated set was dominated by protein-coding genes (n=27,395 
PAS; 86.6%), but also contained hundreds of snRNAs, lncRNAs, miRNAs and 
anti-sense transcripts (Figure 2.2 d). 
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Libraries Samples # of Total 
Reads  
# of reads before 
filtering PCR 
duplicates 
# of reads after 
filtering PCR 
duplicates  
# of reads mapped 
to hg19 genome  
% uniquely 
mapped 
reads 
CTRL N1 23,511,578  23,511,578  21,673,106  13,806,565  63.7 
CTRL N2 29,672,955  29,672,955  28,318,378  18,126,488  64.0 
CTRL N3 22,490,543  22,490,543  19,599,350  13,344,396  68.1 
CTRL N4 39,123,865  39,123,865  32,433,406  21,920,746  67.6 
CTRL N5 11,599,110  11,599,110  10,130,195  7,126,542  70.3 
CTRL N6 23,200,677  23,200,677  22,826,611  14,095,599  61.8 
EO-PE P1 24,601,335  24,601,335  23,261,667  14,995,294  64.5 
EO-PE P2 23,555,010  23,555,010  20,145,239  13,266,060  65.9 
EO-PE P3 7,308,017  7,308,017  6,715,379  4,847,280  72.2 
LO-PE P4 36,170,272  36,170,272  24,955,305  17,184,747  68.9 
LO-PE P5 28,092,206  28,092,206  27,274,495  18,112,595  66.4 
EO-PE P6 41,604,215  41,604,215  35,597,242  24,044,206  67.5 
EO-PE P7 33,294,603  33,294,603  30,896,129  21,125,542  68.4 
EO-PE P8 33,199,502  33,199,502  29,467,774  17,419,272  59.1 
EO-PE P9 6,642,588  6,642,588  6,396,058  3,606,549  56.4 
EO-PE P10 6,807,878  6,807,878  6,544,426  3,530,627  53.9 
LO-PE P11 8,249,282  8,249,282  7,791,478  4,438,303  57.0 
Table 2.2 PAS-Seq read mapping statistics 
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By summing all true PAS reads mapping across individual loci, PAS-Seq data 
can be used to assess overall gene expression. That is, the data can be 
collapsed into a single gene expression number (counts per million, CPM) that 
encompasses all polyadenylated isoforms derived from each gene (Derti et al., 
2012).  The top 500 genes in our samples were highly enriched for those 
expressed in placenta (p≤8.4 e-43) and syncytiotrophoblasts (p≤6.5 e-42) (see 
Methods).  Consistent with a previous RNA-Seq report (Sõber et al., 2015), 
nearly all of the 20 most highly expressed genes in the CTRL, EO-PE and LO-PE 
samples (Figure 2.3 a, b, c and 2.7 a) were placental or pregnancy-related (Table 
2.3). This highest abundance set was dominated by hormones (e.g., CSH1, 
CSH2 and CGA), positive and negative regulators of cell growth (e.g., GDF15 
and TFPI2) and hemoglobin genes (HBA1, HBA2, HBB and HBG2); also 
included were two high abundance lncRNAs, H19 and NEAT1. 
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Gene Gene Name Protein Atlas (V14) Summary 
ADAM12 ADAM metallopeptidase domain 12 Placenta enriched This gene encodes a member of a family of proteins that are 
structurally related to snake venom disintegrins and have been 
implicated in a variety of biological processes involving cell-cell and 
cell-matrix interactions, including fertilization, muscle development, 
and neurogenesis. Expression of this gene has been used as a 
maternal serum marker for pre-natal development. Alternative 
splicing results in multiple transcript variants encoding different 
isoforms. Shorter isoforms are secreted, while longer isoforms are 
membrane-bound form. (provided by RefSeq, Jan 2014) 
CGA Glycoprotein hormones, alpha polypeptide Placenta enriched The four human glycoprotein hormones chorionic gonadotropin 
(CG), luteinizing hormone (LH), follicle stimulating hormone (FSH), 
and thyroid stimulating hormone (TSH) are dimers consisting of 
alpha and beta subunits that are associated noncovalently. The 
alpha subunits of these hormones are identical, however, their beta 
chains are unique and confer biological specificity. The protein 
encoded by this gene is the alpha subunit and belongs to the 
glycoprotein hormones alpha chain family. Two transcript variants 
encoding different isoforms have been found for this gene. (provided 
by RefSeq, Nov 2011) 
CRH Corticotropin releasing hormone Placenta enriched Corticotropin-releasing hormone is secreted by the paraventricular 
nucleus (PVN) of the hypothalamus in response to stress. Marked 
reduction in this protein has been observed in association with 
Alzheimer disease and autosomal recessive hypothalamic 
corticotropin deficiency has multiple and potentially fatal metabolic 
consequences including hypoglycemia and hepatitis. In addition to 
production in the hypothalamus, this protein is also synthesized in 
peripheral tissues, such as T lymphocytes and is highly expressed 
in the placenta. In the placenta it is a marker that determines the 
length of gestation and the timing of parturition and delivery. A rapid 
increase in circulating levels of the hormone occurs at the onset of 
parturition, suggesting that, in addition to its metabolic functions, this 
protein may act as a trigger for parturition. (provided by RefSeq, Apr 
2010) 
CSH1 Chorionic somatomammotropin hormone 1 (placental lactogen) Placenta enriched The protein encoded by this gene is a member of the 
somatotropin/prolactin family of hormones and plays an important 
role in growth control. The gene is located at the growth hormone 
locus on chromosome 17 along with four other related genes in the 
same transcriptional orientation; an arrangement which is thought to 
have evolved by a series of gene duplications. Although the five 
genes share a remarkably high degree of sequence identity, they 
are expressed selectively in different tissues. Alternative splicing 
generates additional isoforms of each of the five growth hormones, 
leading to further diversity and potential for specialization. This 
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particular family member is expressed mainly in the placenta and 
utilizes multiple transcription initiation sites. Expression of the 
identical mature proteins for chorionic somatomammotropin 
hormones 1 and 2 is upregulated during development, although the 
ratio of 1 to 2 increases by term. Mutations in this gene result in 
placental lactogen deficiency and Silver-Russell syndrome. 
(provided by RefSeq, Jul 2008) 
CSH2 Chorionic somatomammotropin hormone 2 Placenta enriched The protein encoded by this gene is a member of the 
somatotropin/prolactin family of hormones and plays an important 
role in growth control. The gene is located at the growth hormone 
locus on chromosome 17 along with four other related genes in the 
same transcriptional orientation; an arrangement which is thought to 
have evolved by a series of gene duplications. Although the five 
genes share a remarkably high degree of sequence identity, they 
are expressed selectively in different tissues. Alternative splicing 
generates additional isoforms of each of the five growth hormones. 
This particular family member is expressed mainly in the placenta 
and utilizes multiple transcription initiation sites. Expression of the 
identical mature proteins for chorionic somatomammotropin 
hormones 1 and 2 is upregulated during development, while the 
ratio of 1 to 2 increases by term. Structural and expression 
differences provide avenues for developmental regulation and tissue 
specificity. (provided by RefSeq, Jul 2008) 
CYP19A1 Cytochrome P450, family 19, subfamily A, polypeptide 1 Placenta enriched This gene encodes a member of the cytochrome P450 superfamily 
of enzymes. The cytochrome P450 proteins are monooxygenases 
which catalyze many reactions involved in drug metabolism and 
synthesis of cholesterol, steroids and other lipids. This protein 
localizes to the endoplasmic reticulum and catalyzes the last steps 
of estrogen biosynthesis, three successive hydroxylations of the A 
ring of androgens. Mutations in this gene can result in either 
increased or decreased aromatase activity; the associated 
phenotypes suggest that estrogen functions both as a sex steroid 
hormone and in growth or differentiation. The gene expresses two 
transcript variants. (provided by RefSeq, Jul 2008) 
FBLN1 Fibulin 1 – Fibulin 1 is a secreted glycoprotein that becomes incorporated into a 
fibrillar extracellular matrix. Calcium-binding is apparently required 
to mediate its binding to laminin and nidogen. It mediates platelet 
adhesion via binding fibrinogen. Four splice variants which differ in 
the 3' end have been identified. Each variant encodes a different 
isoform, but no functional distinctions have been identified among 
the four variants. (provided by RefSeq, Jul 2008) 
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FLT1 Fms-related tyrosine kinase 1 Placenta enriched This gene encodes a member of the vascular endothelial growth 
factor receptor (VEGFR) family. VEGFR family members are 
receptor tyrosine kinases (RTKs) which contain an extracellular 
ligand-binding region with seven immunoglobulin (Ig)-like domains, 
a transmembrane segment, and a tyrosine kinase (TK) domain 
within the cytoplasmic domain. This protein binds to VEGFR-A, 
VEGFR-B and placental growth factor and plays an important role in 
angiogenesis and vasculogenesis. Expression of this receptor is 
found in vascular endothelial cells, placental trophoblast cells and 
peripheral blood monocytes. Multiple transcript variants encoding 
different isoforms have been found for this gene. Isoforms include a 
full-length transmembrane receptor isoform and shortened, soluble 
isoforms. The soluble isoforms are associated with the onset of pre-
eclampsia.(provided by RefSeq, May 2009) 
GDF15 Growth differentiation factor 15 Placenta enhanced This gene encodes a secreted ligand of the TGF-beta (transforming 
growth factor-beta) superfamily of proteins. Ligands of this family 
bind various TGF-beta receptors leading to recruitment and 
activation of SMAD family transcription factors that regulate gene 
expression. The encoded preproprotein is proteolytically processed 
to generate each subunit of the disulfide-linked homodimer. The 
protein is expressed in a broad range of cell types, acts as a 
pleiotropic cytokine and is involved in the stress response program 
of cells after cellular injury. Increased protein levels are associated 
with disease states such as tissue hypoxia, inflammation, acute 
injury and oxidative stress. [provided by RefSeq, Aug 2016] 
H19 Imprinted Maternally Expressed Transcript  – This gene is located in an imprinted region of chromosome 11 near 
the insulin-like growth factor 2 (IGF2) gene. This gene is only 
expressed from the maternally-inherited chromosome, whereas 
IGF2 is only expressed from the paternally-inherited chromosome. 
The product of this gene is a long non-coding RNA which functions 
as a tumor suppressor. Mutations in this gene have been associated 
with Beckwith-Wiedemann Syndrome and Wilms tumorigenesis. 
Alternative splicing results in multiple transcript variants. [provided 
by RefSeq, Apr 2015] 
HBA1 Hemoglobin Subunit Alpha 1 – The human alpha globin gene cluster located on chromosome 16 
spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - 
mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 
(HBA2) and alpha-1 (HBA1) coding sequences are identical. These 
genes differ slightly over the 5' untranslated regions and the introns, 
but they differ significantly over the 3' untranslated regions. Two 
alpha chains plus two beta chains constitute HbA, which in normal 
adult life comprises about 97% of the total hemoglobin; alpha chains 
combine with delta chains to constitute HbA-2, which with HbF (fetal 
hemoglobin) makes up the remaining 3% of adult hemoglobin. Alpha 
thalassemias result from deletions of each of the alpha genes as 
well as deletions of both HBA2 and HBA1; some nondeletion alpha 
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thalassemias have also been reported. [provided by RefSeq, Jul 
2008] 
HBA2 Hemoglobin Subunit Alpha 2 – The human alpha globin gene cluster located on chromosome 16 
spans about 30 kb and includes seven loci: 5'- zeta - pseudozeta - 
mu - pseudoalpha-1 - alpha-2 - alpha-1 - theta - 3'. The alpha-2 
(HBA2) and alpha-1 (HBA1) coding sequences are identical. These 
genes differ slightly over the 5' untranslated regions and the introns, 
but they differ significantly over the 3' untranslated regions. Two 
alpha chains plus two beta chains constitute HbA, which in normal 
adult life comprises about 97% of the total hemoglobin; alpha chains 
combine with delta chains to constitute HbA-2, which with HbF (fetal 
hemoglobin) makes up the remaining 3% of adult hemoglobin. Alpha 
thalassemias result from deletions of each of the alpha genes as 
well as deletions of both HBA2 and HBA1; some nondeletion alpha 
thalassemias have also been reported. [provided by RefSeq, Jul 
2008] 
HBB Hemoglobin Subunit Beta – The alpha (HBA) and beta (HBB) loci determine the structure of the 
2 types of polypeptide chains in adult hemoglobin, Hb A. The normal 
adult hemoglobin tetramer consists of two alpha chains and two 
beta chains. Mutant beta globin causes sickle cell anemia. Absence 
of beta chain causes beta-zero-thalassemia. Reduced amounts of 
detectable beta globin causes beta-plus-thalassemia. The order of 
the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- 
gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008] 
HBG2 Hemoglobin, gamma G Placenta enriched The gamma globin genes (HBG1 and HBG2) are normally 
expressed in the fetal liver, spleen and bone marrow. Two gamma 
chains together with two alpha chains constitute fetal hemoglobin 
(HbF) which is normally replaced by adult hemoglobin (HbA) at birth. 
In some beta-thalassemias and related conditions, gamma chain 
production continues into adulthood. The two types of gamma 
chains differ at residue 136 where glycine is found in the G-gamma 
product (HBG2) and alanine is found in the A-gamma product 
(HBG1). The former is predominant at birth. The order of the genes 
in the beta-globin cluster is: 5'- epsilon -- gamma-G -- gamma-A -- 
delta -- beta--3'. [provided by RefSeq, Jul 2008] 
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IGF2 Insulin-like growth factor 2 Placenta enriched This gene encodes a member of the insulin family of polypeptide 
growth factors, which are involved in development and growth. It is 
an imprinted gene, expressed only from the paternal allele, and 
epigenetic changes at this locus are associated with Wilms tumour, 
Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-
Russell syndrome. A read-through INS-IGF2 gene exists, whose 5' 
region overlaps the INS gene and the 3' region overlaps this gene. 
Alternatively spliced transcript variants encoding different isoforms 
have been found for this gene. [provided by RefSeq, Oct 2010] 
KISS1 KiSS-1 metastasis-suppressor Placenta enriched This gene is a metastasis suppressor gene that suppresses 
metastases of melanomas and breast carcinomas without affecting 
tumorigenicity. The encoded protein may inhibit chemotaxis and 
invasion and thereby attenuate metastasis in malignant melanomas. 
Studies suggest a putative role in the regulation of events 
downstream of cell-matrix adhesion, perhaps involving cytoskeletal 
reorganization. A protein product of this gene, kisspeptin, stimulates 
gonadotropin-releasing hormone (GnRH)-induced gonadotropin 
secretion and regulates the pubertal activation of GnRH nuerons. A 
polymorphism in the terminal exon of this mRNA results in two 
protein isoforms. An adenosine present at the polymorphic site 
represents the third position in a stop codon. When the adenosine is 
absent, a downstream stop codon is utilized and the encoded 
protein extends for an additional seven amino acid residues. 
[provided by RefSeq, Mar 2012] 
NEAT1* nuclear paraspeckle assembly transcript 1/ trophoblast derived 
non-protein coding RNA 
– This gene produces a long non-coding RNA (lncRNA) transcribed 
from the multiple endocrine neoplasia locus. This lncRNA is retained 
in the nucleus where it forms the core structural component of the 
paraspeckle sub-organelles. It may act as a transcriptional regulator 
for numerous genes, including some genes involved in cancer 
progression. [provided by RefSeq, Mar 2015] 
PAPPA Pregnancy-associated plasma protein A, pappalysin 1 Placenta enriched This gene encodes a secreted metalloproteinase which cleaves 
insulin-like growth factor binding proteins (IGFBPs). It is thought to 
be involved in local proliferative processes such as wound healing 
and bone remodeling. Low plasma level of this protein has been 
suggested as a biochemical marker for pregnancies with aneuploid 
fetuses. [provided by RefSeq, Jul 2008] 
PAPPA2 Pappalysin 2 Placenta enriched This gene encodes a member of the pappalysin family of metzincin 
metalloproteinases. The encoded protein cleaves insulin-like growth 
factor-binding protein 5 and is thought to be a local regulator of 
insulin-like growth factor (IGF) bioavailability. Alternative splicing 
results in multiple transcript variants. [provided by RefSeq, Jul 2010] 
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PRG2 Proteoglycan 2 Placenta enriched The protein encoded by this gene is the predominant constituent of 
the crystalline core of the eosinophil granule. High levels of the 
proform of this protein are also present in placenta and pregnancy 
serum, where it exists as a complex with several other proteins 
including pregnancy-associated plasma protein A (PAPPA), 
angiotensinogen (AGT), and C3dg. This protein may be involved in 
antiparasitic defense mechanisms as a cytotoxin and 
helminthotoxin, and in immune hypersensitivity reactions. The 
encoded protein contains a peptide that displays potent 
antimicrobial activity against Gram-positive bacteria, Gram-negative 
bacteria, and fungi. It is directly implicated in epithelial cell damage, 
exfoliation, and bronchospasm in allergic diseases. Alternatively 
spliced transcript variants encoding different isoforms have been 
found for this gene. [provided by RefSeq, Nov 2014] 
PSG2 Pregnancy specific beta-1-glycoprotein 2 Placenta enriched The human pregnancy-specific glycoproteins (PSGs) are a family of 
proteins that are synthesized in large amounts by placental 
trophoblasts and released into the maternal circulation during 
pregnancy. Molecular cloning and analysis of several PSG genes 
has indicated that the PSGs form a subgroup of the 
carcinoembryonic antigen (CEA) gene family, which belongs to the 
immunoglobulin superfamily of genes. Members of the CEA family 
consist of a single N domain, with structural similarity to the 
immunoglobulin variable domains, followed by a variable number of 
immunoglobulin constant-like A and/or B domains. Most PSGs have 
an arg-gly-asp (RGD) motif, which has been shown to function as an 
adhesion recognition signal for several integrins, in the N-terminal 
domain (summary by Teglund et al., 1994 [PubMed 7851896]). For 
additional general information about the PSG gene family, see 
PSG1 (MIM 176390).[supplied by OMIM, Oct 2009] 
S100P S100 Calcium Binding Protein P – The protein encoded by this gene is a member of the S100 family of 
proteins containing 2 EF-hand calcium-binding motifs. S100 proteins 
are localized in the cytoplasm and/or nucleus of a wide range of 
cells, and involved in the regulation of a number of cellular 
processes such as cell cycle progression and differentiation. S100 
genes include at least 13 members which are located as a cluster 
on chromosome 1q21; however, this gene is located at 4p16. This 
protein, in addition to binding Ca2+, also binds Zn2+ and Mg2+. 
This protein may play a role in the etiology of prostate cancer. 
[provided by RefSeq, Jul 2008] 
TFPI2 Tissue factor pathway inhibitor 2 Placenta enriched This gene encodes a member of the Kunitz-type serine proteinase 
inhibitor family. The protein can inhibit a variety of serine proteases 
including factor VIIa/tissue factor, factor Xa, plasmin, trypsin, 
chymotryspin and plasma kallikrein. This gene has been identified 
as a tumor suppressor gene in several types of cancer. Alternative 
splicing results in multiple transcript variants. [provided by RefSeq, 
Aug 2012] 
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TGM2 Transglutaminase 2 – Transglutaminases are enzymes that catalyze the crosslinking of 
proteins by epsilon-gamma glutamyl lysine isopeptide bonds. While 
the primary structure of transglutaminases is not conserved, they all 
have the same amino acid sequence at their active sites and their 
activity is calcium-dependent. The protein encoded by this gene acts 
as a monomer, is induced by retinoic acid, and appears to be 
involved in apoptosis. Finally, the encoded protein is the autoantigen 
implicated in celiac disease. Two transcript variants encoding 
different isoforms have been found for this gene. [provided by 
RefSeq, Jul 2008] 
   *Repression of major histocompatibility complex genes by a human 
trophoblast ribonucleic acid. 
Peyman JA et al. Biol. Reprod. 1999 Jan;60(1):23-31 
PMID: 9858482 Europe PMC Pubmed  
Human trophoblast noncoding RNA suppresses CIITA promoter III 
activity in murine B-lymphocytes. 
Geirsson A et al. Biochem. Biophys. Res. Commun. 2003 
Feb;301(3):718-724 
PMID: 12565840 Europe PMC Pubmed  
Table 2.3 Top 20 most abundant genes in placenta 
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Figure 2.2 Overview of bioinformatics analyses 
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a. Schematic overview of PAS-Seq library preparation workflow. b. PAS-Seq 
bioinformatics pipeline schematic.  c. Representative view of read alignment locations 
(top track) and called PAS peaks (bottom track) on the ADAM12 3'-UTR. Our algorithm 
is able to remove background noise, filter out internal priming sites and accurately 
identify true polyadenylation sites. d. Distribution of PAS peaks among named gene 
classes and intergenic regions. 
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2.2.2 EO-PE and LO-PE placentas exhibit distinct gene expression 
signature  
To determine whether the different patient sets had distinct gene expression 
patterns, we next performed Principal Component Analysis with all detected 
genes with sufficient read coverage (total read count across all 17 libraries ≥10; n 
=15,765).  By assessing variability across all samples independent of any 
externally imposed subsets, Principal Component Analysis (aka PCA) allows one 
to determine how closely related individual samples are to one another. For the 
top 2000 most variable genes across all libraries, Principal Component 1, 2 and 3 
accounted for 21.8, 15.4 and 10.4 percent of the variance, respectively.  In a plot 
of Principal Component 1 vs. Principal Component 2, the CTRL samples formed 
a coherent cluster readily distinguishable from the PE samples (Figure 2.3 d).  
Further, the EO-PE and LO-PE samples formed distinct but overlapping clusters 
primarily defined by PC1, with the EO-PE cluster being more distant from CTRL 
than the LO-PE cluster. This suggested that EO-PE and LO-PE had overlapping 
but distinct gene expression signatures. 
 
To define the sets of differentially expressed genes between our three groups, 
we performed pairwise differential gene expression analyses between CTRL, 
EO-PE and LO-PE using DESeq2 (Figure 2.3 e,f, g).  In agreement with the PCA 
analysis, the pair exhibiting the greatest differential expression profile was 
between CTRL and EO-PE (n= 701, padj ≤0.05). The most highly upregulated 
gene in EO-PE compared to CTRL was FLT1 (4.3-fold up), followed by Myosin 
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7B (MYO7B, 3.4-fold up) and Endoglin (ENG, 3-fold up). Other upregulated 
genes previously linked to PE included Inhibin Alpha (INHA, 2.8-fold up), Inhibin 
Beta A (INHBA, 2.5-fold up), Vascular Endothelial Growth Factor A (VEGFA, 2.2-
fold up), MicroRNA 210 Host Gene (MIR210HG, 2.4-fold up) and Pappalysin 2 
(PAPPA2, 2.6-fold up).  Genes exhibiting the greatest downregulation were 
Somatostatin Receptor Type 1 (SSRT1, 4.3-fold down), Signaling Lymphocytic 
Activation Molecule Family Member 1 (SLAMF1, 4.1-fold down), Hyaluronan And 
Proteoglycan Link Protein 1 (HAPLN1, 3.2-fold down) and Cell Adhesion 
Molecule 3 (CADM3; 2.8-fold down).   
 
Overall, 349 genes were differentially expressed at a padj ≤0.01 between CTRL 
and EO-PE (Figure 2.3 e).  Using a variety of online tools like 
GeneCoDis(Nogales-Cadenas et al., 2009; Tabas-Madrid et al., 2012a) 
(Carmona-Saez et al., 2007)and Genomatix, we performed extensive gene 
ontology analyses of this set, using all other expressed 13,299 genes as 
background (table S2 online).  Recurring themes (tables S4 and S5 online) were 
Biological/Cellular Adhesion and the HIF1a, HIF2a, Interleukin 6, Angiogenesis, 
Cadherin, and Wnt signaling pathways, all of which have been previously linked 
to PE (Knöfler and Pollheimer, 2013; Maynard and Karumanchi, 2011; Sitras et 
al., 2009).  Also enriched were Pol II transcription factors and genes with LEF1 
and TATA transcription factor binding sites (padj ≤0.01).  
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Consistent with the PCA, fewer genes were differentially expressed between 
CTRL and LO-PE, with only 40 reaching the padj ≤ 0.01 threshold (Figure 2.3 f). 
Those exhibiting the greatest fold change in LO-PE were Perilipin 2 (PLIN2; 2.1-
fold up), Zinc Finger Protein 175 (ZNF175, 2.1-fold up), Acyl-CoA Synthetase 
Long-Chain Family Member 1 (ACSL1, 2.1-fold up), Dual Specificity 
Phosphatase 15 (DUSP15, 2.3-fold down) and Forkhead Box S1 (FOXS1, 2.3-
fold down). The 97 differentially expressed genes (padj ≤ 0.05; 13,265 
background gene set) were highly enriched for Pol II transcription factors and 
components of the HIF2a signaling pathway (tables S3, S6 and S7 online). 
  
Comparison of the differentially expressed genes in EO-PE and LO-PE revealed 
that they have overlapping but clearly distinct gene expression profiles (Figure 
2.7 c).  Gene ontology terms associated with the 50 differentially expressed 
genes common to both EO-PE and LO-PE (padj ≤0.05) includes the HIF1a, 
HIF2a  and VEGFR1 (FLT1) signaling pathways (table S8 online).  Differential 
expression analysis between EO-PE and LO-PE sets revealed 19 genes 
reaching the padj ≤ 0.05 threshold (Figure 2.3 g), with the genes exhibiting the 
greatest differences being Family With Sequence Similarity 19 Member A2 
(FAM19A2, 2.5-fold higher in EO-PE), Pleiomorphic Adenoma Gene-Like 2 
(PLAGL2f, 2.3-fold higher in EO-PE), TNF Receptor Superfamily Member 10a 
(TNFRSF10A, 1.9-fold higher in LO-PE) and HAPLN1 (1.9-fold higher in LO-PE).  
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Thus, while EO-PE and LO-PE have similar clinical presentations, their distinct 
gene expression signatures suggest different mechanistic drivers. 
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Figure 2.3 Analysis of differentially expressed genes 
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Box-plots of top twenty most abundant transcripts in a. Normal, b. EO-PE, and c. LO-PE 
patients.  Gene expression measured as Counts Per Million (CPM) mapped reads.  Dark 
bar: median; box: 25-75% interquartile; whiskers and dots: range.  d. Principal 
component analysis (PCA) of highly variable genes.  Axes are principal components 1 
and 2 (PC1 and PC2). Each point represents a single patient, with colors indicating the 
patient type as in Figure 2.1 c   Volcano plots showing differential gene expression for e. 
CTRL vs. EO-PE, f. CTRL vs. LO-PE, and g. EO-PE vs. LO-PE.  X axis: log2 Fold 
Change (FC) between samples; Y axis: -log10 false discovery rate after false positive 
removal (padj).  Each dot is a gene:  purple, padj≤0.01; black, padj≤0.05; n, number of 
genes in each group.  h. Venn diagram illustrating overlap of differentially expressed 
genes (padj cutoffs as indicated) between our EO-PE and LO-PE PAS-Seq datasets, two 
published RNA-Seq datasets(Kaartokallio et al., 2015; Sõber et al., 2015)and a large 
meta analysis of available microarray data(Leavey et al., 2015).  i. Scatter plot of FLT1 
RNA expression (CPM) vs. Systolic Blood Pressure (mmHg).  Each point represents a 
single patient, with colors indicating the patient type as in Figure 2.1c. 
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2.2.3 Comparison to previous RNA-Seq and microarray studies 
Numerous other studies have employed microarrays or RNA-Seq to investigate 
differential gene expression in PE. We therefore compared our differentially-
expressed EO-PE and LO-PE gene sets (padj≤0.05) to similar gene sets from two 
recent RNA-Seq studies (Kaartokallio et al., 2015; Sõber et al., 2015) and a large 
scale meta analysis of microarray datasets (Leavey et al., 2015) (Figure 2.3 h).  
As expected from the heterogeneous and multifactorial nature of PE, the gene 
sets reported in the three previous studies were largely non-overlapping (Figure 
2.3 h and 2.7 b).  Our gene lists were most similar to the microarray list (Leavey 
et al., 2015), with 289 of 701 (41%) differentially-expressed EO-PE genes and 32 
of 97 (33%) differentially-expressed LO-PE genes being among the 1295 genes 
(padj≤0.01) in the microarray set.  Notably, only one gene, NRIP1 (nuclear 
receptor-interacting protein 1; aka RIP140), intersected all five lists (Figure 2.3 
h).  Upregulated in all datasets, NRIP1 is a ubiquitously-expressed nuclear 
protein that acts as a co-activator and/or co-repressor for numerous nuclear 
receptor transcription factors (Nautiyal et al., 2013).   
 
The only other differentially-expressed gene reported in ours and all previous 
studies was FLT1.  Although FLT1 did not appear in the list of differentially 
expressed genes in the Kaartokallio et al. study (Kaartokallio et al., 2015), it was 
stated in the text as being differentially expressed. The magnitude of FLT1 
overexpression in PE varies greatly among published reports – whereas the 
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microarray and RNA-Seq values ranged from 1.5 to 2.0-fold (Leavey et al., 2015; 
Sõber et al., 2015), qPCR analyses specifically interrogating the FLT1 locus 
range from 3.86-fold to 4.5-fold above normal(Jebbink et al., 2011; Sõber et al., 
2015).  In our PAS-Seq data, FLT1 was the most highly upregulated gene in the 
EO-PE patient set, exhibiting a 4.3-fold increase relative to the CTRL set 
(padj=2.21E-13; Figure 2.3 e).  FLT1 was also upregulated the LO-PE set, but 
only by 1.9-fold (padj ≤ 0.01; Figure 2.3 f).  Further, consistent with Flt1 
overexpression being a significant driver of clinical symptoms, total Flt1 gene 
expression strongly correlated with systolic blood pressure over all samples (r = 
0.84) (Figure 2.3 i). Flt1 also correlated with body mass index (BMI), but to a 
much lesser degree (r = 0.51, Figure 2.7 d).  Thus our PAS-Seq data validate 
previous findings that Flt1 overexpression is central to PE. 
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Figure 2.4 FLT1 alternative polyadenylation isoform analyses 
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a. Schematic of FLT1 gene and six previously identified mRNA isoforms arising from 
alternative polyadenylation.  Thick boxes: protein coding exons; thin boxes: 3'-UTRs; 
lines: introns; arrows: sFlt1 and mFlt1 polyadenylation sites.  Table shows all previous 
isoform names and new systematic names. b. UCSC genome browser view showing 
PAS-Seq peak distribution on the FLT1 gene for a representative CTRL (top track), EO-
PE (middle-track) or LO-PE (bottom track) patient.  Arrows: sFlt1 and mFlt1 
polyadenylation sites for isoforms in a.  c. Bar graph showing mean expression (counts 
per million; CPM) across all libraries for all 16 detected mRNA isoforms at the FLT1 
locus.  
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2.2.4 Non-coding RNAs and intergenic regions 
In addition to protein-coding genes, our PAS-Seq data also provided expression 
values for numerous non-coding RNAs (Supplementary Table S3).  For example, 
many miRNAs (miRs) derive from long non-coding polyA+ primary transcripts 
(pri-miRNAs)(Lee et al., 2004). Pri-miRNAs exhibiting particularly high placental 
expression include the chromosome 14 and 19 miR clusters (C14MC and 
C19MC, respectively), the miR-371-3 cluster and the mir210 host gene 
(mir210HG)(Mouillet et al., 2015).  C19MC is transcribed by Pol III (Borchert et 
al., 2006), so was not represented in our PAS-Seq data.  Of the remaining three, 
only the mir210HG exhibited differential expression among our patient sets, 
being 2.4 and 1.8-fold increased in EO-PE and LO-PE, respectively, relative to 
CTRL.  Previously shown to be upregulated in PE (Enquobahrie et al., 2008), 
miR210 is known to downregulate the THSD7A gene (Luo et al., 2016).  
Consistent with this, THSD7A was 1.5-fold downregulated in EO-PE (padj≤0.043), 
and 1.3-fold downregulated in LO-PE (although not statistically significant; 
padj≤0.58).  
 
Other differentially-expressed noncoding transcripts with embedded miRNAs 
were DNM3OS (miR214; 1.7-fold down in both EO-PE and LO-PE) and RP6-
99M1.2 (miR221/miR222; 1.6-fold down in EO-PE). Finally, some miRNAs derive 
from the introns or 3'-UTRs of protein coding genes, including SREBF1 (miR33b 
and miR6777; 1.6-fold up in EO-PE, 1.5-fold up in LO-PE), PDCD4 (miR4680; 
 65 
1.5-fold up in EO-PE), and FAM172A (miR2277; 1.4-fold down in EO-PE).  
Among this set, only miR214 has been previously linked to PE, with microarray 
data indicating its downregulation (Xu et al., 2014). Mir214 is thought to regulate 
both PLGF (Gonsalves et al., 2015) and components of the β-catenin pathway 
(Xia et al., 2012), with its own expression being modulated by HIF1a (Gonsalves 
et al., 2015). 
 
Our datasets also included PAS for 170 lncRNAs, 112 anti-sense transcripts and 
133 "processed transcripts" (defined in GenCode as a transcript with no ORF). 
Although nine of these were differentially expressed in EO-PE, LO-PE or both 
(table S3 online), careful examination of the associated PAS peaks on the UCSC 
genome browser revealed that nearly all could be explained by differential 
expression of an overlapping protein coding gene. Thus we conclude that 
differential lncRNA expression is not a general hallmark of PE.  The sole 
exception was TP73-AS1 (downstream of and antisense to TP73, expression of 
which was undetectable in our dataset), a lowly expressed transcript (base mean 
= 62.5 CPM) that was 1.4 fold-downregulated (padj= 0.02) in EO-PE. TP73-AS1 is 
differentially expressed in multiple cancers (Zang et al., 2016), and recent 
evidence suggests that it functions to positively regulate expression of BDH2, a 
cytosolic type 2 hydroxybutyrate dehydrogenase involved in mitochondrial 
function (Zang et al., 2016). While BDH2 expression was 1.4-fold reduced in our 
EO-PE set, this change was not statistically significant (padj=0.15).    
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Finally, we examined the 3,482 intergenic PAS.  Compared to the mean CPM 
distribution for genic PAS, the vast majority of intergenic PAS were lowly 
expressed (Figure 2.5 a), and DESeq2 analysis yielded only 13 and 8 
differentially expressed intergenic PAS in EO-PE and LO-PE, respectively (table 
S9 online).  Many of these were associated with LINE and LTR repeat elements, 
suggesting that activation of select endogenous retroviral elements might occur 
in PE.  For example, three intergenic PAS upregulated in EO-PE lie between the 
LTF and CCRL2 genes in a region containing numerous retroviral elements, and 
an RNA-Seq track of multimapping reads confirmed the existence of an 
independent multiple LTR-containing transcript (Figure 2.5 b). 
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Table 2.4 Differentially expressed intergenic PAS in EO-PE 
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Figure 2.5 Frequency distribution of called peaks and called intergenic PAS 
peaks 
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a. Frequency distribution of called PAS peaks (mean values across all datasets) 
in called genes and intergenic regions. b. UCSC genome browser view of PAS-Seq 
reads (bottom track) mapping to intergenic region between the LTF and CCRL2 genes 
(top track).  Also shown from top to bottom are repeat elements (Repeat Masker track), 
an RNA-Seq track of multi-mapping reads from an EO-PE patient, called genic PAS 
peaks, uniquely mapping PAS-Seq reads from a CTRL patient, called intergenic PAS 
peaks, and uniquely mapping PAS-Seq reads from an EO-PE patient.  
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Location base
Mea
n 
log2Fol
dChang
e 
pvalu
e 
padj log10p
adj 
fold 
chan
ge 
annotation Repeatmaske
r elements 
Cl
as
s 
chr1_1518288
29_151828830 
12.1 -
0.89780
6753 
6.45E
-06 
0.003 2.471
03459
5 
1.9 Upstream of 
THEM5 
LTR61  LT
R 
chr1_1721081
91_172108192 
29.5 -
0.85534
7122 
5.89E
-05 
0.017 1.779
40568
8 
1.8 Intron of DNM3 None 
observed 
– 
chr16_855880
37_85588038 
5.3 0.56211
9321 
3.98E
-05 
0.012
69998 
1.896
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1.5 Upstream of RP11-
118F19.1 and 
GSE1  
None 
observed 
– 
chr5_1799102
92_179910293 
5.1 0.46703
4317 
0.000
2296
4 
0.037
87258
7 
1.421
67502
9 
1.4 Upstream of 
CNOT6 
MLT1J2  LT
R 
Table 2.5 Differentially expressed intergenic PAS in LO-PE 
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2.2.5 All Flt1 isoforms are upregulated in PE 
A major goal of this study was to determine which sFlt1 mRNA isoform(s) to 
target with therapeutic siRNAs (Turanov et al., in preparation). Our PAS-Seq 
data revealed a total of 16 PAS in the Flt1 gene (Figure 2.4 b and c; table S10 
online), including all 6 previously reported Flt1 mRNA isoforms.  Thirteen are low 
abundance, each representing <0.6% of true PAS reads mapping to the Flt1 
locus.  Two previously reported isoforms, sFlt1-i14 (previously sFlt1-v4) and 
sFlt1-e15b (previously sFlt1-v3), were among this low abundance set, so 
contribute little to sFlt1 expression. The four high abundance species are sFlt1-
i13S (previously sFlt1_v1 short 3'UTR), sFlt1-i13L (previously sFlt1_v1 long 
3'UTR), sFlt1-e15a (previously sFlt1_v2) and m-Flt1 (full-length Flt1 mRNA) 
(Figure 2.4 a and b).  Among these, sFlt1-e15a is the most abundant, accounting 
for ~50% of Flt1 PAS reads in all samples (Figure 2.4 b and c). The sFlt1-i13 
short and long isoforms each accounted for 20 to 25% of PAS reads, whereas 
full-length m-Flt1 mRNA represented only ~5% of PAS reads. Thus, at time of 
delivery, sFlt1-i13 short, sFlt1-i13 long and sFlt1-e15a comprise the vast majority 
(88 to 97%) of placental Flt1 mRNAs. 
 
Comparison among datasets revealed that all four high-abundance Flt1 isoforms 
are upregulated in EO-PE vs. CTRL (p ≤0.05; two-way t-test) (Figure 2.6 a). A 
similar trend is also observed comparing LO-PE to CTRL, but only the sFlt1-i13 
long isoform reached statistical significance (p ≤ 0.05; two-way t-test), likely due 
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to the small sample size.  To assess whether this general upregulation of the Flt1 
locus was accompanied by any shift in PAS usage, we examined how the 
fraction of total reads mapping to each of the four major PAS differed among the 
EO-PE, LO-PE and CTRL datasets (Figure 2.6 b). The only statistically 
significant (two-way t-test) differences were a 1.5-fold increase in sFlt1-i13 short 
and a 2.0-fold reduction in mFlt1 in EO-PE compared to CTRL.  Thus in EO-PE, 
use of the sFlt1-i13 short PAS increases at the expense of the mFlt1 PAS.  
Nonetheless, the predominant feature associated with both EO-PE and LO-PE is 
transcriptional upregulation of the entire locus Flt1 locus. 
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Figure 2.6 Differential PAS isoform analyses on FLT1, SDC1 and ADAM12 
genes 
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a. Superimposed scatter plots showing expression (counts per million mapped reads; 
CPM) of the four most abundant FLT1 mRNA isoforms. b. Superimposed scatter plot 
comparing fractions of total PAS reads mapping to the FLT1 locus represented by each 
indicated mRNA isoform. For a. and b., each point represents an individual CTRL, EO-
PE or LO-PE patient with the color indicating patient type as described in Figure 2.1c. A 
two-way t-test was used for statistical comparisons between indicated groups.  
Horizontal line: mean; n.s.: not statistically significant. c. UCSC genome browser view of 
SDC1 gene illustrating differential PAS isoform abundance (Distal-to-Proximal Switch) 
for a representative CTRL (top track), EO-PE (middle-track) or LO-PE (bottom track) 
patient. d. Same as c., but ADAM12 gene (Proximal-to-Distal Switch). 
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2.2.6 Other genes with altered isoform abundances  
The altered Flt1 mRNA isoform abundance associated with EO-PE prompted us 
to ask whether this phenomenon was detectable at any other gene loci.  Using 
one-vs.-others model (see Methods), we observed PAS switches (padj≤0.05) in 
only eight genes in EO-PE compared to CTRL (ADAM12, FLT1, NEAT1, TIMP2, 
CRH, PAPPA, PSAP and SDC1) and only four genes in LO-PE compared to 
CTRL (EIF2A, PSG1, SDC1 and PHLDB2) (online table S11), with SDC1 being 
common to both. The switches were almost equally divided between proximal-to-
distal (n=6) and distal-to-proximal (n=5) isoform shifts. Most of the altered 
isoform abundances were limited to shifts within untranslated regions and so 
were not expected to alter protein isoform ratios.  The exceptions were FLT1 
(discussed above), SDC1 and ADAM12.  In all three cases, the affected mRNA 
isoforms change the ratio of secreted and membrane-bound isoforms. The SDC1 
gene encodes short (secreted or "shed") and long (membrane-bound) forms of 
the major transmembrane heparan sulfate proteoglycan syndecan 1 from mRNA 
isoforms having different PAS (Figure 2.6 c). In both EO-PE and LO-PE, the 
isoform encoding membrane-bound Sdc1 was preferentially upregulated.  
Likewise, ADAM12 expresses two alternate PAS mRNA isoforms, ADAM12-S 
and ADAM12-L, encoding short (secreted) and long (membrane-bound) forms of 
metalloproteinase-disintegrin 12 (Biadasiewicz et al., 2014) (Christians and 
Beristain, 2016) (Figure 2.6 d).  Whereas the entire gene is 1.6-fold upregulated 
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in EO-PE, the ADAM12-L isoform increases more than the ADAM12-S isoform 
(1.8-fold vs. 1.3-fold, respectively).  
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Table 2.6 FLT1 isoforms 
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Figure 2.7 Top 20 abundant genes in normal, EO-PE and LO-PE and 
analyses 
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a. Box-plots of the most abundant transcripts in CTRL, EO-PE, and LO-PE patients. 
Gene expression measured as counts per million (CPM).  b. Venn diagram illustrating 
the overlap of differentially expressed genes between the three previously published 
data sets. c. Venn diagram demonstrating overlap of differentially expressed genes 
between EO-PE and LO-PE in our PAS-Seq data. d. Scatter plot showing correlation of 
FLT1 mRNA expression vs. body mass index (BMI).   
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2.3  Methods 
2.3.1 Human Subjects 
Placentas were collected from CTRL and PE subjects (Table 2.1) in accordance 
with all institutional policies and with approval of the institutional review board at 
the Beth Israel Deaconess Medical Center (Boston, MA, USA). The diagnosis of 
PE was based on the updated criteria of American College of Obstetrician and 
Gynecology Task force on Hypertension in Pregnancy(American College of 
Obstetricians and GynecologistsTask Force on Hypertension in Pregnancy, 
2013). Patients with history of diabetes, chronic hypertension, renal disease or 
multiple gestations were excluded. Pre-delivery maternal plasma samples were 
used to measure circulating sFlt1 and PlGF using commercial ELISA kits (R & D 
systems, MN) as described elsewhere(Goel et al., 2015) 
 
2.3.2 Ethics 
The study was approved by the Beth Israel Deaconess Medical Center 
Institutional Review Board (IRB), #2008P-000061. All subjects provided written 
informed consent for use of placental and blood samples for research.  
 
2.3.3 Tissue collection, storage and RNA isolation 
We excised placental biopsies (2x2 cm) without basal and chorionic plates and 
wiped with cotton gauze to remove blood and debris.  The villous tissue, the 
spongy layer that is in between the decidua (maternal side) and the chorion (fetal 
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side) was collected since it is the main source of sFlt1(Rajakumar et al., 2012). 
These tissue samples were flash-frozen in liquid nitrogen within 30 min of 
placental delivery.   
 
2.3.4 PAS-Seq library preparation 
For preparation of PAS-Seq libraries, we adapted a previously published method 
for making libraries from RNA fragments (Heyer et al., 2015a); (Figure 2.2 a). 
Total RNA integrity was first confirmed by agarose electrophoresis (data not 
shown) and then polyA+ RNA enriched by oligoT hybridization.  PolyA+ RNA 
samples were then fragmented to 60-80 nt via chemical hydrolysis and reverse 
transcribed with one of twelve anchored oligoT oligonucleotides containing 
forward and reverse Illumina sequencing primer sites separated by a hexa-
ethyleneglycol spacer (Sp18) linker.  At the 5′ end, each oligonucleotide began 
with 5'p-GG to promote ligation (Heyer et al., 2015a), followed by 5 random 
nucleotides (unique molecular index, UMI) to enable PCR duplicate removal. 
Each primer also harbored a unique 5 nt Hamming barcode (BC), allowing for 
sample multiplexing (Table 2.7).  Following cDNA circularization with CircLigase 
I, libraries were PCR amplified (12-14 cycles) and subjected to single end 100 nt 
sequencing on the Illumina HiSeq platform in the UMass Medical School Deep 
Sequencing Core. 
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2.3.5 PAS-Seq bioinformatics analysis 
After confirming overall library quality with FASTQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, S.Andrews, 2011), 
we removed duplicate reads with the same UMI. We then used Cutadapt (Martin, 
2011) to trim residual adaptor/spacer sequences and poly-A stretches from read 
3' ends and mapped the reads to hg19 reference genome using Bowtie2 (with 
parameters –m –best –p4). Only uniquely mapping reads with high quality scores 
(>20) were used for further analysis. Such reads represented 70-85% of total 
reads for all libraries.  
 
We defined the polyadenylation cleavage site as the base closest to the poly-A 
stretch captured within read sequence, thus, very last base at the 3’-end site 
after the trimming. Based on this, we calculated read coverages of every 
genomic location considering only 3’-end of the aligned reads. This forms a sharp 
peak of read coverage around the cleavage sites with an average width 40nt 
(ranging between 1nt-120nt). We then clustered sites that are in proximity closer 
than 40nt window and summed the counts of clustered sites. In order to 
determine all possible PAS, which might possibly differ from sample to sample, 
we pooled all candidate locations of all samples and reiterated the clustering 
using the same window length. Since genomic DNA containing poly-A stretches 
can be hybridized and pulled with the oligo-T primers, aka internal priming, we 
used a Naïve Bayes classifier(Sheppard et al., 2013) based software to 
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determine the likelihood of all sites being false priming sites. In addition to 
filtering internal priming locations based on this, we also removed background 
noise caused by widespread base level read alignments by fitting the count 
distribution of each gene to Poisson distribution. After determining precise PA 
locations, we then calculated expression/read counts of every PAS for each 
sample and annotated using Gencode v19. We also marked known polyA sites 
with PolyA DB (http://exon.umdnj.edu/polya_db/). For differential gene 
expression tests, we used sum of all PAS counts of each gene and calculated 
library sizes based on this. The raw read counts for genes were used as an input 
for differential gene expression analyses using DESeq2 (Love et al., 2014) in R 
(https://www.R-project.org). The default normalization using 
'estimateSizeFactors' function was used. Adjusted p-values were calculated 
using the Benjamini and Hochberg method (Benjamini and Hochberg, 1995). In 
order to determine significance levels of alternative polyA site switches, we 
constructed a 2 by 2 contingency table composed of mean normalized read 
counts of one site and the mean of rest of the sites, if there are multiple, in each 
of the condition. We tested the significance with Chi-square test for given site 
and iterated through all sites of the gene. We then corrected p-values for multiple 
hypotheses testing using Benjamini and Hochberg method. 
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Primer name Sequence 
AA-HiSeq RT 
oligodT BC 1 
/5Phos/GGNNNNNATCACAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/i
Sp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTTT
TTTVN-3' 
AA-HiSeq RT 
oligodT BC 2 
/5Phos/GGNNNNNCGATGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 3 
/5Phos/GGNNNNNTAGCTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/i
Sp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTTT
TTTVN-3' 
AA-HiSeq RT 
oligodT BC 4 
/5Phos/GGNNNNNGCTCCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 5 
/5Phos/GGNNNNNACAGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 6 
/5Phos/GGNNNNNCAGATAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 7 
/5Phos/GGNNNNNTCCCGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 8 
/5Phos/GGNNNNNGGCTAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 9 
/5Phos/GGNNNNNAGTCAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
AA-HiSeq RT 
oligodT BC 
10 
/5Phos/GGNNNNNCTTGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/i
Sp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTTT
TTTVN-3' 
AA-HiSeq RT 
oligodT BC 
11 
/5Phos/GGNNNNNTGAATAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/i
Sp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTTT
TTTVN-3' 
AA-HiSeq RT 
oligodT BC 
12 
/5Phos/GGNNNNNGTAGAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT/
iSp18/CTCGGCATTCCTGCTGAACCGCTCTTCCGATCTTTTTTTTTTTTTTTTT
TTTTVN-3' 
Table 2.7 PAS-Seq RT primer sequences 
 
Red represents the Barcodes (BC), V is either base A or C or G, N is any base. 
Sp18 is a spacer.  
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2.4  Discussion 
 Here we present comprehensive differential gene expression and PAS isoform 
abundance analysis of placental RNA from subjects having an abnormal plasma 
angiogenic profile accompanying either EO-PE or LO-PE.  We find that EO-PE 
and LO-PE are distinct conditions with different but related gene expression 
signatures.  Common to both is overexpression of the anti-angiogenic factor 
sFlt1, expression of which strongly correlates with systolic blood pressure (Fig. 
3i).  Our PAS-Seq analysis confirms previous reports identifying sFlt1-e15a as 
the predominant sFlt1 mRNA isoform in both normal and PE placentae 
(Heydarian et al., 2009; Palmer et al., 2015; Sela et al., 2008; Thomas et al., 
2009a), with the next most abundant isoforms being sFlt1-i13 short and long 
(Kendall and Thomas, 1993).  Together sFlt1-i13-short, sFlt1-i13-long and sFlt1-
e15a account for >94% of all sFlt1 expression in both normal and PE placentae. 
This information enabled us to identify siRNAs that decrease sFlt1 expression as 
a potential therapeutic for PE (Turanov et al.). Our observation that all Flt1 
isoforms increase in PE indicates that Flt1 upregulation is primarily a 
transcriptional response.  Intriguingly, the only other gene differentially expressed 
in PE across all transcriptome-wide analyses to date is the transcriptional 
coregulator NRIP1 (RIP140)(Nautiyal, 2017; Nautiyal et al., 2013).   
 
Because sFlt1 is a key negative regulator of angiogenesis in both normal (Ambati 
et al., 2006) and cancerous tissues (Shibuya, 2011), how its production is 
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modulated has been the topic of multiple studies outside the placenta.  One 
condition known to alter sFlt1 expression is hypoxia (Munaut et al., 2008; 
Nagamatsu et al., 2004).  In human microvascular endothelial cells (HMVECs), 
the predominant sFlt1 mRNA isoform is sFlt1-i13-short.  Under hypoxic 
conditions, sFlt1-i13-short levels decrease, but mFlt1 levels are unaffected 
suggestive of a post-transcriptional mechanism (Ikeda et al., 2011).  More recent 
work (Ikeda et al., 2016) identified heterogeneous nuclear ribonucleoprotein D 
(hnRNP D) as a negative regulator of sFlt1-i13-short production, possibly acting 
through binding to an AU-rich element near the sFlt1-i13-short PAS and thereby 
blocking access of the polyadenylation machinery to this location.  That study 
further showed that this inhibitory activity was a function of both overall hnRNP D 
levels and the methylation status of a specific hnRNP D arginine residue.  In EO-
PE placental samples, however, we observed the opposite trend – a small 
increase in sFlt1-i13 short at the expense of mFlt1 (Fig. 5b).  We also observed 
no differential gene expression for arginine methyltransferase (PRMT1), arginine 
demethylase (JMJD6), hnRNP D or any other hnRNP protein (data not shown).  
Thus sFlt1 upregulation in PE appears to be mechanistically unrelated to the 
hypoxia-dependent modulation of sFlt1-i13-short production in HMVECs.  
 
Our data clearly show that all FLT1 mRNA isoforms increase in abundance in PE 
(Fig. 5a), with no general shift toward the more promoter proximal PAS (Fig. 5b). 
When we considered the entire transcriptome, we detected no general 3'-UTR 
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shortening (data not shown) and only eleven statistically significant PAS isoform 
abundance changes overall (Supplementary Table S11 and Fig. 5c, d).  Among 
these, there was no consistent proximal-to-distal or distal-to-proximal switch 
pattern.  Thus there is no general polyadenylation pattern shift associated with 
PE, and alternative polyadenylation is not a major contributor to sFlt1 
upregulation.  Rather our data indicate that the increased sFlt1 expression in PE 
is primarily due to increased transcription of the entire FLT1 locus. 
 
What is driving this increased FLT1 transcription?  Because of its central role in 
regulating angiogenesis, FLT1 transcriptional regulation has been intensely 
investigated in other tissues and several upstream transcription factors including 
EPAS1, PAX3, p53 and ETS have been characterized (Barber et al., 2002; 
Ciribilli et al., 2010; Das et al., 2005; Jinnin et al., 2008; Koyano-Nakagawa et al., 
2015; Menendez et al., 2007). Notably, the differentially expressed gene sets 
(padj≤0.05) in both EO-PE and LO-PE included numerous Pol II transcription 
factors.  Common to both sets were CEBPA, SP3, DLX5, BHLHE40 and 
SREBF1, all of which had increased expression, and ZEB2, which had 
decreased expression. The CEBPA (CCAAT/enhancer binding protein alpha) 
pathway is particularly interesting, as CEBPA is expressed in the labyrinthine 
trophoblasts (the same cells that express Flt1) and has been shown to regulate 
placental development (Begay et al., 2004). 
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Intriguingly, the only other gene identified by every transcriptome-wide gene 
expression analysis method to date (microarray, RNA-Seq and PAS-Seq) as 
being differentially-expressed in PE is NRIP1 (nuclear receptor-interacting 
protein 1; aka RIP140) (Fig.2h).  In all cases, NRIP1 was upregulated.  A 
ubiquitously-expressed nuclear protein, NRIP1 modulates the activities of 
numerous nuclear receptor transcription factors (Nautiyal et al., 2013).  Its best 
understood role is as a regulator of energy expenditure in adipose and muscle 
tissues, but it has also been linked to ovarian fertility and maintenance of a 
pregnancy state (White et al., 2007).  Whether NRIP1 contributes to the 
metabolic syndrome often associated with PE or it directly regulates sFlt1 
expression remains to be explored.  We note that NRIP1 has been implicated in 
the pathogenesis of obesity(Nautiyal, 2017; Nautiyal et al., 2013)a major risk 
factor for PE.  It is possible that upregulated NRIP1 may synergize with anti-
angiogenic factors to induce the endothelial dysfunction ultimately leading to PE.  
 
 
Consistent with previous findings (Junus et al., 2012b), our data suggest that EO-
PE and LO-PE are discrete conditions with distinct gene expression signatures.  
EO-PE was associated with many more differentially expressed genes than LO-
PE, although the small size of our LO-PE dataset (n=3) may have precluded all 
but the most consistently differentially expressed genes from reaching statistical 
significance.  An additional caveat is that some gene expression differences 
could be due to gestational age differences, particularly between the EO-PE 
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(gestational delivery week <34) and CTRL (gestational delivery week >37-40) 
groups.  Nonetheless the HIF1a, HIF2a  and VEGFR1 (FLT1) signaling pathways 
were differentially expressed in both groups, consistent with hypoxia and altered 
angiogenesis being generally associated with PE (Nevo, 2006; Pratt et al., 2014; 
Rajakumar et al., 2001; Soleymanlou et al., 2005).  But unique to the EO-PE set 
were genes involved in Biological/Cellular Adhesion and the Interleukin 6, 
Cadherin, and Wnt signaling pathways.   This suggests that EO-PE placentae 
may have defects in epithelial to mesenchymal transition which may lead to 
defective trophoblast invasion noted in this syndrome (E Davies et al., 2016). 
 
Due to its highly heterogeneous presentation, definitive diagnosis of PE based 
solely on maternal signs and symptoms can be erroneous (Luef et al., 2016; 
Malshe and Sibai, 2017).  A variety of underlying conditions can serve as 
mechanistic drivers, confounding gene expression analysis of diverse patient 
populations.  Differences in sample collection methodologies across institutions 
can also introduce variability.  These factors likely explain the relatively poor 
overlap among prior transcriptome-wide analyses of placental gene expression in 
PE (Fig. 2h).  For the current study, we aimed to eliminate as many variables as 
possible. In addition to using highly selective criteria for PE diagnosis based 
solely on quantitative measures (Fig. 1c) and excluding known confounding 
drivers (e.g., multi-parity, preexisting hypertension and gestational diabetes 
mellitus), all samples were collected by the same personnel in a single hospital, 
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all libraries were prepared by a single researcher, and all sequencing was 
performed on a single instrument.  Therefore our libraries should represent highly 
coherent sets.  Nonetheless, our study does have its own limitations.  Because 
all but one PE subject delivered at ≤36 weeks gestational age, whereas all CTRL 
patients delivered closer to term (≥37 weeks), PE and CTRL placentas were not 
gestationally matched.  Therefore, additional studies using placentas delivered 
for other medical reasons (e.g., preterm labor) will be needed to evaluate which 
gene expression changes, if any, are simply attributable to earlier gestational age 
in the PE subjects.  As stated above, our study was also limited by small sample 
size particularly for the LO-PE group (n=3). Future studies with adequate sample 
numbers are need to fully characterize the transcriptional signature specific to 
LO-PE. 
 
In addition to assessing protein-coding genes, we interrogated our PAS-Seq data 
with regard to non-coding and intergenic transcripts.  While we found little 
evidence of differential lncRNA expression in PE, our data do suggest a potential 
association between EO-PE and endogenous retroviral element activation.  Thus 
it may be of interest to interrogate repeat-associated transcripts in existing PE 
placenta RNA-Seq data (Sõber et al., 2015) (Kaartokallio et al., 2015)  Our PAS-
Seq data also confirm upregulation of mir210 and downregulation of mir214 in 
PE (Enquobahrie et al., 2008). Thus, some gene expression differences 
associated with PE are likely driven by post-transcriptional mechanisms.  
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3. CHAPTER III: PILOT SCREENING of siRNAs AGAINST Homo sapiens 
and Mus musculus sFlt1 mRNAs 
 
 
 
PREFACE: 
 
This work is unpublished and was conducted by me in Dr. Melissa J. Moore’s 
laboratory. The work presented here is a proof-of-concept study to knockdown 
sFlt1-i13 in cells using cloning, transfection and RNAi technology.  
 
Additionally, this chapter also describes the siRNA sequences that effectively 
knock down both mammalian sFlt1 and mice sFlt1. In Chapter III, I lay the 
foundation for Chapter IV. In Chapter IV, the siRNAs selected from Chapter III 
were chemically modified for efficient uptake and animal studies in collaboration 
with Dr. Anastasia Khvorova.  
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3.1. Introduction 
 
Alternative polyadenylation (APA) of human mRNAs is emerging as a major 
source of posttranscriptional diversity. APA generates mRNA isoforms that can 
even encode functionally different proteins. It has been estimated that around 
20% of human genes undergo AP events in introns, termed intronic 
polyadenylation (IPA)(Di Giammartino et al., 2011; Tian et al., 2005). A striking 
example of this phenomenon is Fms like tyrosine kinase receptor (Flt1) where 
the switch from a canonical 3’UTR site to an upstream intronic site leads to 
expression of a soluble form of the protein called soluble Flt1 receptor protein 
(sFlt1). Preeclampsia  occurs in 5-8% of pregnant women in the United States 
and 2-16 % pregnant women worldwide, with high morbidity and mortality for 
both the mother and the fetus. It has been shown that prolonging gestation 
period during PE leads to higher chance of infant viability. Reduction in levels of 
sFlt1 protein in preeclamptic patients enables such an increase in gestation 
length.  Recent data has shown that a one-time reduction of sFlt1 by 30-40% is 
enough to prolong PE pregnancies by 14-21 days(Thadhani, 2010; Thadhani et 
al., 2011; 2016). They also reported an improvement in proteinuria and blood 
pressure. This elongation in gestational time is especially crucial for EO-PE 
where the lungs of the infants are not yet completely developed.  
Given all the background, we were interested and motivated to develop siRNA-
based therapy for PE. We are convinced that this is an ideal approach, because 
as opposed to antibodies and small-molecules, siRNAs are relatively cheaper to 
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produce.  siRNA’s have a stable shelf life and require no refrigeration if delivered 
as a lyophilized powder. In the developing world, shortage of electricity and 
infrastructure leads to issues with refrigeration. This problem can be tackled with 
siRNA therapy. The adsorption device therapy would also be very expensive and 
out of reach for majority of the patients in the developing world.  
sFlt1 is an attractive and validated target that has been shown to improve 
outcome for the neonate(Thadhani et al., 2011). The half-life of circulating sFlt1 
in the mother’s blood-stream is ~ 6 hours(Powers et al., 2005). Additionally, it has 
been reported that on knockdown of Flt1 and sFlt1 in the placental cells 
(trophoblasts) specifically, the mice develop normally(Hirashima et al., 2003). All 
this evidence suggests that siRNA based approach will reduce sFlt1 and prolong 
the preeclamptic pregnancy. The placenta is the main source of sFlt1 (Jebbink et 
al., 2011) (Figure 2.1 b)and we hypothesize that reducing sFlt1 is less likely to 
affect other organs of the mother and fetus. Also, sFlt1 is not required in the mice 
model and therefore reducing sFlt1 is not going to affect the fetal development.  
Currently there are several therapeutic siRNAs in clinic for various 
diseases(Khvorova, 2017; Tiemann and Rossi, 2009) siRNAs produce 
sequence-specific silencing and have several advantages over other rRNA 
based approaches like shRNA or miRNA. Their in vivo half-lives are enough to 
produce a silencing effect 2-3 weeks post-injection. We therefore hypothesize 
that modulation of sFlt1 pre-mRNA using siRNAs could be a potential therapeutic 
 96 
approach to alleviate PE.  
My goal was to identify siRNAs that would reduce the sFlt1-i13 isoform. Such a 
manipulation should reduce levels of sFlt1 mRNAs and in turn the soluble sFlt1 
protein. Given the fact that the 3’UTR of sFlt1-i13 is distinct from the mFlt1, we 
designed siRNAs that targeted the 3’UTR of sFlt1-i13 isoform. From Chapter II, 
we have seen that the two isoforms sFlt1-i13 S and sFlt1-i13 L share a common 
region. We hypothesized that we design siRNAs targeting that region of overlap; 
we would be able to reduce both the isoforms with a common siRNA. Due to use 
of a polyadenylation site internal to intron 13, the sFlt1-i13 mRNA includes 
intronic sequences not present in full-length Flt1 mRNA. 
As reported previously (Thadhani et al., 2010) the goal here was to knockdown 
sFlt1-i13 levels by 30-40% and not complete 100% knockdown. We wanted to 
aim for transient silencing (6-8 hours) and aiming for long-term (weeks) silencing. 
By using synthesized siRNAs we were at advantage as we skipped the 
intermediate siRNA-processing step by Dicer. Designing the siRNAs was done 
by first conducting a BLAT search to ensure that there was no match between 
the sequence of interest and other genes. Then the best siRNAs were selected 
based on various criteria (see Methods).  
Additionally, we also wanted to design siRNAs against the sFlt1-e15a isoform. 
However, at the time of this experiment, we wanted to test the siRNAs in mice. 
Mice do not express the sFlt1-e15a isoform, so we initiated the pilot study by 
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targeting sFlt1-i13 S and sFlt1-i13 L isoforms.  
To this end, a luciferase reporter system was used to clone the 3’-ends of sFlt1-
i13. Co-transfection assays were used where the plasmid containing the cloned 
sFlt1-i13 3’-UTR and the siRNA were transfected in HEK-393 cells using 
lipofectamine.  
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Figure 3.1 Position of tested siRNAs on sFlt1-i13 S 
Red lines represent the target sequence. The sequence in black represents the 
sFlt1-i13 3’UTR. siRNAs targeting the sequence are labeled.  
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3.2. Results 
3.2.1 Pilot screening of anti-human-sFlt1 siRNAs in 393-D1 cells 
In order to find an anti-sFlt1-i13 siRNA and determine the efficiency of the 
siRNAs, we first cloned the sFlt1-3’UTR  (Figure 3.1) in a psiCheckTM Vector.  A 
total of ten siRNAs were designed to target and tiled across the sFlt1-i13-3’-UTR 
(Figure 3.1). In a co-transfection experiment, each anti-sFlt1 siRNA and the 
plasmid carrying 3’-UTR was transfected in HEK-393 cells. These siRNAs were 
transfected “naked” i.e. the siRNAs were not chemically modified and did not 
have any conjugations added to their 5’ or 3’ends. The advantage of using the 
psiCHECKTM reporter vectors is the presence of both firefly and renilla luciferase. 
The sFlt1-i13 3’UTR was cloned downstream of the renilla luciferase gene and 
firefly is was used as a normalization control. The luciferase activity was 
measured by a luminometer and IC50 values (Table 3.3) were determined from 
dose response curves (Figure 3.2). 
 
3.2.2 Two highly efficient anti-sFlt1 siRNAs identified 
Given their potency and low IC50 values, siRNAs H29 and H33 were chosen for 
further study in fresh trophoblast villous cultures derived from preeclamptic 
human placentas (Chapter IV). These siRNAs gave efficient knockdown of sFlt1. 
They were further used in mice model. For delivery in the animal, the siRNAs 
have to be chemically modified for uptake and delivery. The siRNAs used in this 
pilot study were without any modifications or conjugations and therefore not 
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suitable for studies in mice. 
3.2.3 Pilot testing of anti-mice-sFlt1 siRNAs in 393-D1 cells 
Using the  psiCHECKTM Vector system, I cloned the mice sFlt1-i13 3’-UTR. 
Using the same methods as for human sFlt1 siRNAs,  I also identified siRNAs 
capable of decreasing expression of mouse sFlt1 (Table 3.2, sense strand 
sequences: M504, 5'- AGUAACAGUUGUCUCUUAUUU-3'; and M506, 5'-
ACUUUCAGGCCCAGAGGAAUU-3'). These siRNAs were used in Chapter IV to 
assess in vivo efficacy of this silencing approach.  
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Number siRNA  Sense Strand Sequence 
1 H27 5' -GGAGAUGAUAGCAGUAAUAUU -3' 
2 H29 5'- CCACACAAAGUAAUGUAAAUU -3' 
3 H31 5'- CGGAGAUGAUAGCAGUAAUUU -3' 
4 H33 5'- UCUCGGAUCUCCAAAUUUAUU -3' 
5 H35 5'- AGUAACAGUUGUCUCAUAUUU -3' 
6 H37 5'- CCAAAAUGAGUUCGGAGAUUU -3' 
7 H39 5'- GUUUGUUGCUCUUGCUGUUUU -3' 
8 H41 5'- CCCAAAAUGAGUUCGGAGAUU -3' 
9 H43 5'- UGUCACUGUUGCUAACUUUUU -3' 
10 H45 5'- GAGAUGAUAGCAGUAAUAAUU -3' 
 
Table 3.1 Sequence information of tested human siRNAs 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Sequence information of mice siRNAs 
 
 
 
Number siRNA  Sense Strand Sequence 
1 M504  5'- AGUAACAGUUGUCUCUUAUUU -3' 
2 M506 5'- ACUUUCAGGCCCAGAGGAAUU -3' 
3 M508 5'- UGGACAUGAUAACGUAAUAUU -3' 
4 M510 5'- CCGGUGUGUGUUUGGAUUUUU -3' 
5 M512 5'- UGCCAAAGACGGACAUGAAUU -3' 
6 M514 5'- GUAAAUAGUUCCUGGAUAAUU -3' 
7 M516 5'- UGUGUUUCCUGCUGUGUUAUU -3' 
8 M518 5'- CACCAAGCUUUGAUGGCAUUU -3' 
9 M520 5'- AGUGGAGAUUUAAUGCAAUUU -3' 
10 M522 5'- ACCCAUGAGAGAAAGAAAAUU -3' 
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Figure 3.2 siRNAs against human sFlt1-i13 isoforms 
Different concentrations of the human anti-sFlt1-i13 siRNAs were tested and 
renilla and firefly activity was measured. X-axis is the concentration of siRNA (in 
nM). Y-axis is the normalized renilla to internal firefly luciferase ratio.  
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Figure 3.3 siRNAs against mouse sFlt1-i13 isoform 
Different concentrations of the mice anti-sFlt1-i13 siRNAs were tested and renilla 
and firefly activity was measured. X-axis is the concentration of siRNA (in nM). Y-
axis is the normalized renilla to internal firefly luciferase ratio.  
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Table 3.3 siRNA IC50s and efficiencies 
H denotes human and M denotes mice  
 
siRNA IC50 [nM] Efficiency 
H27  0.46 ± 0.05  35% 
H29  1.2 ± 0.1  88% 
H31  1.5 ± 1.1  51% 
H33  0.8 ± 0.3  95% 
H35  2.8 ± 0.8  26% 
H37  Not detected  NA 
H39  1.5 ± 0.1  66% 
H41  2±8  62% 
H43  0.09 ± 0.1  13% 
H45  0.6 ± 0.4  30% 
M504  0.10 ± 0.03  89% 
M506  0.5 ± 0.2  76% 
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3.3. Methods 
3.3.1. Plasmids 
psiCHECKTM  reporter vectors (Promega, USA) were used to optimize the RNAi 
experiment. The vector is especially designed to quantify the effect of RNAi. The 
vector consists of 2 luciferases- Firefly and Renilla. The firefly is used as a 
normalization control and the sequence of interest is cloned under renilla 
luciferase.  The insertion sites for sFlt1-i13 3’UTR were constructed by digesting 
the vector with XhoI and NotI and inserting the 3′ UTR target site-containing 
XhoI–NotI sites downstream of renilla reporter gene. The new plasmid was called 
psiCHECK-sFlt-i13-3’UTR.  Dual Reporter Luciferase assays were conducted 
using Dual-Luciferase Reporter Assay reagents (Promega) in a Veritas 
Microplate Luminometer according to the manufacturers’ directions. 
 
3.3.2. Cell Culture and Transfection 
NIH-3T3 cell cultures were maintained at 37ºC and 5% CO2 in DMEM 
supplemented with 10% FBS and 50 U/ml ampicillin. Briefly, to test the efficacy of 
siRNAs targeting this region, we inserted the appropriate sequences from both 
human (Figure 3.1) and mouse (not shown) downstream of Renilla luciferase in 
the psiCHECKTM Vector system (Promega). This construct was transiently 
transfected into NIH3T3 cells along with 0-20 nM of each test siRNA, and then 
Renilla and Firefly luciferase activities measured 48 hours later. Cells were 
seeded at a density of 1.1 × 106 cells per well in 24 well plates in DMEM 
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(Invitrogen) containing 10% FBS (Invitrogen) twenty-four hours before the day of 
transfection. On the day of transfection experiment, 25ng/ul of psiCHECK-sFlt-
i13-3’UTR in DMEM and lipofectamine and siRNAs ranging from 0 to 20nM 
concentrations were incubated for 20 minutes. After 20-minute incubation period 
the mixture was added to each well individually. The cells were then incubated at 
37°C in a CO2 incubator for 4 hours. Luciferase was measured 48 hours post-
transfection.  A control siRNA (scrambles sFlt1-3’UTR sequence) was used to 
equalize the total amount of siRNA in each transfection.  
3.3.3. Luciferase Assays  
The screening of siRNAs was performed using the luciferase reporter assays. 
Cells were washed once in 500 µl PBS and lysed in 100 ml of Passive Lysis 
Buffer (Promega) at room temperature for 20 min in 24 well plates. For each well 
10 µl 55 lysate was read in triplicate using dual luciferase reagents (Promega) in 
the luminometer. The renilla and control firefly luciferase activities were 
measured 40 hours post-transfection. The normalized reporter activity was 
measured by dividing renilla luciferase by firefly luciferase in the same sample. 
This allowed to also normalize for transfection efficiencies.  
 
3.3.4. Data Analysis  
The individual biological replicates for normalized Renilla luciferase activity 
versus siRNA concentration was fit using Igor Pro 6.10 software. The Hill 
equation was used to determine IC50.  
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3.4. Discussion 
 
The role of sFlt1 as a causative factor of PE symptoms is well established.  sFlt1 
is a validated target and studies report that a 30-40% reduction in sFlt1 levels 
ameliorates high blood pressure and proteinuria in PE patients. The approach of 
apheresis is a proof-of-concept study and it uses expensive machine. Our goal 
here was to develop a PE therapeutic, which would be affordable not only in 
developed countries but also in developing countries siRNAs have a lot of 
advantages like relative cheap cost of manufacturing, stable shelf-life, no need 
for refrigeration and ease of delivery in the body. Here, we aimed to identify 
efficient anti-sFlt1 siRNAs.  
 
 
I performed in vitro screening of synthetic, “naked” siRNAs using a luciferase-
reporter assay in NIH3T3 cells. Two sequences against human sFlt1-i13 were 
identified which were expanded further in Chapter IV. The work here 
demonstrates that knockdown of sFlt1-i13- 3’UTR is an effective way to 
knockdown the mRNA laying the foundation for further RNAi therapeutics to treat 
PE. 
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4. Chapter IV: DEVELOPING anti-sFlt1 siRNAs to alleviate preeclampsia  
 
 
 
Chapter IV was taken verbatim from the following manuscript, which is 
preparation during the time of this thesis submission.  
 
Anton  A. Turanov, Matthew R. Hassler, Ami Ashar-Patel, Angela Makris, Agnes 
Lo, Julia F. Alterman, Andrew H. Coles, Reka A. Haraszti, Loic Roux, Bruno 
MDC Godinho, Dimas Echeverria, Annemarie Hennessy, S. Ananth Karumanchi, 
Melissa J. Moore, and Anastasia Khvorova  
Developing anti-sFlt1 siRNAs to alleviate preeclampsia 
 
 
Author contributions statement:  
A.A.T., M.R.H. and J.F.A designed and M.R.H and D.E synthesized all 
compounds. A.A.T., A.H.C., B.DMC.G. and A.L. conducted all in vivo 
experiments and imaging.  A.A.T., A.AP. and J.F.A conducted all in vitro 
screening and data analysis.    R.A.H. developed and conducted PNA analysis.  
A.K., M.J.M, A.A.T., S.A.K. came up with the concept and wrote the manuscript. 
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4.1. Introduction 
The most notable characteristics of PE are hypertension, edema and excess 
protein in the urine (proteinuria) after the 20th week of pregnancy. Consequences 
for the fetus can be grave, ranging from small-for-gestational-age infancy to 
hypoxia-induced neurologic injury (e.g., cerebral palsy) to death.  Maternal 
complications include renal failure, HELLP syndrome (hemolysis, elevated liver 
enzymes, and low platelets), seizures, stroke, and death.  PE and related 
hypertensive disorders are causing close to 76,000 maternal and 500,000 infant 
deaths globally each year.  In the US, PE is responsible for 100,000 premature 
births and 10,500 infant deaths yearly, at a yearly cost of roughly 7 billion dollars 
(3 billion for maternal disabilities and 4 billion related to infant morbidity) to the 
US health care system (www.preeclampsia.org). Thus PE represents a highly 
significant unmet public health need. 
 
Overwhelming evidence from epidemiological and experimental studies indicates 
that PE is caused by elevated levels of "soluble decoy" proteins (soluble FLT1s; 
sFlt1s) in the mother's blood stream expressed from the Flt1 gene (aka, 
VEGFR1)(Heydarian et al., 2009; Levine et al., 2004; Maynard et al., 2003; 
Young et al., 2010) (Aubuchon et al., 2011).  FLT1 is a receptor tyrosine kinase 
(RTK) predominantly expressed in the placenta.  A general mechanism for RTK 
modulation is production of truncated, secreted forms of the receptor that act as 
dominant negative regulators of the overall signaling pathway.  Ligand 
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sequestration by such soluble decoys inhibits intracellular signaling by the full-
length receptor, thereby desensitizing the system to ligand concentration(Vorlová 
et al., 2011).  In the case of FLT1, the soluble decoys are expressed from 
truncated mRNAs generated by polyadenylation sites within two introns (sFlt1-i13 
and sFlt1-e15a) upstream of the exons encoding the fl-FLT1 transmembrane 
(TM) and kinase domains. 
 
FLT1 is predominantly expressed in the placenta, with human placental FLT1 
mRNA levels being 10-100 times higher in other adult tissues(Cerdeira and 
Karumanchi, 2012).  The full-length isoform predominates in all tissues in non-
pregnant adult humans(Cerdeira and Karumanchi, 2012), whereas placental 
expression is dominated by three truncated isoforms, sFlt1-i13 short, sFlt1-i13 
long and sFlt1-e15a, all of which encode sFlt1 proteins (Figure 4.1.A).  This 
same pattern of high FLT1 in placenta and low expression in other non-pregnant 
adult tissues is observed in rodents.  However, because rodents lack the intron 
14 polyadenylation site, they only express a single soluble decoy form:  sFlt1-
i13(Sela et al., 2008).  In PE, both full-length and truncated FLT1 mRNAs 
accumulate to higher levels in the placenta than in normal pregnancies, with the 
truncated isoforms being even more pronounced (Figure 4.1.B).  These changes 
at the mRNA level likely explain the significant rise in sFlt1 proteins in the 
maternal bloodstream during PE. 
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sFlt1 level have been recently identified and as a biomarker for PE, helping to 
discriminate between other cause of high blood pressure and proteinuria. 
Thus selective modulation of sFlt1 is believed to be a viable clinical approach. As 
difference between sFlt1 and full length FLT1 on a protein level is minimal, 
attempts to develop antibodies and small molecules selective for the sFlt1 were 
not successful.  
The alternative strategy of apheresis of the PE patient's blood with dextran 
column which eliminates sFlt1 (as well as other circulating factors) was shown to 
extend pregnancies and control blood pressure and proteinuria, clinically 
validating sFlt1 as a therapeutic target(Thadhani et al., 2011; 2016). While 
difference on the protein level is minimal, sFlt1-i13 and sFlt1-e15a isoforms have 
relatively large RNA regions, which are unique to sFlt1 producing mRNAs, and 
thus can be targeted for selective modulation of sFlt1 expression. siRNA are new 
class of therapeutic modalities, which directly target mRNA in a sequence 
selective manner and are ideal for differential modulation of FLT1.  
 
4.2. Results 
 
4.2.1. sFlt1-i13 and sFlt1-e15a isoforms of FLT1 are overexpressed in 
human placentas 
Overexpression of sFlt1 is one of the key molecular mechanisms behind PE. 
There are several alternative polyadenylation variants exists which produce the 
same sFlt1 protein(Thomas et al., 2010; 2009a). The major isoform are based on 
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use of two polyadenylation signals after exon 13 and 15 generating sFlt1-i13 
short and sFlt1-i13 long isoform and sFlt1-e15a truncated mRNAs. All of these 
truncated variants are responsible for expression of soluble FLT1, which lack the 
transmembrane domain of full length FLT1 (fl-Flt1). To evaluate which of these 
isoforms are clinically relevant we compared sFlt1-i13 and sFlt1-e15a expression 
in placentas derived from CTRL and PE pregnancies. By performing 
polyadenylation site sequencing (PAS-Seq) on total RNA from multiple normal 
and PE placentas, we have shown that PE placentas overexpress sFlt1-i13 and 
sFlt1-e15a mRNAs with sFlt1-i13 being responsible for ~45% of reads and sFlt1-
e15a ~55% (Chapter II, Figure 4.1.A-B). The intrinsic variability in isoform ratios 
in different samples suggests that targeting both isoforms might be the best 
option to cover the majority of PE patients. The common region between sFlt1-
i13 short and sFlt1-i13 long and sFlt1-e15a are unique and present only in 
truncated sFTL1 mRNAs and their target allows selective modulation of sFlt1 
without effect on full length FLT1 expression, which is critical for the safety of 
future therapy. 
 
4.2.2. Screen to identify hsiRNAs selectively silencing sFlt1-i13 and 
i15 sFlt1 isoforms 
Using standard bioinformatics criteria we have designed and synthesize all 
possible siRNAs targeting sFlt1-i13 S and sFlt1-e15a isoforms( Chapter III and  
(Figure 4.1 C-E) show the screen of compounds targeting sFlt1-i13 and sFlt1-
e15a unique regions with numbers denoting the siRNA targeting positions. The 
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exact chemical configuration and sequences of all oligonucleotides used in the 
study are shown in Supplemental Table1. For top five compounds from each 
screen, the concentration curves were generated using luciferase reporter 
constructs in HeLa cells or directly in primary cytotrophoblast  (CTB) and WM-
115 melanoma cells.  Based on this data the compounds 2283 and 2318 
targeting sFlt1-i13 and 2519 and 2585 targeting i15a were selected for detailed 
evaluation (Figure 4.1 E-F). Figure 4.1.G-J  shows concentration curve dose 
response using reporter assay in HeLa cells and after the treatment of primary 
CTB on mRNA level.  sFlt1 mRNA silencing was also responsible for reducing 
soluble Flt1 protein in CTB conditioned media as well (Figure 4.1 K).  Although 
initial screen was performed on mRNA sequences for human sFlt1-i13 isoforms, 
target sequence for compound 2283 shares hundred percent identity between 
mouse, baboon and human.  Having such compound as a lead candidate 
facilitates in-vivo validation in pre-clinical rodent models. Thus pair of compounds 
2283 and 2519 was further selected for in-vivo evaluation with 2318/2585 serving 
as a backup. 
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Figure 4.1 Development of hydrophobically modified chemically stabilized 
siRNA compounds against sFlt1 
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a. Schematic representation of exon-intron structure of sFlt1 i13 and sFlt1-e15a 
isoforms. b. Identification of  alternative FLT1 mRNA polyadenylation sites in human 
placentas. Total RNA was isolated from 5 normal and 6 preeclamptic human 
placentas and analyzed by Polyadenylation Site sequencing (PAS-Seq). c-d. 
Systematic screen for identification of hsiRNA targeting sFlt1-i13 and sFlt1-e15a in 
luciferase reporter assay in HeLa cells (Dual-Glo, Promega). HeLa cells were 
transfected with sFlt1 reporter plasmid (psiCheck-2, Promega) and treated with 
hsiRNAs (2.5 mmol/l, passive uptake) and luciferase expression was measured 72-
hours after treatment with siRNA. (n=3, mean + SD)   e. sFlt1-i13 and sFlt1-e15a 
mRNA sequences. Locations of leading  siRNAs hits are indicated (underlined). Stop 
codons are shown in red. f. hsiRNAs targeting sFlt1-i13 and sFlt1-e15a. g-j. 
hsiRNAsFlt1  validation and activity in vitro. HeLa, transfected with sFlt1 reporter 
plasmid or CTB cells were incubated with siRNA at concentrations shown for 72h. 
mRNA levels were measured using Dual-Glo System (Promega) normalized to 
background gene  (hluc+) (HeLa, g, h) or QuantiGene® (Affymetrix) normalized to  
housekeeping gene (YWHAZ) (CTB, i, j) (n=3, mean + SD). k. sFlt1 protein 
knockdown in human trophoblasts. sFlt1-i13-2283 siRNAsFlt1 and NTC siRNA were 
added to CTBs at concentration shown. Level of sFlt1 protein was measured by 
ELISA (#MVR100, R&D systems) in conditioned culture medium after 72 h. CTB – 
cytotrophoblast cells (from placenta); UNT – untreated cells; NTC – non-targeting 
control with matching chemistry. 
 
 
 
 
 117 
 
4.2.3. Efficient delivery of fully chemically stabilized hydrophobically 
modified siRNAs to placental labyrinth 
 
To achieve placenta delivery, we have used an asymmetric siRNAs, with a 
short duplex region (15 base-pairs) with single-stranded, fully 
phosphorothioated tail, where all bases are fully modified using alternating 
2'-fluoro and 2'-O-methyl modification pattern, and the 3' end of the 
passenger strand is conjugated to a bioactive hydrophobic conjugate 
(TEG-Cholesterol). The cholesterol enables quick membrane association, 
while the single-stranded phosphorothioated tail is essential for cellular 
internalization by a mechanism similar to that used by conventional 
antisense oligonucleotides ((Alterman et al., 2015),(Hassler and 
Khvorova) (Navaroli et al.)) (Figure 4.2.A). We and others have screened 
a wide range of chemical variants and identified that an alternating 2’-
fluoro/2'-O-methyl pattern optimally configures the guide strand to adopt a 
geometry that closely mimics that of an individual strand in a A-form RNA 
duplex, is recognized by the RISC . Modified siRNAs are as effective as 
"naked" (unmodified) siRNA in RISC entry and represent the complete 
chemical modification pattern with no negative impact on RISC function. 
Fully chemical stabilization is absolutely essential for non-formulated 
siRNA delivery upon systemic administration. 
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Figure 4.2 Modified siRNA enables selective delivery to placental labyrinth 
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 a. Structure of chemically modified siRNA. b. siRNAsFlt1 distribution in mouse placenta. 
C57BL/6J mice (E15) were injected with Cy3-labeled 2283 siRNAsFlt1 (red) (10 mg/kg; IV 
tail vein or SC interscapular). Twenty-four hours later mice were sacrificed, tissues fixed  
and 4 mm sections were used for microscopy. Nuclei were stained with DAPI (blue). 
Matched slides were stained with hematoxylin and eosin (HE). Images were captured 
using Leica DM5500B fluorescent microscope with 10x and 63x objectives. All images 
were acquired at identical settings. Images were processed with LAS AF software 
package (Leica). Scale bars - 1 mm (upper panels) and 25 mm (lower panels). c. 
siRNAsFlt1 distribution in mouse fetus. C57BL/6J mice (E15) were injected with Cy3-
labeled 2283 siRNAsFlt1 (red) (10 mg/kg; IV tail vein). Twenty-four hours later mice were 
sacrificed, tissues fixed  and 4 mm sections were used for microscopy. Nuclei were 
stained with DAPI (blue). Representative image of two experiments. d-e. Amount of 
siRNAsFlt1 accumulated in tissue measured by PNA hybridization assay in mice from b. 
(n=3, mean + SD). TGC –Trophoblast Giant Cells; SpT –SpongioTrophoblast;  L – 
Labyrinth; Jz – Junctional zone; D – Decidua. 
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4.2.4. Systemic administration of siRNA in vivo resulted in efficient    
delivery to placental labyrinth 
To evaluate siRNAs potential for placenta targeting, wild-type (WT) pregnant 
mice (gestation day 15) were injected with Cy3-labeled siRNAsFlt1 2283 and 
distribution examined by two independent assays. Fluorescence microscopy 
revealed that most of the siRNAsFlt1 accumulated to three tissues: liver 
endothelium, kidney endothelium and placental labyrinth (Figure 4.2.B). This 
distribution profile is most likely defined by a combination of blood flow/filtration 
rate. In placenta we observe efficient delivery to CTB cells in labyrinth with 
effectively no uptake in a decidua. Placenta labyrinth mostly consists of CTB 
trophoblasts, primary cell type responsible for sFlt1 overexpression. Efficient 
siRNAsFlt1 delivery to placental labyrinth consistent with its primary function as a 
barrier (blood-placental-barrier) and active nutrient transporting organ between 
mothers and fetus blood (Figure 4.2.B). 
 
While we have observed efficient delivery to placenta, the compounds do not 
cross into the fetus (Figure 4.2.C). To quantitatively estimate oligonucleotides 
tissues accumulation we evaluated guides strand tissue concentration using 
recently developed PNA-hybridization assay (ref and see methods). While 
majority of cholesterol-conjugated siRNA goes to liver, we observe around 7% 
injected dose accumulated in placentas. With same assay, the siRNAs 
concentration fetus lever fell below the detection level. We observe 
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approximately 10-20 ng/mg placenta accumulation at 24 hours, which exceed 
concentrations theoretically necessary to induce silencing (Figure 4.2.D-E). 
4.2.5. Efficient in vivo modulation of sFlt1 in placenta have no impact 
on mouse progeny survival and ability to strive 
Mice express only one truncated form of sFlt1- i13. The siRNAsFlt1 2283 identified 
in initial  screen hit the site fully complementary in mice, human and NHP 
allowing evaluation of compound efficacy in multiple animal models. The primary 
source of circulating sFlt1 is placenta with level of placental expression 
exceeding maternal tissues by orders of magnitude. To estimate ability of 
systemically delivered siRNAsFlt1 2283  to silence sFlt1 in placenta  WT pregnant 
mice were injected twice with 20 mg/kg at gestational days 14 and15 with 
siRNAs (Figure 4.3.A). Animals were sacrificed and levels of sFlt1 silencing was 
evaluated in placenta (Figure 4.3.B), maternal tissues and fetal livers).  
We observed statistically significant silencing in mouse placenta. The effect was 
specific to siRNAsFlt1 2283 where as non targeting control (NTC), siRNA of the 
same chemical composition, was inactive. The productive silencing in placenta 
was only observed with cholesterol conjugated siRNAs, as non- conjugated 
compounds (NoC- siRNAsFlt1 2283) shown no significant efficacy. In addition 
there was no silencing in the fetal livers consistent with lack of delivery. Levels of 
fetal sFlt1 expression are extremely low making reliable quantification 
problematic (data not present). In parallel study (when mice are allowed to 
deliver) we looked at circulating sFlt1 protein using ELISA and show statistically 
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significant silencing of sFlt1 at day 17.   Again, the effect was specific for sFlt1 
targeting compound as NTC treated animals had the same levels of circulated 
sFlt1 as PBS treated (Figure 4.3.D). 
 
We decided to further evaluate kinetic of sFlt1 silencing and separate groups of 
mice was injected with PBS or siRNAsFlt1 2283 and blood samples collected at 
day 15, 17, 19. We observe silencing at all time points with day 19 reaching 
statistical significance (Figure 4.3.E).  
 
The animals from this study were allowed to deliver. The sFlt1 silencing has no 
impact on newborn pubs number, pubs weight at birth and pups ability to strive 
(Figure 4.3. F-H). The levels of liver transaminases ALT and AST were all normal 
(Figure 4.3.K) indicating no liver toxicity upon treatment with siRNAsFlt1 2283.  
These data demonstrate that systemic administration anti-sFlt1 siRNA can 
efficiently modulate sFlt1 placental mRNAs, circulating sFlt1 protein and has no 
detectable impact on progeny. 
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Figure 4.3 Efficient silencing of sFlt1 mRNA and protein by sFlt1-i13_2283 
siRNA in pregnant mice 
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a. Experimental design for in-vivo testing of siRNA. Pregnant CD1 mice were 
injected at E14 and E15 with 2X20 mg/kg of siRNAsFlt1 (IV, tail vein) and delivered at E20 
or  sacrificed at E19. b. sFlt1_i13 mRNA levels were measured using QuantiGene® 
assay (Affymetrix), normalized to housekeeping gene (Flt1), and presented as % of PBS 
control (n=6, mean +SD).  c. Amount of hsiRNA  accumulated in tissues five days after 
first injection measured by PNA-hybridization  assay in mice form b. d. sFlt1 protein 
levels in mice serum measured by ELISA (RD Biosystems) after 2X20 mg/kg dose (n=12 
for siRNA and PBS, n=6 for NTC, mean +SD). e. sFlt1 protein levels measured by 
ELISA (RD Biosystems) for 2X20 mg/kg dose (n=9, mean +SD). f-h. Newborn pups 
number and weights from mice injected with siRNAsFlt1. k. ALT/AST enzymes activities in 
mice injected with 20X2 mg/kg of siRNAsFlt1 at E17 measured by Activity Assay Kits 
(Sigma).  
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4.2.6. Combinatorial silencing of sFlt1-i13 and i15a isoforms in vitro 
and in vivo 
Both sFlt1-i13 and sFlt1-e15a sFlt1 isoforms are expressed in placentas in PE 
(Figure 4.1.A-B). There is no homology between unique regions present in sFlt1-
i13 and sFlt1-e15a. To silencing both isoform we decided to use the mixture of 
two compounds. 
We treated WM-115 cells, which are expressing both isoforms with 2283, 2519 
and 2283/2519 siRNAsFlt1 mixture. siRNAsFlt1 2283 and the mixture of  2283/2519 
efficiently  silencing sFlt1-i13 (Figure 4.4.A). While 2519 siRNAsFlt1 and mixture of 
2283/2519 efficiently silencing sFlt1-e15a (Figure 4.4.B). None of the these 
compounds along or in mixture effect expression of full length FLT1 (Fig. 4.4.C). 
For both isoforms the potency of the 2283/2519 compounds mixture was higher 
than individual compounds with effect being more pronounced for sFlt1-i13 
isoform. This experiment has been repeated several times with similar results 
and is not an experimental artifact. We are studying this phenomena, which is 
outside the scope of this paper. 
In summary, siRNAsFlt1 mixture of 2283/2519 support efficient modulation of 
sFlt1-i13 and sFlt1-e15a sFlt1 isoforms without impact on full length of FLT1 and 
was selected for further in-vivo analysis. 
Consistent with data presented in Figure 3 injection of 2283/2519 equimolar 
mixture in mice resulted in efficient modulation of sFlt1 mRNA in placenta and 
other parental tissues (Figure 4.4. D). The PK/PD properties of therapeutic 
oligonucleotides are mainly depend on the chemical configuration and expected 
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to be similar for different sequences. Indeed when we evaluated placenta 
accumulation of 2283 and 2519 and it was nearly identical with no detectable 
transfer to the fetus (Figure 4.4.E). Subsequent decrease of sFlt1protein level 
after siRNAsFlt1  administration   had no impact on progeny numbers, weight, 
ability to strive (data not present) and no impact on the liver enzymes (Figure 
4.4.F-G). 
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Figure 4.4 Efficient silencing of sFlt1 by siRNA mixture (sFlt1-
i13_2283/sFlt1-e15a_2519) in vitro and in vivo 
a-c. siRNAsFlt1 (i13_2283/e15a_2519) equimolar mixture activity in vitro. WM-115 
cells were incubated with hsiRNA mixture at concentrations shown for 72h. mRNA levels 
were measured using QuantiGene® (Affymetrix) normalized to  housekeeping gene 
(FLT1) (n=3, mean +SD).  d. CD1 mice were injected at E14 with 20 mg/kg of siRNAsFlt1 
equimolar mixture (IV, tail vein) and sacrificed at E19. mRNA levels were measured 
QuantiGene® (Affymetrix) normalized to  housekeeping gene (Flt1) and presented as % 
of PBS control (n=8, mean +SD). e. Amount of hsiRNA  accumulated in tissues five days 
after injection measured by PNA-hybridization  assay in mice from d. f. sFlt1 protein 
levels were measured by ELISA (RD Biosystems) (n=8, mean +SD). g. ALT/AST 
enzymes activities in mice injected with siRNAsFlt1 equimolar mixture at E17 measured 
by Activity Assay Kits (Sigma).  
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4.3. Methods 
4.3.1 siRNA Design 
We designed and synthesized a panel of 47 siRNA compounds targeting 
the human sFlt1 i13 and sFlt1-e15a. These   sequences span the unique 
genes sequences and were selected to comply with standard siRNA 
design parameters(Cerdeira and Karumanchi, 2012)  including 
assessment of GC content, specificity and low seed compliment 
frequency(Fedorov et al., 2006), elimination of sequences containing 
miRNA seeds, and examination of thermodynamic bias. 
4.3.2 Oligonucleotide synthesis, deprotection and purification 
Oligonucleotides were synthesized using standard phosphoramidite, solid-
phase synthesis conditions on a 0.2-1-µmole scale using a Mermaid 192 
and Expedite DNA/RNA synthesizer. Oligonucleotides with unmodified 3′ 
ends were synthesized on controlled pore glass (CPG) functionalized with 
long-chain alkyl amine and a Unylinker® terminus. Oligonucleotides with 
3′-Cholesterol modifications were synthesized on modified solid support. 
Phosphoramidites solutions were prepared at 0.15 M in acetonitrile for 2′–
TBDMS, 2′–O–Me, and Cy3 modifications or 0.13 M for 2′–fluoro. 
Phosphoramidites were activated in 0.25 M 4,5-dicyanoimidazole in 
acetonitrile. Detritylation was performed in 3% dichloroacetic acid in 
dichloromethane for 80 seconds.  Capping was performed in 16% N-
methylimidazole in THF and acetic anhydride:pyridine:THF, (1:2:2, v/v/v) 
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for 15 seconds. Oxidation was performed using 0.1 M iodine in 
pyridine:water:THF (1:2:10, v/v/v). 
 
The CPG is removed from the solid phase column and placed in a 
polypropylene screw cap vial.  Dimethylsulfoxide (DMSO) (100 µL) and 
40% methylamine (250 µL) are added directly to the CPG and shaken 
gently at 65°C for exactly 16 min.  The vial is cooled on dry ice before the 
cap is removed.  The supernatant is transferred to another polypropylene 
screw cap vial, and the CPG is rinsed with two 150 µL portions of DMSO, 
which are combined with original supernatant.  Oligonucleotides without 
2′–TBDMS protecting groups were lyophilized. Oligonucleotides with 2′–
TBDMS protecting groups were desilylated by adding 375 µL triethylamine 
trihydrofluoride (~1.5 volumes relative to 40% methylamine) and 
incubating for exactly 16 min at 65°C with gentle shaking. Sample were 
quenched by transferring to a 15 ml conical tube containing 2 mL of 2 M 
triethylammonium acetate buffer (pH 7.0). The sample was stored at –
80°C until HPLC purification. 
Oligonucleotides were purified by reverse-phase HPLC on a Hamilton 
PRP-C18 column using an Agilent Prostar 325 HPLC. Buffer A 0.05M 
tetraethylammonium acetate with 5% acetonitrile, Buffer B 100% 
acetonitrile. Purified oligonucleotides were lyophilized to dryness, 
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reconstituted in water and passed over a Hi-Trap cation exchange column 
to exchange the tetraethylammonium counter-ion with sodium. 
 
4.3.3 Cell Culture 
HeLa and WM-115 cells were purchased from ATCC (ATCC, Manassas, 
VA; #CCL-2, #CLR-165).   HeLa cells were maintained in Dulbecco's 
Modified Eagle's Medium (Cellgro, Corning, NY; #10-013CV) 
supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA; 
#26140) and 100 U/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA; 
#15140) and grown at 37°C and 5% CO2. Cells were split every 2 to 5 
days, and discarded after fifteen passages. WM-115 cells were 
maintained in Eagle's Minimum Essential Medium  (Gibco, Carlsbad, CA; 
#11095) supplemented with 2mM Glutamine, 1% Non Essential Amino 
Acids, 1% Sodium Pyruvate, 10% % fetal bovine serum (all form Gibco) 
and 100 U/mL penicillin/streptomycin (Invitrogen) and grown at 37°C and 
5% CO2. Cells were split every 2 to 4 days. Cytotrophoblasts isolated from 
human placenta were provided by S. A. Karumanchi and were cultivated 
as described previously(Anderson et al., 2008; Rajakumar et al., 2005). 
Isolated CTB cells were maintained in M199 medium  (Gibco, Carlsbad, 
CA; #11043023).  
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4.3.4 Direct Delivery (passive uptake) of oligonucleotides 
For initial siRNA library screening cDNA sequences corresponding to 
unique regions of human sFlt1 i13 and sFlt1-e15a were cloned into 
psiCheck-2 vector (Promega, Madison, WI; #C8021) and DualGlo 
luciferase assay system was used (Promega, Madison, WI; #E2920) 
according to manufacturer's manual.  
 
Briefly, HeLa cells on 10cm dish were transfected with psiCheck-2-i13 or 
psiCheck-2-e15a plasmids using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA; #11668019) according to manufacturer's manual. 24 hours 
later cells were plated in DMEM containing 6% FBS at 10,000 cells per 
well in 96-well cell culture plates. siRNA was diluted to twice the final 
concentration in OptiMEM (Carlsbad, CA; #31985-088), and 50 µL diluted 
siRNA was added to 50 µL of cells, resulting in 3% FBS final. Cells were 
incubated for 72 hours at 37°C and 5% CO2. The primary screen for active 
siRNAs was performed at 3-1.5 µM compounds, which also served as the 
maximal dose for in vitro dose response assays. To test siRNAs in CTB 
and WM-115 cells, cells were plated at 20,000-30,000 cells per well in 96-
well plates in M199 or EMEM media containing 6% FBS and treated with 
siRNAs for 72 hours.  
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4.3.5 mRNA quantification in cells and tissue punches 
mRNA was quantified from both cells and tissue punches using the 
QuantiGene® 2.0 DNA Assay (Affymetrix, # QS0011) as described 
previously30, 31. Cells were lysed in 250 µl diluted lysis mixture composed 
of 1 part lysis mixture (Affymetrix, #13228), 2 parts H2O, and 0.167 µg/µl 
proteinase K (Affymetrix,# QS0103) for 30 minutes at 55°C. Cell lysates 
were mixed thoroughly, and 40-80 µl of each lysate was added per well of 
a capture plate with 20 µl diluted lysis mixture without proteinase K. Probe 
sets for Human  FLT1, sFlt1-i13, sFlt1-e15a , HPRT, PPIB and  YWHAZ 
(Affymetrix; # ) or mouse Flt1, sFlt1, Hprt and Ppib were diluted and used 
according to the manufacturer’s recommended protocol.  
 
For analysis of mRNA in mouse tissues, tissue punches (2-5 mg) were 
homogenized in 300-400 µl of Homogenizing Buffer (Affymetrix, #) 
containing 2 µg/µl proteinase K in 96-well plate format on a QIAGEN 
TissueLyser II, and 20-60 µl of each lysate was added to a bDNA capture 
plate. Diluted probe sets were added to each well of the capture plate for a 
final volume of 100 µL. Signal was amplified according to the Affymetrix 
protocol.  Luminescence was detected on a Veritas Luminometer 
(Promega, Madison, WI; #998–9100) or  Tecan M1000  (Tecan, 
Morrisville, NC). 
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4.3.6 Fluorescence Imaging 
Mice were injected intravenously (tail vein) or subcutaneously 
(intrascapular) with 10 mg/kg of Cy3-labeled siRNA. After 24 hours, mice 
were sacrificed and tissues were removed, embedded in paraffin, and 
sliced into 4-µm sections that were mounted on glass slides. Sections 
were deparaffinized by incubating in Xylene twice for 8 minutes. Sections 
were rehydrated in serial ethanol dilutions (100%, 95%, and 80%) for 4 
minutes each, and then washed twice for 2 minutes with PBS, stained with 
DAPI. All fluorescent images were acquired with a Leica DMi8 inverted 
tiling microscope (Leica Microsystems). Images were processed using the 
Leica software suite (LAS X and LAS X Lite). 
 
4.3.7 PNA Hybridization assay 
siRNA guide (antisense) strand accumulation in mouse tissues was 
quantified using a PNA hybridization assay, as described previously31. 
Briefly, tissue punches were homogenized in MasterPure Tissue Lysis 
Solution (EpiCentre) with added proteinase K (2 mg/mL, Invitrogen) and 
homogenized using a TissueLyser II (Qiagen), using 100 µL of lysis 
solution per 10 mg tissue. Following lysis, sodium dodecyl sulfate  (SDS) 
was precipitated with KCl (3 mol/l) and cleared supernatant was 
hybridized to a Cy3-labeled PNA oligonucleotide fully complementary to 
the guide strand (PNABio) (Supp. Table 2). This mixture was analyzed by 
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high-performance liquid chromatography (HPLC) . Cy3-labeled peaks 
were integrated and plotted on an internal calibration curve. Mobile phase 
for HPLC was 50% water, 50% acetonitrile, 25 mmol/l Tris-HCl (pH 8.5) 
and 1 mmol/l ethylenediamine-tetraacetate. The salt gradient was 0-800 
mmol/l NaClO4. 
 
4.3.8 Statistical Analysis 
 
Data were analyzed using GraphPad Prism 7 software (GraphPad 
Software, Inc., San Diego, CA). Concentration-dependent IC50 curves 
were fitted using a log(inhibitor) vs. response – variable slope (four 
parameters). The lower limit of the curve was set at zero, and the upper 
limit of the curve was set at 100. For each independent mouse 
experiment, the level of knockdown at each dose was normalized to the 
mean of the control group (PBS or untreated groups). ). In vivo data were 
analyzed using a Kruskal-Wallis one-way ANOVA with Dunn’s post-hoc 
analysis. Differences in all comparisons were considered significant at P-
values less than 0.05.   
 
4.4. Discussion 
The overall goal of this study was to explore RNA interference (RNAi) as a 
novel therapeutic approach for the treatment of preeclampsia (PE).  PE is a 
major unmet public health need that worldwide causes >500,000 maternal 
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and infant deaths annually.  PE is characterized by high maternal blood 
pressure, proteinuria and edema after the 20th week of pregnancy.  It is 
now well established that these symptoms are due to overproduction by the 
placenta of a protein called soluble FLT1 (sFlt1).  This protein is secreted 
into the maternal bloodstream and causes maternal kidney and liver 
dysfunction.  Currently, the sole treatment option for PE is to deliver the 
placenta (and therefore the immature fetus) regardless of gestational age 
when maternal symptoms become life threatening; once the placenta is 
removed, maternal symptoms abate within 24-48 hours due to the short 
half-life of circulating sFlt1 protein (~4 hrs).  Although it is possible to lower 
circulating sFlt1 in the maternal bloodstream by apheresis (blood washing) 
and thereby prolong PE pregnancies (Thadhani et al., 2011; 2016), this 
procedure is still in early stage clinical trials.  It is also expensive with high 
medical infrastructure requirement, so an alternative approach is needed. 
 
Our aim is to develop small interfering RNAs (siRNAs) that would target 
and destroy the placental mRNAs that encode sFlt1 protein.  siRNAs can 
be manufactured at low cost, are long-lived with high heat stability, and can 
be administered via subcutaneous (SC) injection.  Recent demonstration of 
multi-month effect duration from a single SC injection with negligible side 
effects signals that siRNA therapeutics have now come of age (Alnylam, 
NEJM, 2017; Khvorova, NEJM, 2017).  Therefore, this emerging class of 
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"informational drugs" represents a unique opportunity to develop a simple 
and cost-effective treatment for PE.  
 
A siRNA-based therapeutic might be an ideal solution for the treatment of 
PE. First, both preclinical and clinical data support lowering sFlt1 levels as 
a valid therapeutic strategy for prolonging PE pregnancies. Second, the 
unique region specific to each sFlt1 protein is very small, with only a 
handful of unique amino acids being appended to each C-terminus. This 
small target size hinders development of conventional drugs (small 
molecules and antibodies) that target only sFlt1s and not fl-FLT1.  On the 
other hand, the target window at the RNA level is much larger, with the 
sFlt1-i13 and sFlt1-e15a mRNA isoforms having 435 and 567 unique 
bases, respectively, none of which are present in fl-Flt1 mRNA.  Because 
RNAi requires a target size of only 19-22 nts, this is more than sufficient 
nucleotide space in which to design multiple isoform-selective siRNAs.  
Further, siRNA half-life in vivo is of sufficient duration that a single 
intravenous dose is well suited for a 2-6 week inhibition of sFlt1 production. 
Finally, from a clinical perspective, the possibility that a single dose 
delivered subcutaneously will be sufficient to prevent runaway sFlt1 
expression for several weeks could make treatment simple and affordable.  
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The desired level of sFlt1 silencing is only 30-40%, and a higher degree of 
silencing might be disadvantageous. Our preliminary data indicate that a 
20-40 mg/kg dose produces > 50% silencing in mice, so lesser silencing 
may simply be achieved with lower dosing. But because the desired 
product profile is a one-time injection, higher doses might be required to 
extend effect duration.  Thus we might also consider selecting sFlt1-i13 or 
sFlt1-e15a alone as a clinical candidate and make the final decision on the 
exact composition of our preclinical candidate for IND after completion of 
mouse and non-human primate efficacy studies.  
We have evaluated the efficiency of siRNA uptake in CTB and have seen 
efficient uptake by all cells upon addition of Cy3-labeled compound to the 
media (data not shown). 
 
The siRNAs are asymmetric compounds, with a short duplex region (15 
base-pairs) and single-stranded fully phosphorothioated tail, where all 
bases are fully modified using alternating 2'-fluoro and 2'-O-methyl 
modification pattern (providing stabilization and avoidance of PKR 
response), and the 3' end of the passenger strand is conjugated to TEG-
Cholesterol (Figure 4.2.A). The cholesterol enables quick membrane 
association, while the single-stranded phosphorothioated tail is essential 
for cellular internalization by a mechanism similar to that used by 
conventional antisense oligonucleotides (data not shown). Addition of Cy3-
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labeled siRNA to any cultured cell type shows quick and efficient 
internalization through an EE1 related part of the endocytosis pathway. 
One of the major advances the Khvorova lab has made in recent years is 
to develop a chemical modification pattern that does not interfere with 
primary RISC entry. We and others have screened a wide range of 
chemical variations and identified that an alternating 2’-fluoro/2'-O-methyl 
pattern optimally configures the guide strand to adopt a geometry that 
closely mimics that of an individual strand in a A-form RNA duplex, is 
recognized by the RISC complex and supports proper positioning of the 
target mRNA within the cleavage site. By starting the alternating pattern 
with a 5'-phosphorylated 2’-O-methyl ribose (a 5' phosphate is necessary 
for PIWI domain interaction); this fixes placement of the 2’-fluoro 
modifications in even numbered positions 2-14; positions 2 and 14 were 
previously shown to be intolerant of bulkier 2'-ribose modifications, 
 
These fully chemically stabilized compounds are at least as or more 
effective as naked siRNA in RISC entry and represent the first complete 
chemical modification pattern with no negative impact on RISC function. 
This discovery was transformative for the PE project, as complete chemical 
stabilization is absolutely essential for tissue accumulation upon systemic 
administration. Another benefit of non-RNA containing siRNAs is ease of 
manufacturing – their DNA-like chemistry with no necessity for orthogonal 
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ribose protection shortens de-protection procedures and increases 
coupling efficiencies. Finally, complete elimination of all 2'-OH groups helps 
with avoidance of the innate immune response, which relies mainly on 2'-
OH interactions.  
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5. CHAPTER V: DISCUSSION AND FUTURE PERSPECTIVES 
 
Preface:  
 
The conclusions and discussions in this chapter are adapted from the discussion 
sections in Chapters II and IV.  
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5.1. Discussion 
 
PE is a life-threatening disorder with increased levels of sFlt1 protein that 
causes maternal symptoms of HBP and proteinuria to manifest from 20th 
week onwards of pregnancy. The overall goals of this thesis were to build 
a foundation to understand the pathophysiology of PE by characterizing 
the transcriptome of normal and PE patients, characterize FLT1 isoforms 
and transcriptome-wide polyadenylation site changes between normal and 
PE patients and identify the most abundant sFl1t isoform to target as a 
therapeutic in PE patients. This study is the first PAS-Seq study in PE and 
an important step towards characterizing the PAS sites and transcriptome 
changes in PE placentae. 
 
The first question that I set out to ask with my thesis was which 
mechanism regulates sFlt1 mRNA upregulation in PE? Is it due to 
transcriptional upregulation of the entire gene or because of APA and 
preferential proximal PAS site usage that gave rise to the sFlt1 isoforms? 
The second aim of this thesis was to find other differentially expressed 
genes between normal, EO-PE and LO-PE placentae. The third aim was 
to identify the most abundant sFlt1 isoform expressed in the PE placentae 
in order to develop novel siRNAs as a potential therapeutic. 
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Several studies have reported that FLT1 gene is upregulated in PE 
patients compared to the control. However, I wanted to take a step further 
and understand FLT1 expression in PE with a clinical lens. We therefore 
divided our PE samples into early-onset (EO-PE; GDW < 34) and late-
onset (LO-PE; GDW > 34) groups. To answer the first question, I used 
total RNA from CTRL, EO-PE and LO-PE placenta to construct deep 
sequencing libraries.  To understand whether sFlt1 isoforms upregulated 
is due to increase in full length Flt1 or because of   APA and alternative 
splicing, I prepared two sets of deep sequencing libraries from the same 
patient sample: PAS–Seq and RNA–Seq. PAS-seq is a transcriptome-
wide, 3’-sequencing methodology which detects changes in the various 
APA isoforms arising from the same gene. I developed a kit-free PAS-seq 
by optimizing the published RNA-Seq protocol (Heyer et al., 2015b). 
Furthermore, PAS-Seq is also a great proxy for calculating differential 
gene expression. My results indicate that the entire FLT1 locus and 
therefore both the m-Flt1 and sFlt1 (encompasses sFlt1-i13 S, sFlt1-i13 L 
and sFlt1-e15a) isoforms are significantly upregulated in EO-PE (Chapter 
II). I also find that sFlt1-e15a isoform is the most abundant isoform in PE 
placentae, with ~50% of the FLT1 reads mapping to it. The remaining 
reads map to sFlt1-i13 S (19%) followed by sFlt1-i13 L (18%) isoforms. 
Few reads corresponding to the sFlt1-i14 and sFlt1-e15b isoforms were 
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mapped, indicating that these are lowly expressed sFlt1 isoforms in the 
PE placentae and may not play a major role in the pathophysiology of PE.  
 
In order to address the second question, we did differential gene 
expression analysis and report 349 (padj ≤0.01) differentially expressed 
genes in EO-PE and 40 (padj ≤0.01) in LO-PE (Chapter II).  We find 50 
genes (padj ≤0.05) common between EO-PE and LO-PE including FLT1 
(4.3-fold up in EO-PE and 1.9-fold upregulated in LO-PE). The gene 
ontology terms associated with these 50 genes includes the HIF1α, HIF2α 
and VEGFR1 (FLT1) signaling pathways. It is interesting to note that FLT1 
gene is upregulated under hypoxic conditions (Ferrara, 2004; Goldman et 
al., 1998; Nevo, 2006). Using PCA analysis and differential gene 
expression this dissertation also agrees with the clinical phenotypes and 
extends the idea that there is distinct gene signature for EO-PE and LO-
PE. Thus PAS-Seq has been able to confirm (distinct EO-PE and LO-PE 
subsets) bioinformatically what has been previously reported clinically.  
There is a significant enrichment of differentially expressed genes 
associated with transcription factors, again indicating that there is a highly 
transcriptional response in PE as previously reported(Sõber et al., 2015; 
Vaiman et al., 2013). In particular, there are several studies that FLT1 is 
transcriptionally regulated by HIF-1α under hypoxic conditions. Additional 
studies have reported multiple transcription factors that regulate FLT1 
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expression. It is thus not a surprise that cellular stresses like hypoxia and 
oxidative stress in the PE placenta activates the transcription factors 
leading to wide spread transcriptional changes. However, future studies 
are needed highlight our understanding of what triggers the upregulation 
of FLT1 in PE and in particular the sFlt1-e15a isoform.  
 
Nuclear Receptor-Interacting Protein (NRIP1) is upregulated in the EO-PE 
and LO-PE samples compared to the controls. Interestingly, analysis of 
other published datasets show a similar upregulation (Kaartokallio et al., 
2015; Leavey et al., 2015; Sõber et al., 2015). NRIP1 has been shown to 
play an important role in metabolic disorders and lipid imbalances 
(Nautiyal, 2017; Nautiyal et al., 2013) indicating a change in the cellular 
metabolic pathways in patients with PE. Women with a high BMI have 
been shown to have lipid disturbances and often suffer from low-grade 
inflammation and endothelial dysfunction (Thadhani et al., 1999). Further 
NRIP1 was found to be differentially expressed when comparing the birth 
weight and gestational age of the infant in PE when compared to normal 
samples (Sõber et al., 2015). Interestingly, genome-wide association 
studies in women suffering from endometriosis identified SNP variants in 
NRIP1, which may have functional relevance (Caballero et al., 2005). 
Similar genome-wide and functional studies in PE patient samples will 
help shed light on the role of NRIP1 in the disease.  
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In addition to analyzing the protein-coding gene expression, we also used 
the novel PAS-Seq method to annotate non-coding RNAs in normal and 
PE pregnancies. This dissertation demonstrates that several PAS peaks 
were annotated on retrotransposon elements. In particular we found PAS-
peaks distributed on long interspersed elements (LINEs) and non-long 
terminal repeats (LTRs). These elements have been shown to play an 
important role in regulating gene expression. Several studies report that 
these elements play an important role in Drosophila neurodevelopment 
(Perrat et al., 2013), central nervous system diseases (Reilly et al., 2013) 
and autoimmune disorders in humans (Balada et al., 2010). There is scare 
data available on the role of repeat elements in pregnancy disorders. 
Additionally, we also found RNA-Seq reads (Chapter II) corresponding to 
the same regions as PAS-Seq reads on the LTR and LINE elements in PE 
patients. Interestingly, sFlt1-e15a isoform has a unique Alu 
retrotransposon within its 3’-UTR leading a unique polyserine stretch in 
the C-terminal end of the sFlt1-e15a protein.  Studying the role of Alu, 
LINE and LTR elements in future PE studies may help shed light on the 
biological regulation of sFlt1-e15a isoform in PE.  
 
The third aim of this dissertation was to identify the sFlt1 isoform that was 
most abundantly expressed in the PE placenta. In order to address this 
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question, I conducted a pilot screening of siRNAs targeting the unique 
3’UTR of sFlt1-i13 S (Chapter III). I along with our collaborators 
demonstrate that targeting sFlt1-i13 S, sFlt1-sFlt1-i13 L and sFlt1-e15a 
mRNAs is a viable therapeutic approach to alleviate PE (Chapter III and 
Chapter IV). We also provide evidence that siRNAs can be used in animal 
models to knockdown various sFlt1 isoforms effectively without affecting 
the placenta or the fetus (Chapter IV).  
 
Some of the caveats in this study are as follows. We had a small sample 
size for the LO-PE group. In future studies, we will need to include a 
higher number of the LO-PE patients. Another caveat of this study 
(Chapter II) is that the libraries are made from placental tissue, which is a 
mix of both maternal and fetal cells. Even though complete effort was 
made to collect only the villous tissue, which is the main source of sFlt1, 
the possibility of contamination from surrounding decidual cells (maternal 
cells) cannot be completely eliminated. There are a couple of ways to 
manage this inherent tissue variation. One is to make next-generation 
sequencing libraries at a cell level (ex: Single-Cell RNA-Seq) or second to 
make next-generation sequencing libraries at a tissue level (ex: PAS-Seq 
and RNA-Seq from various placental compartments). This approach will 
aid in distinguishing the noise from the real data.  
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Single-Cell RNA-Seq or laser microdissection as has been shown recently 
for normal placentas (Pavličev et al., 2017). Studying gene expression 
from different sections of the placenta has been done before for 
microarrays (Sood et al., 2006) and RNA-Seq (Kim et al., 2012) from 
normal placenta. Similar strategy can be applied to making next-
generation libraries from these sections like the decidua (maternal side of 
the placenta), amnion and chorion (fetal side of the placenta). In order to 
further refine the PE placental transcriptome, future experiments can be 
designed to make PAS-Seq also from placental cells or tissue sections as 
described above. 
 
5.2. Future Directions 
 
PE is a difficult disease to study mainly because the molecular changes 
are likely to occur prior to symptom manifestation, which occurs after the 
20th week of pregnancy. This makes it impossible to study this disease in 
vivo because of difficulty in getting the early stage placenta due to ethical 
limitations. Additionally, there are limited numbers of animal models 
because the placentation process differs between humans and mice or 
rats. As the two stage-models suggest that something goes awry in the 
placentation stage, studying placental cells i.e. primary trophoblasts during 
placentation has been a common approach to studying PE. I believe that 
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in the future, one could use stem cells derived from the embryo to 
differentiate them into trophoblasts, the earliest cells derived from the 
placenta (Chang and Parast, 2017) (Horii et al., 2016). This would allow 
us to study PE and understand the pathophysiology of PE as early as in 
the placentation stage (Horii et al., 2015). 
 
Another technology that can help dissect the molecular players of PE is 
called Method for Analyzing RNA following Intracellular Sorting (MARIS). 
Placenta is a complex tissue with cells coming from the mother (decidual 
cells) and cells coming from the fetus (chorion and amnion). In order to 
study the various cells coming from the different compartments MARIS 
technique can be applied. In this, cells from the placenta can be separated 
in two separate fractions; cells can be collected from the maternal and the 
fetal side. Furthermore, we can separate the various cells within each 
fraction. For example, in the decidual side, we could use fluorescent 
antibodies to label the lymphocytes, macrophages etc. On the fetal side, 
we could use antibodies for the cytotrophoblasts, syncytiotrophoblasts. 
These cells are further sorted using Fluorescence-activated cell sorting 
(FACS). The RNA can then be extracted for each the maternal cells and 
fetal cells and used for further deep sequencing. This method provides 
more depth than single-cell RNA-Seq (Hrvatin et al., 2014).  
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This thesis has demonstrated that in PE conditions, the entire FLT1 gene 
is transcriptionally upregulated. To further our understanding of the 
transcriptional regulation of FLT1 gene, future studies should include 
Chromatin Immunoprecipitation followed by deep sequencing (ChIP-Seq) 
experiments. ChIP-Seq allows for identifying the binding sites of various 
proteins including transcription factors in a precise manner. For example, 
the DNA-bound protein can be isolated from normal, EO-PE and LO-PE 
pregnancies. The DNA can be further purified and sequenced. This would 
allow us to compare the binding sites of enhancers, transcription factors 
and other regulatory proteins.   
 
In the future, I predict that diagnostic tests for PE will be used commonly 
than at present. Genome-wide studies for heterogeneous disorders like 
PE have grown in popularity over the last two years (Kaartokallio et al., 
2015; Lekva et al., 2016; McGinnis et al., 2017; Sõber et al., 2015). I 
predict that studies similar to given in this thesis (Chapter II) and 
elsewhere will shed light in to the pathophysiology of PE. Studying layers 
of gene regulation by understanding the RNA splicing, RNA 
polyadenylation and RNA stability in PE will be the future, as I believe a 
wealth of information can be extracted by these genome-wide studies. 
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5.3. Conclusions 
 
In conclusion, I developed a new 3’-end sequencing protocol that allows 
simultaneously studying alternative polyadenylation and gene expression 
from placental tissues. Using PAS-Seq, I first identified that sFlt1-e5a of 
the most abundantly expressed alternative polyadenylated sFlt1 isoform 
followed by sFlt1-i13S and sFlt1-i13 L in both EO-PE and LO-PE. 
Secondly, I also provide evidence for a potential new therapeutic using 
anti-sFlt1 siRNAs. This work is further expanded in Dr. Anastasia 
Khvorova’s lab where they use chemically modified siRNAs to alleviate PE 
in animal models of PE. Thirdly, I have utilized PAS-Seq to profile 
transcriptome-wide polyadenylation changes between normal, EO-PE and 
LO-PE pregnancies. Lastly, I have studied the differential gene expression 
changes between normal, EO-PE and LO-PE pregnancies.  
 
Furthermore, the findings in this thesis underscore the impact of genome-
wide deep sequencing studies on multifactorial pregnancy disorder like 
PE.  In addition, this study also validates the idea that EO-PE and LO-PE 
are distinct sub-types of the PE spectrum. 
 
The data provided here gives us a better understanding of the 
pathophysiology of PE and potentially aid in further development of RNAi 
based drugs for pregnancy disorders.  
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An exciting promising study (McGinnis et al., 2017) was published during 
the preparation of this thesis, wherein they found SNP variants near the 
gene FLT1 that has been the focus of Chapter II. These SNPs have been 
found near the FLT1 promoter region which can is an important implication 
to understand FLT1 gene regulation (McGinnis et al., 2017). This opens 
an exciting avenue for understanding how sFlt1’s are upregulated in PE.   
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APPENDIX A: RNA SEQUENCING 
 Introduction 
 
In addition to constructing PAS-Seq libraries from placental samples, we 
also constructed RNA-Seq libraries from the same patient samples 
(CTRL, EO-PE and LO-PE) as PAS-Seq. There were multiple aims to 
address with RNA-Seq libraries. One of the main aims was to study the 
RNA processing like splicing, alternate 5’ promoter usage, differential 
isoform and gene analysis. RNA-Seq would be another way to compare 
and contrast our PAS-Seq results. Also, at the time when this project 
began and ongoing (September 2011- August 2015), there were published 
RNA-Seq datasets only for CTRL placenta(Kim et al., 2012; Sood et al., 
2006) and none from PE placenta.  
 
Results 
Placental RNA-Seq samples 
RNA-Seq libraries were made from the same samples as we used in 
Chapter II. Using highly selective criteria for patient inclusion, we limited 
our sample set to singleton pregnancies, and excluded any patients with 
preexisting hypertension or diabetes mellitus.  We had a control set 
(CTRL; n = 6) delivered at term with no other pregnancy and our PE set 
(n=11) included patients with systolic blood pressures ≥ 140 mm Hg and 
circulating sFlt1:PlGF ratios ≥ 85, an accepted diagnostic measure of PE 
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associated with adverse PE related maternal/fetal outcome(Verlohren et 
al., 2010; 2012b) (Figure 2.1 c and Table 2.1). Based on the Gestational 
Delivery Week, we further divided the PE patients into Early-Onset (EO-
PE; GDW <34; n=8) and Late-Onset (LO-PE; GDW >34; n=3) subgroups.  
The placental tissue was collected in the same manner as in Chapter II.  
The placenta was collected within 30 minutes of delivery and flash frozen 
in liquid nitrogen. Using these frozen samples, we isolated total RNA from 
the villous tissue, which is the spongy layer in between the decidua 
(maternal side) and the chorion (fetal side), and the main source of 
sFlt1(Rajakumar, 2011; Rajakumar et al., 2012). The rRNA was depleted 
from the total RNA (see Figure A.1 and Methods). The remainder rRNA 
minus fraction contained all the polyA+ RNA plus the snRNAs, snoRNAs 
and other non-coding RNAs. Briefly, this RNA pool was used to reverse 
transcribe using RT primers (Table A.1), followed by circularization and 
PCR amplification. 
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Figure A.1 RNA-Seq method flowchart 
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Bioinformatics analyses 
Before mapping the sequencing reads to the human transcriptome, we 
checked the initial quality of the data using FASTQC program. Out of the 
sixteen libraries, we got mixed results in terms of quality. Some of the 
libraries (Figure A.2.B-D) had very poor quality. Some of the reasons for 
bad quality are that the RNA had degraded over the time of the library 
preparation, issues with sequence length distribution or a problem with the 
sequencing run.  
 
We decided to continue analyzing these libraries and used the Dolphin 
pipeline to further filter reads to any non-mRNA reads before mapping to 
hg19 genome. We found that a wide range (4%-80%) of our reads 
mapped to the rRNA (Table A.2). This was concerning as it could mean 
two things, either the rRNA depletion step was inadequate or the RNA 
was degraded causing degradation of the rRNA and therefore the rRNA 
depletion step was inefficient. We decided not to analyze the data, but just 
out of curiosity we wanted to explore the differential gene expression in 
these samples.  
RNA-Seq library issues 
Given the two observations as follows 1. Bad quality reads and 2. 
Difference in size selection, we chose not to move forward with further 
analyses of the RNA-Seq data.  
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Figure A.2 BoxWhisker plot showing the quality score across all bases on 
every position in the fastq file 
a b. Examples of CTRL libraries c. d. Example of EO-PE and LO-PE library respectively. 
X-axis represent the position in read (bp) The Y-axis shows the quality score. Higher 
number on the Y-axis represents good read calls, with the background color 
representing very good (green), medium (orange) and bad (pink) quality calls. The 
yellow boxes shows the inter-quartile range (25-75%), the blue line running through the 
plot represents the mean quality and the upper and lower whiskers represent 10-90% 
points.  
a 
b 
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Methods 
Isolation of mRNA for deep sequencing 
As rRNA makes up 80% of the total RNA contents, the total RNA was 
depleted of rRNA using the Ribo-Zero Magnetic Gold kit 
(Human/Mouse/Rat)  (Illumina # MRZG12324). This allowed to enrich 
for mRNA and other RNAs (tRNAs, snRNAs etc.). The rRNA depleted 
RNA samples were further fragmented using RNA Fragmentation Reagent 
(Ambion #AM8740). RNAs were size selected for 100-150 nts and 
dephosphorylated as above. 
Library Preparation 
The dephosphorylated RNA was fragmented and a preadenylated adaptor 
(sequence–TGGAATTCTCGGGTGCCAAGG) was ligated to RNA 3' ends, 
after which the ligated RNAs were reverse transcribed. The RT product 
was gel purified, circularized, and PCR amplified prior to sequencing as 
described in (Heyer et al., 2015b).  
 
RNA-Seq Bioinformatics analysis 
The reads were demultiplexed using the barcodes (Table A.1). After 
separating the reads in different libraries, the FASTQC program was used 
to look at the quality of the reads. The adapter (sequence–
TGGAATTCTCGGGTGCCAAGG) at the 3′end of the reads was trimmed 
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using Trimmomatic-0.32 (parameters: adapter.fa:1:30:5 MINLEN:15), 
allow 1 mismatch, min length-drop reads below 15 nt) 
 
 rRNA, miRNA, tRNA, snRNA and repeat elements were filtered out using  
and put away in a separate folder (parameters: bowtie2-2.2.3/bowtie2 -p 2 
-N 1 --no-unal) (-p=threads, -N allows one mismatch, no-unal=Suppress 
SAM records for reads that failed to align) 
 
Reads were mapped to human transcriptome (hg19) using rsem-calculate-
expression function in RSEM (parameters: bowtie-0.12.9, -p 4 --bowtie-e 
70 --bowtie-chunkmbs 100 --output-genome-bam --calc-ci). P= number of 
threads,  bowtie e=Bowtie parameter max sum of mismatch quality scores  
across the alignment, chunkmbs=memory allocated for best first alignment 
calculation, calc-ci=Calculate 95% credibility intervals and posterior mean 
estimates, output bam=Generate a BAM file, 
'sample_name.genome.bam', with alignments mapped to genomic 
coordinates and annotated with their posterior probabilities. In addition, 
RSEM will call Samtools (included in RSEM package) to sort and index 
the bam file.) 
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BC1: 5' - pGGATCACAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC2: 5' - pGGCGATGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC3: 5' - pGGTAGCTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC4: 5' - pGGGCTCCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC5: 5' - pGGACAGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC6: 5' - pGGCAGATAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC7: 5' - pGGTCCCGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC8: 5' - pGGGGCTAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC9: 5' - pGGAGTCAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC10: 5' - pGGCTTGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC11: 5' - pGGTGAATAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3'  
BC12: 5' - pGGGTAGAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-SP18- 
CTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-CCTTGGCACCCGAGAATTCCA – 3' 
 
 
 
 
 
Table A.1 RNA-Seq RT primer sequences 
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RNA-Seq Differential gene expression 
The reads were analyzed using the DEBrowser package in R 
(https://github.com/UMMS-Biocore/debrowser). The raw counts for each 
gene in each library were uploaded to the DEBrowser. Default 
normalization parameters were used for further DESeq2 analyses. 
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Figure A.3 Scatter plot showing differential gene expression between CTRL and 
EO-PE samples.  
Red dot indicates genes, which are downregulated in EO-PE, and green dot indicates 
gene, which are upregulated in EO-PE. Grey dots indicate genes whose expression is 
unchanged between CTRL and EO-PE.   
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Figure A.4 Scatter plot showing differential gene expression between CTRL and 
LO-PE samples 
 
Green dot indicates gene, which are upregulated in LO-PE. Grey dots indicate genes 
whose expression is unchanged between CTRL and LO-PE.   
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Libr
ary 
Total 
Reads 
ERCC 
(spike-in) rRNA miRNA tRNA snRNA rmsk 
Reads After 
Filtering 
Reads 
aligned to 
hg19 
Multimap
ped reads  
Uniquely 
mapped 
reads  
N1 
19,570
,586 
24 (0.00 
%) 
3,269,546 
(16.71 %) 
1,056 
(0.01 %) 
8,287 
(0.04 %) 
11,271 (0.06 
%) 
19,672 (0.10 
%) 
16,291,673 
(83.25 %) 
110,909 
(0.57 %) 
17,364 
(0.09 %) 
684,329 (3.50 
%) 
N2 
10,568
,603 
17,327 
(0.16 %) 
2,803,870 
(26.53 %) 
16,804 
(0.16 %) 
176,298 
(1.67 %) 
560,960 (5.31 
%) 
749,310 
(7.09 %) 
7,554,304 
(71.48 %) 
1,425,757 
(13.49 %) 
198,770 
(1.88 %) 
2,895,039 
(27.39 %) 
N3 
16,181
,750 
8,354 
(0.05 %) 
7,170,726 
(44.31 %) 
11,729 
(0.07 %) 
116,533 
(0.72 %) 
360,496 (2.23 
%) 
500,125 
(3.09 %) 
8,874,408 
(54.84 %) 
960,698 
(5.94 %) 
106,972 
(0.66 %) 
1,862,545 
(11.51 %) 
N4 
21,279
,360 
180 (0.00 
%) 
15,690,967 
(73.74 %) 
9,808 
(0.05 %) 
16,798 
(0.08 %) 
3,287 (0.02 
%) 
36,877 (0.17 
%) 
5,561,607 
(26.14 %) 
107,413 
(0.50 %) 
14,803 
(0.07 %) 
280,348 (1.32 
%) 
N5 
23,439
,588 
23,404 
(0.10 %) 
7,315,275 
(31.21 %) 
25,659 
(0.11 %) 
106,427 
(0.45 %) 
1,159,018 
(4.94 %) 
1,440,305 
(6.14 %) 
15,968,823 
(68.13 %) 
2,124,144 
(9.06 %) 
278,064 
(1.19 %) 
4,413,167 
(18.83 %) 
N6 
16,227
,998 
264 (0.00 
%) 
12,847,331 
(79.17 %) 
6,875 
(0.04 %) 
10,488 
(0.06 %) 
5,140 (0.03 
%) 
20,180 (0.12 
%) 
3,363,040 
(20.72 %) 
66,358 (0.41 
%) 
10,914 
(0.07 %) 
160,947 (0.99 
%) 
P1 
32,155
,457 
840 (0.00 
%) 
335,993 (1.04 
%) 
74,730 
(0.23 %) 
513,122 
(1.60 %) 
7,069,547 
(21.99 %) 
3,457,736 
(10.75 %) 
31,230,772 
(97.12 %) 
6,146,897 
(19.12 %) 
946,475 
(2.94 %) 
14,632,112 
(45.50 %) 
P2 
14,633
,670 
36,734 
(0.25 %) 
2,691,646 
(18.39 %) 
18,636 
(0.13 %) 
179,778 
(1.23 %) 
1,321,161 
(9.03 %) 
1,623,860 
(11.10 %) 
11,706,876 
(80.00 %) 
2,212,957 
(15.12 %) 
371,069 
(2.54 %) 
4,800,926 
(32.81 %) 
P3 
33,763
,123 
79,365 
(0.24 %) 
4,352,764 
(12.89 %) 
50,304 
(0.15 %) 
414,933 
(1.23 %) 
11,073,492 
(32.80 %) 
3,170,995 
(9.39 %) 
28,865,757 
(85.49 %) 
4,236,960 
(12.55 %) 
663,234 
(1.96 %) 
10,422,001 
(30.87 %) 
P4 
19,837
,693 
11,050 
(0.06 %) 
7,667,206 
(38.65 %) 
32,845 
(0.17 %) 
527,574 
(2.66 %) 
553,624 (2.79 
%) 
840,700 
(4.24 %) 
11,599,018 
(58.47 %) 
1,523,540 
(7.68 %) 
276,501 
(1.39 %) 
3,074,130 
(15.50 %) 
P5 
32,452
,634 
47,487 
(0.15 %) 
10,147,410 
(31.27 %) 
34,921 
(0.11 %) 
267,470 
(0.82 %) 
2,185,547 
(6.73 %) 
2,064,083 
(6.36 %) 
21,955,346 
(67.65 %) 
4,387,649 
(13.52 %) 
562,014 
(1.73 %) 
9,543,242 
(29.41 %) 
P6 
10,285
,189 
282 (0.00 
%) 
4,317,988 
(41.98 %) 
5,783 
(0.06 %) 
16,049 
(0.16 %) 
62,063 (0.60 
%) 
214,222 
(2.08 %) 
5,945,087 
(57.80 %) 
517,257 
(5.03 %) 
80,753 
(0.79 %) 
1,209,500 
(11.76 %) 
P7 
8,630,
710 
76 (0.00 
%) 
402,324 (4.66 
%) 
6,504 
(0.08 %) 
16,956 
(0.20 %) 
1,802,679 
(20.89 %) 
999,105 
(11.58 %) 
8,204,850 
(95.07 %) 
1,967,059 
(22.79 %) 
226,670 
(2.63 %) 
3,845,987 
(44.56 %) 
P8 
8,386,
620 
6 (0.00 
%) 
138,242 (1.65 
%) 
5,354 
(0.06 %) 
9,822 
(0.12 %) 
1,211,001 
(14.44 %) 
1,002,209 
(11.95 %) 
8,233,196 
(98.17 %) 
2,584,394 
(30.82 %) 
503,719 
(6.01 %) 
5,510,431 
(65.71 %) 
P9 
8,620,
433 
53 (0.00 
%) 
3,818,003 
(44.29 %) 
3,688 
(0.04 %) 
10,953 
(0.13 %) 
123,836 (1.44 
%) 
292,975 
(3.40 %) 
4,787,736 
(55.54 %) 
780,837 
(9.06 %) 
119,685 
(1.39 %) 
1,563,694 
(18.14 %) 
P10 
6,890,
858 
32 (0.00 
%) 
677,982 (9.84 
%) 
4,616 
(0.07 %) 
18,087 
(0.26 %) 
1,076,087 
(15.62 %) 
720,012 
(10.45 %) 
6,190,141 
(89.83 %) 
1,528,518 
(22.18 %) 
233,917 
(3.39 %) 
3,087,346 
(44.80 %) 
P11 
6,327,
604 
119 (0.00 
%) 
1,351,666 
(21.36 %) 
5,858 
(0.09 %) 
19,979 
(0.32 %) 
345,705 (5.46 
%) 
579,081 
(9.15 %) 
4,949,982 
(78.23 %) 
1,165,342 
(18.42 %) 
216,395 
(3.42 %) 
2,254,833 
(35.63 %) 
 
Table A.2 RNA-Seq mapping statistics
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rRNA	sub-units	
Library	 28S	 18S	 5.8S	 5S	
N1	 2255886	 1013373	 258	 29	
N2	 2494010	 308777	 980	 103	
N3	 6384688	 785096	 847	 95	
N4	 15594215	 96095	 567	 90	
N5	 6923320	 391370	 538	 47	
N6	 12808152	 38770	 357	 52	
P1	 213268	 120545	 2053	 127	
P2	 2492543	 197452	 1542	 109	
P3	 4292320	 59154	 880	 410	
P4	 7382889	 278698	 5197	 422	
P5	 10027692	 117905	 1371	 442	
P6	 2912451	 1402369	 2936	 232	
P7	 164705	 236815	 798	 6	
P8	 122241	 15977	 24	 0	
P9	 1962586	 1855024	 373	 20	
P10	 355448	 321322	 1199	 13	
P11	 665984	 684124	 1520	 38	
Table A.3 RNA-Seq reads mapping to rRNA sub-units 
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Discussion 
 
During the analyses of the libraries it was observed that our data suffered 
with rRNA contamination, which made any analyses difficult to conduct. 
As we were aware of the limitations of our libraries, we decided to limit the 
analyses of our data. Even though we could not make any biologically 
relevant conclusions, we decided to instead present here the problems we 
encountered in our data so future researchers can be aware of these 
problems.  
 
The rRNA contamination we observed could either be 1. the rRNA 
removal kit was freeze-thawed multiple times and the reagents were 
degraded, 2. the total RNA was degraded prior to making libraries or 3. . 
the total RNA was degraded during the library preparation. Additionally 
when batch effect analysis (data not shown) was conducted on the RNA-
Seq libraries, the samples showed bias in library preparation method.  
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APPENDIX B: Staufen1 senses overall transcript secondary structure 
to regulate translation 
 
 
 
Preface 
 
Appendix B was taken verbatim from the following published manuscript: 
 
 
Staufen1 senses overall transcript secondary structure to regulate 
translation 
 
Emiliano P Ricci, Alper Kucukural, Can Cenik, Blandine C Mercier, Guramrit 
Singh, Erin E Heyer, Ami Ashar-Patel, Lingtao Peng & Melissa J Moore 
 
(2014). Staufen1 senses overall transcript secondary structure to regulate 
translation. Nature Structural & Molecular Biology, 21(1), 26–35. 
http://doi.org/10.1038/nsmb.2739 
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Abstract 
Human Staufen (Stau) is a double-stranded RNA (dsRNA)-binding protein 
implicated in multiple post-transcriptional gene- regulatory processes. Here we 
combined RNA immunoprecipitation in tandem (RIPiT) with RNase footprinting, 
formaldehyde cross-linking, sonication-mediated RNA fragmentation and deep 
sequencing to map Staufen -binding sites transcriptome wide. We find that Stau 
binds complex secondary structures containing multiple short helices, many of 
which are formed by inverted Alu elements in annotated 3′ untranslated regions 
(UTRs) or in ‘strongly distal’ 3′ UTRs. Stau also interacts with actively translating 
ribosomes and with mRNA coding sequences (CDSs) and 3′ UTRs in proportion 
to their GC content and propensity to form internal secondary structure. On 
mRNAs with high CDS GC content, higher Stau levels lead to greater ribosome 
densities, thus suggesting a general role for Stau in modulating translation 
elongation through structured CDS regions. Our results also indicate that Stau 
regulates translation of transcription-regulatory proteins.  
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Introduction 
Staufen proteins are highly conserved dsRNA-binding proteins (dsRBPs) found 
in most bilateral animals(Kerner et al., 2011). Mammals contain two Staufen 
paralogs encoded by different loci. Stau1, expressed in most tissues, has a 
microtubule-binding domain, a dimerization domain and four conserved dsRNA-
binding domains (dsRBDs), only two of which (dsRBDs 3 and 4) are necessary 
for dsRNA binding (LUO et al., 2002a). Within cells, Stau1 can make direct 
interactions both with itself and with Stau2, the more tissue-specific paralog 
(Martel et al., 2010). Functionally, Staufen proteins are involved in multiple post-
transcriptional regulatory processes. In flies, 3′ UTR–bound Staufen is required 
for proper localization and translational control of bicoid and prospero mRNAs 
during oogenesis(St Johnston et al., 1991) (Ferrandon, 1997). In mammals, 
Stau1 has been implicated in mRNA transport to neuronal dendrites, (Köhrmann 
et al., 1999) regulation of translation via physical interaction with the 
ribosome(Dugré-Brisson et al., 2005), a form of translation-dependent mRNA 
degradation known as Staufen-mediated decay (SMD)(Gleghorn et al., 2013; 
Kim et al., 2005; Park et al., 2013) (Gong and Maquat, 2011), regulation of 
stress-granule homeostasis(Thomas et al., 2009b), alternative splicing, nuclear 
export and translation of a gene containing 3′-UTR CUG-repeat 
expansions(Ravel-Chapuis et al., 2012a). Although Stau1 is not essential for 
mammalian development, neurons lacking Stau1 have dendritic spine-
morphogenesis defects in vitro, and knockout mice have locomotor-activity 
deficits(Vessey et al., 2008).  
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Crucial for the understanding of how Stau1 regulates gene expres- sion is 
comprehensive knowledge of its intracellular RNA-binding sites. Although 
mammalian Stau1- and Drosophila Staufen-associated mRNAs were identified 
by microarray analysis after native RNA immunoprecipitation (RIP)(Furic et al., 
2008; Kusek et al.; Laver et al., 2013; Maher-Laporte and DesGROSEILLERS, 
2010), those studies were unable to directly map any individual Stau1-binding 
site, and subsequent bioinformatics analysis yielded no clear consensus for 
identified mammalian targets(Laver et al., 2013). Thus, with the exception of a 
few well-characterized bind- ing sites validated by mutagenesis(Ferrandon et al., 
1994; Kim et al., 2007), the exact target sites and RNA structures recognized by 
mammalian Stau1 remain to be determined. To address this, we here undertook 
a tandem affinity purification strategy (RIPiT(Singh et al., 2014)) to map Stau1-
binding sites transcriptome wide in human tissue-cultured cells. We also knocked 
down and over- expressed Stau1 to measure functional consequences on target-
mRNA levels and translation efficiency. Our results revealed a new role for Stau1 
in regulating translation of GC-rich mRNAs by ‘sensing’ overall transcript 
secondary structure.  
 
 
Results 
 
Transcriptome-wide mapping of Stau-binding sites  
Using the Flp-In system and a tetracycline promoter, we generated HEK293 cells 
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that inducibly expressed a single Flag-tagged copy of either the Stau1 65-kDa 
spliced isoform (Stau1-WT) or a mutant version (Stau1-mut) containing point 
mutations in dsRBDs 3 and 4 known to disrupt binding to dsRNA(LUO et al., 
2002b) (Figure B.1.A). Consistently with its propensity to bind dsRNA through the 
sugar-phosphate backbone(Ramos et al., 2000) and with a previous report 
suggesting poor UV-cross-linking ability (Liu et al., 1996), we found that Stau1 
cross-linked with very poor efficiency to poly(A)+ RNA upon shortwave UV 
irradiation of living cells. Therefore we used a RIPiT approach wherein initial 
immunoprecipitation (IP) with anti-Flag antibody was followed by affinity elution 
with Flag peptide and then a second IP with a polyclonal anti- Stau1 antibody. 
RIPiT was performed under two different regimens: (i) To finely-map stable Stau1 
footprints, we extensively digested samples with RNase I in between native anti-
Flag and native anti-Stau1 IPs, generating 30- to 50-nt Stau1-bound RNA 
fragments (FOOT libraries; Figure B.1.B). However, many of these short reads 
derived from Alu repeat elements (described below) and so were not uniquely 
mappable. Further, under native conditions, Stau1 can make new dsRNA 
associations after cell lysis. (ii) Therefore, we also subjected cells to 
formaldehyde cross-linking before lysis, extensively sonicated the lysates to 
shear long RNAs into 200- to 300-nt fragments (thereby increasing their ability to 
be mapped) and performed a denaturing anti-Flag IP and then a native anti-
Stau1 IP (CROSS libraries; Figure B.1.B). Cross-linking and subsequent 
denaturation should both preserve weak in situ interactions that might otherwise 
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dissociate during sample workup and prevent formation of any new interactions 
after cell lysis.  
We sequenced all libraries constructed by 3′-adaptor ligation to RNA 
fragments, reverse transcription and circularization on GAII or HiSeq 2000 
Illumina platforms and then mapped them to HG18 by using RefSeq gene 
annotations. Biological replicates of WT and mut CROSS and WT FOOT libraries 
exhibited extremely high correlations (r >0.98), thus indicating the reproducibility 
of the approach.  
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Figure B.1 Mapping of Stau1 RNA-binding sites reveal coding regions and 
3'UTRs as major occupancy sites 
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(a) Scheme of the tagged WT and mut Stau1 proteins used in this study. (b) Scheme of 
tandem affinity purifications for footprinting (FOOT) and cross-linking (CROSS) library 
construction. (c) Pie charts showing the distribution of sequencing reads for each library. 
(d) Example of Stau1 cross-linking signal across the CDS of ALDOA (NM_184041.2). (e) 
Composite plot of the distribution of sequencing reads across the 5′ UTR, CDS and 3′ 
UTR of all genes for RNA-seq (red), Stau1-WT CROSS (blue) and Stau1-mut CROSS 
(black) libraries. (f) Per-gene scatter plot of CDS ribo-seq read density versus CDS 
Stau1-WT CROSS read density with the associated Spearman correlation and 
calculated P value (n = 2 biological replicates). 
 
 
 
 
 
 
 
 
 
 174 
Stau associates with translating ribosomes  
In contrast to our previous exon junction complex (EJC) RIPiT libraries(Singh et 
al., 2012), all Stau1 FOOT libraries (WT and mut) were dominated by rRNA-
mapping reads (14–30% versus 74–83%, respectively; Supplementary Fig. 2). 
Further, despite attempts to specifically deplete rRNA fragments during CROSS-
library preparation, WT and mut CROSS libraries also contained abundant rRNA-
mapping reads (Supplementary Fig. 2). These findings are consistent with a 
previous report that Stau1 cosediments with 60S ribosomal subunits via 
interactions independent of the functionality of dsRBDs 3 and 4 (ref. 2).  
To further investigate this ribosome association, we performed sucrose 
sedimentation in the presence of inhibitors that either block elongation 
(cycloheximide) or initiation (harringtonine) (Supplementary Fig. 3a). In the 
presence of cycloheximide, both endogenous Stau1 and Flag–Stau1-WT 
cosedimented with 60S sub- units, 80S monosomes and polysomes, with very 
little Stau1 observable in ribosome-free fractions at the top of the gradient. 
However, when lysates were treated with RNase before sedimentation, ~60% of 
Stau1 sedimented at the top of the gradient, with the remainder cosedimenting 
with 60S and 80S ribosomes (Supplementary Fig. 3a). This suggests that 
dsRBP-independent interactions with the ribosome are not the sole factor driving 
Stau1 polysome association. Finally, when translation initiation was blocked with 
harringtonine and elongating ribosomes allowed to complete translation (i.e., run 
off the mRNAs) before cell lysis, Stau1 sedimentation mirrored that of RPL26, an 
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integral 60S protein. Both Stau1 and RPL26 rapidly shifted from heavy polysomal 
to 80S ribosome fractions upon inhibition of translation initiation (Supplementary 
Fig. 3b), suggesting that Stau1 associates with actively translating ribosomes.  
Consistently with our ribosome-association data, approximately half of mRNA-
mapping WT and mut CROSS reads (49% and 54%, respectively) mapped to 
coding exons (CDS regions; Figure B.1.C–E). To test whether these CDS-
mapping reads were due to Stau1 association with translating ribosomes, we 
compared their density to the density of ribosome footprints (ribo-seq; Figure 
B.1.F). For both Stau1-WT (Figure B.1.F; Spearman correlation = 0.89) and 
Stau1-mut (data not shown), CROSS-read density strongly correlated with 
ribosome density in CDS regions. This correlation held for the entire gene 
population, thus suggesting that Stau1 generally associates with elongating 
ribosomes.  
In sum, our data indicate that Stau1 is generally associated with the 60S 
ribosomal subunit, both on and off mRNA. Further, this ribo- some association 
does not require dsRBD functionality but is partially dependent on RNA integrity. 
Last, Stau1 appears to associate with actively translating, not stalled, ribosomes.  
 
Stau binds paired Alu elements in 3′ UTRs  
Whereas WT and mut libraries were quite similar in their rRNA content, they 
were quite different with regard to Alu repeat– mapping reads. Alu repeats are 
 176 
~300-nt primate-specific mobile elements in the short interspersed nuclear 
element family; the human genome contains ~1 million Alu elements, primarily in 
intergenic regions, introns and 3′ UTRs. Reads mapping to Alu repeats 
constituted 42% and 28% of non-rRNA–mapping reads in WT FOOT and 
CROSS libraries, respectively, but only 19% and 14% in the corresponding mut 
libraries (Supplementary Fig. 2). Greater Alu enrichment in WT libraries 
suggested that their interaction depended on Stau1’s ability to bind dsRNA. 
Consistently with this, WT CROSS reads were often highly enriched over and 
adjacent to closely spaced Alu pairs likely to form dsRNA secondary structures. 
We detected such Alu-pair Stau1-binding sites on only two large intergenic 
noncoding RNAs (NR_026757 and NR_026999) and minimally in introns 
(Supplementary Fig. 4). Conversely, they were highly enriched in 3′ UTRs (Figure 
B.2.A and Supplementary Fig. 4) and in select ‘intergenic’ regions immediately 
3′ to annotated 3′ UTRs (Figure B.2.B and Supplementary Fig. 4). 
Polyadenylation-site sequencing (PAS-seq) revealed the intergenic regions to 
represent strongly distal 3′ UTRs(Miura et al., 2013) (Figure.B2.B). Overall, we 
detected 515 strongly distal 3′ UTRs enriched for Stau1-WT CROSS reads 
(Supplementary Table 1), most of which contained multiple Alu pairs.  
To identify those 3′ UTRs most enriched for dsRBD-dependent Stau1 binding, we 
called peaks in the WT CROSS libraries by using ASPeak (an expression-
sensitive peak-calling algorithm(Kucukural et al., 2013)). We then compared, for 
each gene, the cumulative read counts under peak positions in the WT and mut 
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CROSS libraries (Figure B.2.C-D). Overall, the data sets were highly correlated (r 
= 0.83). Nonetheless, an outlier population (n = 574; Supplementary Table 2) 
exhibited much higher cross-linking (by a factor of 2.7) in WT than in mut (Figure 
B. 2.C-D); these outliers constitute a set of high-confidence 3′ UTRs displaying 
dsRNA-dependent Stau1 binding.  
We next investigated the structural features of these targets. To identify those 
containing Alu pairs, we wrote an algorithm to identify, transcriptome wide, pairs 
of full-length Alu elements in the same (tandem) or opposite (inverted) 
orientation. Overlaying the inter-Alu distance for tandem Alu pairs on the WT 
versus mut CROSS scatter plot (Figure B.2.C) revealed no specific relationship 
between tandem pairs and Stau1 cross-linking. However, the inverted Alu-pair 
over- lay revealed a striking coincidence with the above outlier population (Figure 
B.2.D). Further, inverted Alu elements separated by the least distance were the 
most outlying (Figure B.2.D).  
We confirmed the inverse relationship between dsRBD-dependent Stau1 cross-
linking efficiency and inverted-pair inter-Alu distance in composite plots 
(FigureB.3.A and Supplementary Fig. 5). We found similar, but less striking, 
results for inverted pairs containing partial Alu elements and for inverted pairs in 
introns and strongly distal 3′ UTRs (Supplementary Fig. 5a). As expected, we 
observed no specific mapping of WT reads on tandem Alu pairs or mapping of 
mut reads on Alu pairs in either orientation (Figure B.3.A). The inverse  
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Figure B.2 Inverted Alu pairs are an important class of Stau1 binding sites 
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(a,b) Distribution of sequencing reads obtained from RNA-seq (green), Stau1-WT 
CROSS (yellow), Stau1-mut CROSS (blue), Stau1-WT FOOT (brown), Stau1-mut FOOT 
(violet) and PAS-seq libraries (black) for the 3′ UTR of PAICS (NM_001079524) (a) and 
the strongly distal 3′ UTR of BRI3BP (NM_080626.5) (b). (c,d) Per-gene scatter plots of 
Stau1-WT CROSS and Stau1-mut CROSS read counts under called 3′-UTR Stau1-WT 
CROSS peak positions with associated Spearman correlation and calculated P values (n 
= 2 biological replicates). Genes containing a 3′ UTR Alu pair are colored with respect to 
the distance between each tandem Alu pair (c) or inverted Alu pair (d). The dashed  
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correlation between Stau1-WT cross-linking efficiency and inverted-pair inter-Alu 
distance is consistent  with the expectation that secondary-structure formation 
should inversely correlate with pairing-partner distance. Because intact Alu 
elements are ~300 nt, inverted pairs containing full-length Alu elements could 
potentially form very long helices. However, individual elements in pairs 
exhibiting the highest WT cross- linking signal were often from different Alu 
families unlikely to be fully complementary. Consistently with this, in silico folding 
of an inverted Alu pair exhibiting one of the strongest Stau1-WT occupancies 
suggests the presence of many short helices interrupted by small loops (Figure 
B.3.B). To assess the generalizability of this, we folded in silico all-full-length, 3′-
UTR inverted Alu pairs highly enriched for Stau1-WT cross-linking and compared 
them to 3′-UTR sequences of similar length randomly chosen from nontarget 
genes. Histograms of predicted helix and loop lengths (Figure B. 3.C-D revealed 
that Stau1-interacting Alu pairs tend to form structures with multiple helices 
containing<30 interrupted base pairs, spaced by 2- to 10-nt loops. Conversely, 
nontarget 3′ UTRs were predicted to have significantly shorter paired stretches 
(Wilcoxon rank-sum test, P = 0.04) interrupted by longer loops (Wilcoxon rank-
sum test, P = 6 × 10−5).  
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Non-Alu 3′-UTR targets  
Among the outlier population in Figure B.2.D, 201 of 574 contained clearly 
identifiable inverted Alu pairs (Alu targets), and 373 of 574 did not (non-Alu 
targets; Supplementary Table 2). Many of these non-Alu targets had clearly 
defined WT footprints in regions with high base-pairing probability (Figure B.4.A). 
A few contained a single strong footprint corresponding to a short stem-loop 
structure (Figure B.4.A); others resembled inverted Alu pairs with many 
consecutive helices separated by short loops (Figure B.4.B). The largest set, 
however, consisted of complex structures covering a few hundred nucleotides 
within which Stau1 footprints could be observed on multiple 7- to 40-bp helices 
(Figure B.4.C-D). WT footprints were also present on the Arf1 3′ UTR, for which 
the precise Stau1-binding site was previously mapped by mutagenesis 
(Supplementary Fig. 6a)(Kim et al., 2005).  
Comparison of FOOT and CROSS reads mapping to individual 3′ UTRs revealed 
that CROSS reads generally extended over much more of the 3′ UTR than did 
FOOT reads (for example, Figure B.4.C). We could even observe extensive 
CROSS read coverage for many 3′ UTRs having no detectable footprints 
(Supplementary Fig. 6b). Greater abundance of such CROSS reads in WT 
libraries than in mut libraries indicated that they depended on Stau1’s ability to 
bind dsRNA. This suggested that the kinetically stable Stau1-binding sites 
revealed by native footprinting represent only a small subset of RNA-interaction 
sites occurring within cells. Supporting the notion of many low-affinity Stau1-
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interaction sites in vivo, we observed a strong correlation (r = 0.63, P < 2.2 × 
10−16) over all expressed genes between average per-nucleotide predicted 
secondary- structure strength (∆G of the minimum free-energy structure/3′-UTR 
length) and the ratio of total WT/mut CROSS reads per 3′ UTR (Figure B.5.A). 
We observed a similarly strong correlation (r = 0.55, P < 2.2 × 10−16) between 
this ratio and 3′-UTR GC content in all expressed genes (Figure B.5.B).  
We conclude that some Stau1-binding sites in 3′ UTRs consist of highly defined 
structures containing multiple short helices to which Stau1 binding is kinetically 
stable. Other binding sites, however, are more kinetically labile, and the extent of 
Stau1 occupancy on these sites is a function of overall 3′-UTR secondary 
structure–forming propensity, often driven by high GC content.  
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Figure B.3 Characterization of the structural features of Stau1 Alu-binding 
sites 
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(a) Composite plot of Stau1-WT CROSS, Stau1-mut CROSS and RNA-seq read counts 
around tandem or inverted Alu pairs. Read counts normalized to host gene reads per 
kilobase per million mapped reads (RPKM) were determined for a region spanning 1 kb 
up- and downstream of the paired Alu elements separated by the indicated distance (n = 
2 biological replicates). (b) Example of a 3′-UTR inverted Alu-binding site in C11orf58 
(NM_014267.5) showing read counts per million mapped (pmm) reads for RNA-seq, 
Stau1-WT CROSS and Stau1-mut CROSS libraries. The centroid secondary structure 
for this Alu pair predicted with the Vienna folding package is shown below center. (c,d) 
Length distribution of predicted helices (c) and loop (d) regions within secondary 
structures of 3′-UTR inverted Alu pairs or 3′-UTR sequences of identical size randomly 
picked from nontarget genes. P values corresponding to the comparison of helix and 
loop length distributions between Stau1 Alu targets and random 3′ UTRs were calculated 
with the Wilcoxon rank-sum test (n = 2 biological replicates). 
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dsRBD-dependent binding of Stau to CDS regions  
As previously discussed, both WT and mut CROSS reads mirrored ribosome 
density across CDS regions transcriptome wide (Figure B.1.F). WT and mut 
reads were also similarly distributed relative to start and stop codons (Figure 
B.1.E). In contrast to the general population, how- ever, our 373 non-Alu 3′-UTR 
target genes had significantly greater CROSS reads in CDS regions for WT than 
for mut (Figure B.6.A). This strong relationship between 3′ UTR and CDS 
WT/mut cross-linking initially suggested to us that dsRBD-dependent Stau1 
binding within the 3′ UTR increases its association with CDS-bound ribosomes. 
Consistently with this, the correlation between preferential WT cross- linking in 3′-
UTR and CDS regions held true for the entire mRNA population (Figure B.6.B; r 
= 0.61, P < 2.2 × 10−16), with our identified 3′-UTR target genes simply being 
strongly skewed toward the higher end of both ratios. However, we also found 
that predicted per-nucleotide secondary structure–forming propensity and GC 
content were strongly correlated (r = 0.55 and 0.73, respectively, P < 2.2 × 
10−16) between the 3′-UTR and CDS regions of individual genes (Figure B.6. C-
D); that is, the genes with high 3′-UTR secondary structure–forming propensity 
and GC con- tent also tend to have high CDS secondary structure forming 
propensity and GC content. Consistently with this, preferential WT cross-linking 
in CDS regions strongly correlated with both predicted CDS secondary structure 
and GC content (Figure B.6 and e, r = 0.62 and 0.65, respectively, P < 2.2 × 
10−16) and the 5′ UTR (r = 0.2; data not shown). These analyses suggest that 
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enhanced Stau1-WT binding within CDS regions is primarily driven by GC 
content and secondary structure–forming propensity of the CDS itself, rather than 
by interactions of 3′ UTR–bound Stau1 with CDS-bound ribosomes.  
From the above data, we conclude that Stau1 interacts to varying extents with 
the CDS and 3′-UTR regions of all cellular mRNAs in a manner dependent on 
their secondary structure–forming propensities. Further, the observed correlation 
between dsRBD-dependent Stau1 occupancy in CDS and 3′-UTR regions mainly 
reflects similar GC content between the CDS and 3′ UTR in individual genes 
rather than any direct effect of 3′-UTR binding on CDS binding. Instead, Stau1-
WT occupancy on CDS regions appears to be driven by a combination of direct 
interactions with CDS secondary structures and its dsRBD-independent 
association with actively translating ribosomes.  
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Figure B.4 Examples of 3'-UTR non-Alu Staufen-binding sites 
 (a–d) Read distributions for RNA-seq (green), Stau1-WT CROSS (yellow) and Stau1-
WT FOOT (brown) libraries on the 3′ UTRs of LMBR1 (NM_022458.3) (a), TEP1 
(NM_007110.4) (b), IGF2BP1 (NM_006546.3) (c) and MDM2 (NM_002392) (d) (left) 
together with the corresponding centroid secondary structure colored for base-pairing 
probability as predicted by the Vienna folding package (right). Numbers below the Stau1 
WT FOOT track and in the predicted secondary structure correspond to Stau1-binding 
sites. 
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Gene ontology analysis  
To assess whether any particular gene classes were specifically enriched for 
dsRBD-dependent Stau1 binding, we performed gene ontology analysis using 
GeneCodis(Carmona-Saez et al., 2007; Nogales-Cadenas et al., 2009; Tabas-
Madrid et al., 2012b)(Supplementary Table 3). We obtained the most significant 
associations for the 469 genes having the highest WT/mut CDS cross-linking 
ratios (>1.9) and the 515 genes exhibiting high WT cross-linking to strongly distal 
3′ UTRs. Both sets were highly enriched in transcription-regulatory proteins (P = 
7.1 × 10−13 and P = 1.1 × 10−13, respectively). Among transcription- factor 
types, C2H2 zinc-finger proteins were the most enriched (P = 4.5 × 10−6), with 
homeobox and high-mobility group (HMG) proteins following close behind (P = 
1.3 × 10−5 and 6.9 × 10−5, respectively). Consistently with the strong correlation 
between Stau1 CDS and 3′-UTR occupancy, transcription-regulatory proteins 
were also highly enriched among our 373 non-Alu 3′-UTR targets (P = 6.9 × 
10−7). Thus Stau1 may have a role in post-transcriptional regulation of 
transcription factors. Also enriched in the non-Alu and extended 3′-UTR targets 
(P = 0.001 and P = 5.0 × 10−5, respectively), but not in the 469 high CDS 
targets, were proteins involved in cell-cycle control.  
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Figure B.5 Stau1 binding to 3'-UTRs correlates with GC content and 
predicted secondary-structure free energy 
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(a) Per-gene scatter plot of 3′-UTR predicted secondary-structure free energy 
normalized by the length of the 3′ UTR (kcal/mol/nucleotide) against Stau1 WT/mut 3′-
UTR ratio (log2). (b) Per-gene scatter plot of 3′-UTR GC content (%) against Stau1 
WT/mut 3′-UTR ratio (log2) with associated Spearman correlation and calculated P 
values. Red and yellow dots correspond to called Alu and non-Alu binding sites, 
respectively (n = 2 biological replicates). 
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Functional consequences of varying Stau protein levels  
To directly test the functional consequences of Stau1 binding, we next varied 
intracellular Stau1 concentration (Figure B.7A-B). Transduction of HEK293 FLP-
in cells with a lentivirus expressing an anti-Stau1 short hairpin RNA (shRNA) 
stably reduced endogenous Stau1 to ~20% normal levels (UNDER, Figure 
B.7.A). Incubation of our stably integrated Flag–Stau1-WT cells overnight (16 h) 
with a high level of doxycycline induced transgene overexpression by 300–400% 
relative to endogenous Stau1 (OVER). We then assessed effects of Stau1 
depletion or overexpression by preparing cytoplasmic poly(A)+ RNA-seq and 
ribo-seq libraries.  
RNA-seq and ribo-seq read counts on individual genes were highly correlated 
both between biological replicates (r ≥ 0.98; E.P.R., unpublished data) and 
between UNDER and OVER samples (r ≥ 0.98; Supplementary Fig. 7). Other 
than STAU1 itself, there were no clear outlier genes between UNDER and OVER 
conditions for either RNA-Seq or ribo-seq. Further, no significant changes in 
alternative- splicing patterns could be detected (data not shown); thus, at least in 
HEK cells, binding of Stau1 in introns is of little apparent con- sequence for pre-
mRNA splicing. However, small negative correlations between RNA levels and 
Stau1 levels could be detected when we ordered transcripts by CDS GC content 
or preferential Stau1-WT CDS cross-linking (Figure B.7.C-D). That is, transcripts 
with high CDS GC content (which drives greater Stau1-WT CDS binding) 
exhibited slightly lower cytoplasmic mRNA abundances when Stau1 was 
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overexpressed than underexpressed.  
The strongest observable effect of varying Stau1 concentration was on ribosome 
occupancy. Cumulative histograms revealed positive relationships between 
ribosome occupancy and both Stau1-WT CDS cross-linking and CDS GC 
content across the entire transcriptome (Figure B.7.C-D; Spearman correlation r 
= 0.21 and r = 0.34, respectively, P < 2.2 × 10−16). That is, genes with higher 
Stau1 CDS occupancy and higher CDS GC content exhibited increased 
ribosome occupancy upon Stau1 overexpression compared to Stau1 knockdown; 
conversely, genes with lower Stau1 CDS occupancy and CDS GC con- tent 
exhibited decreased ribosome occupancy upon Stau1 overexpression compared 
to Stau1 knockdown. This suggests that higher Stau1 protein levels increase 
ribosome occupancy on high-GC-content transcripts at the expense of low-GC-
content transcripts. Ontology analysis of the 400 genes exhibiting the greatest 
increase in ribosome occupancy between UNDER and OVER conditions 
revealed significant enrichments for transcription-regulatory proteins (P = 0.004) 
and zinc-binding proteins (P = 1.1 × 10−6; Supplementary Table 3), the same 
terms obtained above for genes exhibiting the highest CDS and extended 3′-UTR 
Stau1 occupancies.  
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Figure B.6 Stau1 occupancy on the CDS strongly correlates with GC 
content and predicted secondary-structure free energy 
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(a) Composite plot of the distribution of sequencing reads across the 5′ UTR, CDS and 3′ 
UTR of called Stau1-target genes for RNA-seq (red), Stau1-WT CROSS (blue) and 
Stau1-mut CROSS (black) libraries. (b) Per-gene scatter plot (log10) of total CDS Stau1-
WT CROSS read counts/total CDS Stau1-mut CROSS reads counts (CDS ratio) versus 
the ratio of Stau1-WT CROSS and Stau1-mut CROSS read counts under called 3′-UTR 
Stau1-WT CROSS peak positions (3′-UTR peak ratio). Red and yellow dots correspond 
to called Alu- and non-Alu–binding sites, respectively. (c) Per-gene scatter plot of 3′ UTR 
against CDS predicted secondary-structure free energy normalized by the length of the 
3′ UTR (kcal/mol/nucleotide). (d) Per-gene scatter plot of 3′ UTR against CDS GC 
content (%). (e) Per-gene scatter plot of CDS predicted secondary-structure free energy 
normalized by the length of the CDS (kcal/mol/nucleotide) against Stau1 WT/mut 3′-UTR 
ratio (log2). (f) Per-gene scatter plot of CDS GC content (%) against Stau1 WT/mut 3′-
UTR ratio (log2). All correlation coefficients and P values were calculated with the 
Spearman rank correlation (n = 2 biological replicates) throughout figure. 
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Although we observed the strongest effects of varying Stau1 protein levels for 
genes with high Stau1 CDS occupancy, we also examined the effects of Stau1 
over- and underexpression on our 3′-UTR non- Alu and Alu target sets. 
Ribosome occupancy increased slightly on non-Alu 3′-UTR targets (10% change 
from UNDER to OVER; P = 0.00005) when compared to the total population, 
whereas their mRNA levels decreased slightly (−2% change from UNDER to 
OVER; P = 0.01). Thus, non-Alu targets behaved like high-GC-content mRNAs. 
Conversely, Alu targets exhibited no significant change in ribosome occupancy, 
but their cytoplasmic mRNA levels increased upon Stau1 upregulation (+8% 
change from UNDER to OVER; P = 0.03; Figure B.7.E). Therefore, mRNAs 
containing 3′-UTR inverted Alu pairs behave differently from other cellular 
mRNAs in response to Stau1 abundance. For the strongly distal 3′-UTR Stau1-
binding sites, we detected no significant effect of Stau1 expression on either 
mRNA levels or ribosome occupancy (E.P.R., unpublished data), possibly 
because such isoforms represent only a minor fraction of transcripts from 
individual loci.  
To confirm that changes in Stau1 levels are of little consequence for levels of 
mRNAs with 3′ UTR–binding sites, we performed quantitative reverse-
transcription PCR (qRT-PCR) on several Alu and non- Alu 3′-UTR target mRNAs 
including Arf1, a previously identified SMD target (Supplementary Fig. 8). 
Consistently with our RNA-seq results, neither downregulation nor 
overexpression of Stau1 had a significant impact on the abundance of tested 
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targets (Supplementary Fig. 8a). Experiments performed in two other cell lines 
(Huh7 and SK-Hep1) in which either Stau1 or Stau2 or both were downregulated 
yielded similar results (Supplementary Fig. 8b,c).  
Taken together, our results indicate that Stau1 binding to the CDS results in 
increased ribosome occupancy and in decreased mRNA levels proportionate to 
both the amount of bound Stau1 and the GC content of the target mRNA. 
Further, at least in the cell lines we tested, Stau1 binding within the 3′ UTR 
appears to be of little or no consequence for translation efficiency or steady-state 
mRNA levels.  
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Figure B.7 Consequences of Stau1 binding on RNA levels and ribosome 
density 
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(a) Inset, western blot of lysates from control cells, cells expressing anti-Stau1 shRNA 
and cells overexpressing Flag–Stau1-WT. Bar graph, quantitation of inset blot (n = 2). 
Uncropped gel image is shown in Supplementary Figure 7a. (b) Workflow for ribosome 
profiling and RNA-seq analysis for cells expressing anti-Stau1 shRNA or overexpressing 
Flag–Stau1-WT. (c) Cumulative plots of cytoplasmic RNA levels (left) and ribosome 
density (right) fold change (log2) between cells overexpressing Flag–Stau1-WT and cells 
expressing anti-Stau1 shRNA, based on Stau1 WT/mut CDS ratio. (d) Same as c but 
based on CDS GC content. (e) Box-plot representation of mRNA levels (left) and 
translation efficiency (right) fold change (log2 scale) between cells overexpressing Flag–
Stau1-WT and cells expressing anti-Stau1 shRNA for genes lacking Stau1 3′ UTR–
binding sites (nontargets), genes with 3′-UTR inverted Alu target sites (Stau1 Alu 
targets) and genes with 3′-UTR non-Alu Stau1-target sites (Stau1 non-Alu targets). The 
upper and lower 'hinges' correspond to the first and third quartiles. The upper whisker 
extends from the hinge to the highest value within 1.5× interquartile range (or distance 
between the first and third quartiles) of the hinge. The lowest whisker extends from the 
hinge to the lowest value within 1.5× interquartile range of the hinge. Data points beyond 
the end of the whisker correspond to outliers. All P values were calculated with the 
Kolmogorov–Smirnov test (n = 2 biological replicates) throughout figure. 
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Figure B.8 Model of Stau1 RNA binding and its functional role in translation 
 
Stau1 interacts with both actively translating ribosomes and secondary structures in 
CDS and 3′-UTR regions. Some 3′ UTRs contain highly complex secondary structures 
(for example, inverted Alu pairs) that serve as kinetically stable Stau1-binding sites. 
However, Stau1 also makes transient interactions with smaller secondary structures 
throughout CDS and 3′-UTR regions. Formation of these structures is a function of 
overall CDS and 3′-UTR GC content. Whereas interaction of Stau1 with 3′-UTR Alu pairs 
has a small positive effect on cytoplasmic mRNA levels, high Stau1 CDS occupancy 
both increases ribosome density and slightly decreases cytoplasmic mRNA levels. 
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Methods 
 
Plasmids and cell lines 
pcDNA5-TetO-Flag was previously described(Ivanov et al., 2008). A cDNA 
encoding Stau1 (HindIII-NotI) was inserted into the polylinker of pcDNA5-TetO-
Flag. A cDNA encoding the Stau1 mutant lacking RNA-binding activity was 
created by PCR using primers carrying the mutations described in ref. 2, in which 
phenylalanines at position 216 in dsRBD3 and at position 319 in dsRBD4 were 
mutated into alanines. 
Stable cell lines were generated as described in ref. 38. In these cells, the 
expression level of the stably integrated Flag-tagged protein was optimized by 
titration of doxycycline (Dox; 0–2,000 ng ml−1) to determine a concentration at 
which exogenous protein expression levels were comparable to those of 
endogenous counterparts. 
Generation of Stau1-knockdown cell line 
HEK293T LentiX cells (Clontech) were transfected with pGIPZ encoding shRNAs 
directed against Stau1 (Open Biosystems, CloneID: V2LHS_42695), pPAX2 and 
pMD2.G at a 12:9:3 ratio with Lipofectamine 2000 (Invitrogen). 2 d after 
transfection, the supernatant of transfected cells was collected and passed 
through a 0.45-µm filter. To generate the Stau1-knockdown cell line, HEK293 
TRex cells (Invitrogen) were transduced with 7 mL of the supernatant of lentiviral-
producing cells in the presence of 10 µg ml−1 polybrene for 6 h. Transduced cells 
were then selected in the presence of puromycin (3 µg ml−1) for 2 weeks. 
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Stau1 RIPiT 
The procedure was performed essentially as described in (ref.(Ivanov et al., 
2008)). For each Staufen purification, TRex-HEK293 cells containing a stable 
copy of Flag-tagged Stau proteins (Stau1-WT and Stau1-mut) or control cells 
(expressing Flag tag only) were grown in four 15-cm plates. Expression of the 
Flag-tagged protein was induced with doxycycline for 16 h. 1 h before cell 
harvesting, cycloheximide (CHX) was added to 100 µg ml−1. The monolayer was 
rinsed and harvested in phosphate-buffered saline (PBS) containing 100 µg ml−1 
CHX. The cells were lysed in 3 ml hypotonic lysis buffer (20 mM Tris-HCl, pH 7.5, 
15 mM NaCl, 10 mM EDTA, 0.5% NP-40, 0.1% Triton X-100, 1× EDTA-free 
protease inhibitor cocktail (ROCHE), and 100 µg ml−1 CHX) for 10 min on ice. 
The suspension was sonicated (Branson Digital Sonifier-250) at 40% amplitude 
with a Microtip for a total of 20 s (in 2-s bursts with 10-s intervals). NaCl was 
adjusted to 150 mM, and the lysate was cleared by centrifugation at 15,000g for 
10 min at 4 °C. The lysate was incubated for 2 h at 4 °C with 420 µl of anti-Flag 
agarose beads (50% slurry, Sigma) prewashed twice with 10 ml isotonic wash 
buffer (IsoWB) (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% NP-40). The 
RNA–protein (RNP) complexes captured on beads were washed four times (4 × 
10 ml) with 10 ml IsoWB. After the fourth wash, bound RNP complexes were 
incubated with one bed volume of IsoWB containing 1 U µl−1 of RNase I for 10 
min at 37 °C with intermittent shaking. RNP complexes were again washed four 
times with 10 ml IsoWB. Flag epitope–containing complexes were affinity eluted 
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from the beads in one bed volume of IsoWB containing 250 µg.ml−1 Flag peptide 
with gentle shaking at 4 °C for 2 h. To prepare the recovered elution for input into 
a second IP, its volume was adjusted to 400 µl and its composition adjusted to 
that of the lysis buffer above with NaCl at 150 mM. The suspension was 
incubated with 7 µg of anti-Stau1 antibody (ab105398, Abcam, validation of IP in 
Supplementary Fig. 1c,d) precoupled to 35 µl of Protein G Dynabeads 
(Invitrogen) according to the manufacturer's instructions. Immunoprecipitation 
was carried out at 4 °C for 2 h. Captured RNP complexes were washed six times 
with 1 ml of ice-cold IsoWB and eluted with 200 µl of clear sample buffer (100 
mM Tris-HCl, pH 6.8, 4% SDS, 10 mM EDTA and 100 mM DTT) at 25 °C for 5 
min and subsequently at 95 °C for 2 min. 
For IPs under protein–cross-linking conditions, cells were collected and rinsed 
once in PBS + CHX and then resuspended in PBS + CHX. Formaldehyde was 
added to 0.1%, and the suspension was gently mixed at RT for 10 min. A one-
tenth volume of quenching buffer (2.5 M glycine, and 25 mM Tris base) was 
added. Cells were pelleted and lysed in hypotonic lysis buffer supplemented with 
0.1% SDS and 0.1% sodium deoxycholate. Sonication after cell lysis was 
performed at 40% amplitude with a Microtip for a total of 90 s (in 5-s bursts with 
30-s intervals). After Flag IP as described above, IP samples were washed twice 
with IsoWB + 0.1% SDS and 0.1% sodium deoxycholate and then with IsoWB. 
All subsequent steps were as above with omission of RNase I treatment. 
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RIPiT RNA extraction 
The volume of RIPiT elution was extracted as described in ref. (Ivanov et al., 
2008). For Stau1 cross-linked RIPiT experiments, extracted RNAs were depleted 
of rRNA before cDNA library construction with the Ribozero rRNA-removal kit 
from Epicentre. 
 
Preparation of samples for RNA-Seq 
75 µg of total RNA were poly(A)-selected with the Dynabeads mRNA-purification 
kit (Invitrogen). After poly(A) selection, mRNAs were fragmented with RNA-
fragmentation buffer (Ambion) for 4 min and 30 s at 70 °C to obtain fragments 
100–125 nt long. After fragmentation, RNAs were precipitated in three volumes 
of 100% ethanol at −20 °C overnight. After a wash with 70% ethanol, RNA was 
resuspended in 5 µl of water and the 3′ ends dephosphorylated with PNK (New 
England BioLabs) for 1 h at 37 °C. After this, RNAs were subjected to cDNA 
library preparation. 
 
Poly(A)-site sequencing (PAS-Seq) 
75 µg of total RNA were poly(A)-selected with the Dynabeads mRNA purification 
kit (Invitrogen). After poly(A) selection, mRNAs were fragmented with RNA 
fragmentation buffer (Ambion) for 5 min at 70 °C to obtain fragments 60–80 nt 
long. After fragmentation, RNAs were reverse transcribed with an anchored and 
barcoded oligo(dT)21VN (where V corresponds to A, C or G residues) containing 
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the sequences complementary to Illumina's paired-end primers (PE1.0 and 
PE2.0) separated by a polyethylene glycol (PEG) spacer. After reverse 
transcription (RT) with Superscript III (Invitrogen), cDNAs were size-selected and 
circularized with Circligase I (Epicentre) for 4 h at 60 °C. This was followed by 
inactivation at 80 °C for 10 min. After circularization, cDNAs were PCR-amplified 
with Illumina's PE1.0 and 2.0 primers for a total of 14 cycles. PCR products were 
size-selected on a nondenaturing polyacrylamide gel and sent for high-
throughput sequencing on Illumina's HiSeq2000 platform. 
 
Quantitative RT-PCR 
Total RNA from HEK293, Huh7 and HepG2 cells transfected with control shRNA 
or a Stau1-targeting shRNA construct was reverse transcribed with the Vilo RT 
kit from Life Technologies. Obtained cDNAs were then used as input for 
quantitative PCR analysis as described in ref. 48 with the following primers: 
GAPDH forward, 5′ tccaccaccctgttgctgtag 3′ and reverse, 
5′acccactcctccacctttgac3′; Arf1 forward, 5′ atcttcgcctcccgactc 3′ and reverse, 
5′atgcttgtggacaggtgga3′; C11orf58 forward, 5′ cagacgacgatctgggatct 3′ and 
reverse, 5′ tgatctcctataacaagacgaccag 3′; PAICS forward, 5′ 
aaggaaaagctgcaatctcaa 3′ and reverse, 5′ ccccacattttctggtgaag 3′; MDM2 
forward, 5′ catgcctgcccactttaga 3′ and reverse, 5′ ggaggctcccaactgctt 3′; MDM4 
forward, 5′ agggatgaaatgcttcttgg 3′ and reverse, 5′ aaggttgctatgaggtctaccttg 3′. 
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Sucrose-gradient sedimentation of Flag–Stau1-WT cells. 
HEK293 cells were plated at 5 million in a 150-mm2 plate and Flag–Stau1-WT 
expression induced overnight with doxycycline at 0.5 ng ml−1. 16 h after 
induction, cells were either incubated with cycloheximide (100 µg ml−1) for 10 min 
or with harringtonine (2 µg ml−1) for either 3, 10 or 40 min. This was followed by 
incubation with cycloheximide (100 µg ml−1) for 10 min. Cells were then washed 
in PBS + cycloheximide (100 µg ml−1) or PBS + harringtonine (2 µg ml−1) + 
cycloheximide (100 µg ml−1) and scraped. Cells were then lysed in 1 ml of lysis 
buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 100 mM KCl, 1% Triton X-100, 2 
mM DTT, 100 µg/ml cycloheximide and 1× Protease-Inhibitor Cocktail EDTA-free 
(Roche). Lysate was homogenized by gentle pipetting up and down with a P1000 
pipettor for a total of eight strokes and incubated at 4 °C for 10 min. The lysate 
was centrifuged at 1,300g for 10 min at 4 °C; the supernatant was recovered. 
After this, samples were loaded on top of a 10–50% (w/v) sucrose gradient (20 
mM HEPES-KOH, pH 7.4, 5 mM MgCl2, 100 mM KCl, 2 mM DTT, and 100 µg 
ml−1 cycloheximide) and centrifuged in a SW-40ti rotor at 35,000 r.p.m. for 2 h 40 
min at 4 °C. Samples were fractionated into 14 individual samples that were 
subjected to SDS-PAGE to monitor Stau1 (ab105398, Abcam, 1:1,000 dilution) 
and Rpl26 (Bethyl, A300-685A, 1:1,000 dilution) levels by western-blotting. 
Experimental validation of antibodies used for western blots can be found at the 
manufacturers' websites. 
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Oligo(dT) pulldown of poly(A) RNAs after UV exposure of living cells 
HEK293 Flp-In cells were exposed to 0, 0.2, 0.4 and 0.8 J cm−2 of 254-nm UV 
light. Cells were then scraped and lysed with binding buffer (0.5 M NaCl, 10 mM 
Tris-HCl, pH 7.5, 0.5% SDS, 0.1 mM EDTA and protease inhibitor cocktail). Cell 
lysates were passed through a 22-gauge syringe needle five times and spun at 
15,000g for 10 min. Cleared cell lysates were added to oligo(dT) cellulose beads 
(Ambion, AM10020) previously washed in binding buffer. After 1 h of incubation 
at room temperature, beads were washed three times with binding buffer and 
once with nondenaturing wash buffer (0.5 M NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% 
NP-40, 0.1% Triton-X 100 and 0.2 mM EDTA). Finally, beads were resuspended 
in elution buffer (10 mM Tris-HCl, pH 7.5, and 1 mM EDTA) complemented with 
RNase A/T1 cocktail (Ambion AM2286) and incubated at 37 °C for 1 h. The 
supernatant was finally recovered and loaded on a 12% SDS-PAGE for western-
blotting of hnRNPA1 and Stau1. 
 
Stau1 RNA reassociation test 
HEK293 Flp-In, Flag–Stau1-WT or Flag–Stau1-mut cells were harvested and 
lysed as described in the Stau1 RIPiT section (above). After cell lysis, 0.1 pmol of 
a radiolabeled in vitro–transcribed Arf1 3′-UTR sequence (labeled with [α-
32P]UTP) was added for each 150-mm2 plate. The remaining procedure is 
identical to that described in the Stau1 RIPiT section until the Flag elution step. 
 208 
Flag eluates on each sample were monitored for radioactivity with liquid 
scintillation. 
 
Ribosome profiling 
HEK293 Flag–Stau1-WT cells incubated in the presence of 1 ng ml−1 of 
doxycycline (Stau1 overexpression) or not (control) as well as HEK293 cells 
expressing the shRNAs against Stau1 (Stau1 knockdown) were seeded at 5 
million cells in a 150-mm dish. After 16 h of culture, cycloheximide was added to 
100 µg ml−1 for 10 min. Cells were then washed two times in ice-cold PBS + 
cycloheximide (100 µg ml−1) and scraped in 1 ml of PBS + cycloheximide (100 µg 
ml−1). Cells were pelleted at 500g for 5 min at 4 °C and lysed in 1 ml of lysis 
buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 100 mM KCl, 1% Triton X-100, 2 
mM DTT, 100 µg/ml cycloheximide and 1× Protease-Inhibitor Cocktail EDTA-free 
(Roche)). Lysate was homogenized with a P1000 pipettor by gentle pipetting up 
and down for a total of eight strokes and incubated at 4 °C for 10 min. The lysate 
was centrifuged at 1,300g for 10 min at 4 °C, the supernatant recovered and the 
absorbance at 260 nm measured. For the footprinting, 5 A260 units of the 
cleared cell lysates were incubated with 300 units of RNase T1 (Fermentas) and 
500 ng of RNase A (Ambion) for 30 min at RT. After this, samples were loaded 
on top of a 10–50% (w/v) linear sucrose gradient (20 mM HEPES-KOH, pH 7.4, 5 
mM MgCl2, 100 mM KCl, 2 mM DTT and 100 µg ml−1 of cycloheximide) and 
centrifuged in a SW-40ti rotor at 35,000 r.p.m. for 2 h 40 min at 4 °C. 
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Samples were then collected from the top of the gradient while absorbance was 
measured at 254 nm and the fraction corresponding to 80S monosomes 
recovered. The collected fraction was complemented with SDS to 1% final and 
proteinase K (200 µg ml−1) and then incubated at 42 °C for 45 min. After 
proteinase K treatment, RNA was extracted with one volume of phenol (pH 
4.5)/chloroform/isoamyl alcohol (25:24:1). The recovered aqueous phase was 
supplemented with 20 µg of glycogen, 300 mM sodium acetate, pH 5.2, and 10 
mM MgCl2. RNA was precipitated with three volumes of 100% ethanol at −20 °C 
overnight. After a wash with 70% ethanol, RNA was resuspended in 5 µl of water 
and the 3′ ends dephosphorylated with PNK (New England BioLabs) in MES 
buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM β-mercaptoethanol 
and 300 mM NaCl) at 37 °C for 3 h. Dephosphorylated RNA footprints were then 
resolved on a 15% acrylamide (19:1), 8 M urea denaturing gel for 1 h 30 min at 
35 W and fragments ranging from 26 nt to 32 nt size-selected from the gel. Size-
selected RNAs were extracted from the gel slice by overnight nutation at RT in 
RNA elution buffer (300 mM NaCl, and 10 mM EDTA). The recovered aqueous 
phase was supplemented with 20 µg of glycogen, 300 mM sodium acetate, pH 
5.2, and 10 mM MgCl2. RNA was precipitated with three volumes of 100% 
ethanol at −20 °C overnight. After a wash with 70% ethanol, RNA was 
resuspended in 5 µl of water and subjected to cDNA library construction. 
The remaining undigested cell lysates were extracted with an equal volume of 
phenol (pH 4.5)/chloroform/isoamyl alcohol (25:24:1). The recovered aqueous 
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phase was supplemented with 20 µg of glycogen, 300 mM sodium acetate, pH 
5.2, and 10 mM MgCl2. RNA was precipitated with three volumes of 100% 
ethanol at −20 °C overnight. After a wash with 70% ethanol, RNA was 
resuspended in 9 µl of water and fragmented with RNA fragmentation buffer 
(Ambion) at 70 °C for 4 min 30 s in order to obtain RNA fragments of 100–150 nt. 
Fragmented RNAs were supplemented with 20 µg of glycogen, 300 mM sodium 
acetate, pH 5.2, and 10 mM MgCl2 and precipitated with three volumes of 100% 
ethanol at −20 °C overnight. After a wash with 70% ethanol, RNA was 
resuspended in 5 µl of water and dephosphorylated as described above with 
PNK. After 3′-end dephosphorylation, RNA fragments were subjected to cDNA 
library construction. 
 
Illumina cDNA library construction 
cDNA libraries were prepared with a homemade kit (E.E.H., unpublished data). 
Briefly, RNA fragments with a 3′-OH were ligated to a preadenylated DNA 
adaptor. Following this, ligated RNAs were reverse transcribed with Superscript 
III (Invitrogen) with a barcoded reverse-transcription primer that anneals to the 
preadenylated adaptor. After reverse transcription, cDNAs were resolved in a 
denaturing gel (10% acrylamide and 8 M urea) for 1 h and 45 min at 35 W. Gel-
purified cDNAs were then circularized with CircLigase I (Epicentre) and PCR-
amplified with Illumina's paired-end primers 1.0 and 2.0 for 5 cycles (ribosome 
footprints), 12 cycles (Stau1 RIPiT) or 16 cycles (RNA-Seq libraries). PCR 
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amplicons were gel-purified and submitted for sequencing on the Illumina HiSeq 
2000 platform. 
 
Mapping of high-throughput sequencing reads 
First, reads were split with respect to their 5′-barcode sequence. After this, 5′-
barcode and 3′-adaptor sequences were removed from reads. Reads were then 
aligned to University of California, Santa Cruz (UCSC) human hg18 assembly 
with TopHat (Trapnell et al., 2009). Unmapped reads from TopHat were then 
mapped with Bowtie50 to a custom set of sequences including 18S, 28S, 45S, 5S 
and 5.8S rRNA, repeat elements, small-nuclear RNAs (snRNAs), tRNAs, 
microRNAs and pre-microRNAs. 
 
Transcript-level quantification and normalization for all high-
throughput sequencing libraries 
Read counts from all high-throughput sequencing libraries were normalized to 
the total number of mapped reads. When a single read aligned across the 
boundary of two different regions (for example, CDS and 3′ UTR), the read was 
divided proportionally to the aligned length in the given region. To quantify gene 
expression, reads per kilobase per million of mapped reads (RPKM) were 
calculated for the most abundant isoform of each gene. 
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Transcriptome-wide pairing of inverted and tandem Alu elements 
Genomic coordinates for all Alu elements were obtained from the repeat-masker 
track of the UCSC genome browser. With the BedTools (Quinlan and Hall, 2010) 
intersectBed function with –s(strand) option, we obtained coordinates of all Alu 
elements located in 3′ UTRs, distal 3′ UTRs and introns. After this step, Alu 
elements in Watson and Crick strands were separated. To pair inverted Alu 
elements, we used the ClosestBed function between Alu elements in the Watson 
and Crick strands. The same steps were also performed to detect same-strand 
pairs on Watson-Watson and Crick-Crick pairs. In this case, tandem pairs that 
had an inverted Alu pair less than 2,000 nt apart were excluded from the 
analysis. 
 
Definition of distal 3′-UTR regions 
To define distal 3′-UTR regions, we used PAS-seq mapped reads. For this, 
peaks were called from the PAS-Seq library with ASPeak. With the BedIntersect 
function (BedTools) we found all genes that had a polyadenylation site within 
10,000 nt of the canonical polyadenylation site, provided that they were upstream 
of the transcription start site of the downstream gene. If multiple peaks were 
called within that interval, the called peak most distal to the canonical 
polyadenylation site was selected. 
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Counting of sequencing reads for Alu pairs separated by different 
distances 
With the genomic coordinates of tandem and inverted Alu pairs described above, 
we created a new file for each region (3′ UTR, distal 3′ UTR and introns) that 
contained the genomic coordinates of each Alu element within every pair in 
addition to 1,000 nt upstream of the 5′-most Alu element and 1,000 nt 
downstream of the 3′-most Alu element. After this, read counts from Stau1-WT 
CROSS, Stau1-mut CROSS and RNA-seq were obtained for each defined region 
within pairs and then normalized with RNA-seq RPKM value for the same 
interval. Normalized read counts for each interval were added for all Alu pairs 
located between 0 and 200 nt, 200 and 500 nt, 500 and 1,000 nt, 1,000 and 
2,000 nt, and 2,000 nt and beyond. 
 
Secondary-structure analysis of inverted Alu pairs 
To analyze the secondary structure of inverted Alu pairs, we obtained the 
sequence of both Alu elements, including the region separating them. As a 
control, same-length sequences were randomly chosen from the list of genes 
devoid of Stau1-target sites. After the sequences were obtained, the Vienna 
Package RNAfold 2.1.1 (ref. (Gruber et al., 2008) ) was used to predict 
secondary structures. 
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Analysis of ribosome-profiling reads 
To calculate translational-efficiency changes upon knockdown or overexpression 
of Stau1, we used a generalized linear model (GLM). We used the number of 
sequencing reads mapping to the annotated coding region (or ORF) for each 
RefSeq transcript. In the GLM, we used the cell type (overexpression of 
Stau1WT, Stau1-shRNA), sequence-library preparation batch and type of 
sequence data (RNA-seq or ribo-seq) as predictor variables of the number of 
mapped reads per transcript. We had two biological replicates for all conditions, 
which were used to estimate a biological variability in the number of counts. We 
used a trended dispersion estimation method, following ref. (McCarthy et al., 
2012). To extract translation-efficiency changes upon a given treatment, we used 
the contrast between type of sequence data, ribo-seq versus RNA-seq, in each 
pair of conditions. 
 
Accession codes 
High-throughput sequencing data corresponding to native and cross-linked Stau1 
RIPiT experiments as well as PAS-seq, RNA-seq and ribo-seq have been 
deposited in the GEO database under accession number GSE52447. 
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Discussion 
Like many RNA-binding factors, the Drosophila and mammalian Staufen proteins 
have been implicated in multiple post-transcriptional processes including 
alternative splicing(Ravel-Chapuis et al., 2012b), RNA localization(Kiebler et al., 
1999; Macchi et al., 2004; Micklem et al., 2000; St Johnston et al., 1991), 
translational activation(Dugré-Brisson et al., 2005) and translation-dependent 
mRNA decay(Cho et al., 2012; Gleghorn et al., 2013; Kim et al., 2005; Kretz et 
al., 2013; Park et al., 2013; Vessey et al., 2008). Which activity is observed 
depends on the cellular context, the identity of the bound RNA and the location of 
the binding site on the target RNA. Many of Staufen’s previously documented 
activities parallel those of the EJC(Cho et al., 2012; Dugré-Brisson et al., 2005; 
Ferrandon et al., 1994; Ghosh et al., 2012; Gleghorn et al., 2013; Kim et al., 
2005; Nott et al., 2004; Wiegand et al., 2003). To better understand EJC function, 
we recently determined the complete EJC RNA-binding landscape in HEK293 
cells(Singh et al., 2012). Here we undertook the same analysis for Stau1.  
Up to now, confirmed Staufen-binding sites were limited to a few well-
characterized structures(Ferrandon et al., 1994; Kim et al., 2005). Broader 
identification of Staufen- associated mRNAs has been attempted in various 
organisms by combination of native RIP protocols with microarray analysis(Furic 
et al., 2008; Kusek et al.; Laver et al., 2013; Maher-Laporte and 
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DesGROSEILLERS, 2010). Unfortunately, however, such methodologies have 
yielded no consensus as to general features of Staufen targets. One recent study 
of Staufen-associated mRNAs from Drosophila oocytes reported enrichment of 
three different secondary-structural motifs that might explain Staufen binding 
specificity in flies(Laver et al., 2013). However, the authors were unable to 
identify similar structural motifs among human Staufen-associated mRNAs from 
available native mammalian Stau1 and Stau2 RIP microarray data(Furic et al., 
2008). We show here that human Stau1 generally associates with actively 
translating ribosomes; therefore, it is impossible to discriminate between sites of 
direct Stau1-mRNA inter- action via dsRNA binding and sites of indirect Stau1-
mRNA association via elongating ribosomes without some sort of footprinting 
approach. Further, because of (i) Stau1’s strong ribosome association, (ii) the 
prevalence of kinetically labile Stau1-binding sites in vivo and (iii) Stau1’s ability 
to form new interactions with dsRNA after cell lysis, native RIP experiments are 
likely to be biased toward both highly translated mRNAs and RNAs containing 
the most stable sites of direct Stau1-dsRNA interaction. Our experimental design, 
which combined formaldehyde cross-linking and fragmentation of Stau1-
associated RNAs, using both WT and mut proteins, allowed us to both avoid 
binding-site reassortment after cell lysis and discriminate between binding modes 
that do or do not require Stau1 dsRBD functionality.  
The majority of non-rRNA reads in our cross-linked libraries mapped sense to 3′ 
UTRs and CDS regions. Within 3′ UTRs, we identified numerous high-occupancy 
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Stau1-binding sites com- posed of either inverted Alu pairs (Alu targets) or 
sequences with extremely high secondary structure–forming propensity (non-Alu 
targets). Observable native Stau1 footprints showed that these struc- tures often 
consist of several closely spaced helices separated by short loops. 
Bioinformatics analysis of the footprints, however, failed to identify any particular 
enriched motif (A.K. and E.P.R., unpublished data), results consistent with the 
idea that Staufen recognizes dsRNA in a sequence-independent manner(Marión 
et al., 1999; Monshausen et al., 2001; Wickham et al., 1999).  
Unexpectedly, in addition to detecting strong binding to large RNA secondary 
structures, we also detected extensive dsRBD-dependent Stau1 cross-linking 
extending throughout the entire length of 3′ UTRs and CDS regions. This cross-
linking strongly correlated with both GC content and per-nucleotide predicted 
secondary-structure strength. Because GC content in CDS and 3′-UTR regions 
also correlate, mRNAs exhibiting preferential Stau1-WT 3′-UTR cross-linking also 
tend to exhibit preferential Stau1-WT CDS cross-linking. Inverted Alu pairs, the 3′ 
UTRs containing them and their associated CDS regions, however, exhibit 
average GC content. Despite high Stau1 occupancy on such 3′ UTRs, their CDS 
occupancies are close to levels that would be expected from their GC content 
alone. We therefore conclude that the strongest feature driving dsRBD-
dependent Stau1 binding within CDS regions is the secondary structure–forming 
propensity of the CDS itself. Thus dsRBD-dependent Stau1 binding to 3′ UTRs 
appears to be functionally uncoupled from dsRBD-dependent Stau1 binding to 
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CDS regions, with the correlation between 3′ UTR and CDS cross- linking driven 
primarily by GC-content similarity.  
Our results suggest that endogenous Stau1 RNA targets can be divided into two 
broad classes dependent on their structural topology. One class corresponds to 
stable RNA secondary structures such as inverted Alu pairs and other sequences 
with extremely high secondary structure–forming propensity. Such elements are 
capable of simultaneously binding multiple Staufen molecules whose association 
may be further stabilized by multimerization. Close association of multiple 
Staufen-binding sites would assure continuous Staufen occupancy even though 
individual protein molecules might come and go. It is of note that we generally 
detected such binding sites in annotated 3′ UTRs and extended 3′ UTRs, the 
latter being particularly rich in inverted Alu pairs. Recently, extended 3′ UTRs 
were shown to be especially prevalent in the brain. Because Stau1 is known to 
have a role in dendritic mRNA targeting, these stable RNA secondary structures 
with their long-lived Stau1 associations could well be the functional binding sites 
through which Stau1 promotes proper subcellular mRNA localization in neurons.  
The second class consists of smaller and more labile secondary structures as 
might occur in GC-rich CDS regions. Here our data indicate that transient Stau1 
binding, perhaps by Stau1 molecules simultaneously interacting with elongating 
ribosomes has a role in regulating translation. We arrived at this conclusion by 
analyzing cytoplasmic poly(A)+ RNA-seq and ribo-seq data from cells under- and 
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overexpressing Stau1. This allowed us to assess the effects of varying 
intracellular Stau1 concentration on both cytoplasmic mRNA levels and ribosome 
occupancy. Observable changes in mRNA levels were extremely subtle. 
Consistently with recent data indicating that Stau1 binding to mRNAs containing 
inverted Alu elements enhances their nucleocytoplasmic export(Elbarbary et al., 
2013), we did observe a small positive effect of increasing Stau1 on cytoplasmic 
mRNA levels for our 3′-UTR Alu targets. Conversely, for all other sets of mRNAs 
exhibiting preferential Stau1-WT cross-linking, Stau1 levels negatively influenced 
cytoplasmic mRNA levels proportionately to CDS Stau1 occupancy but not to 3′-
UTR occupancy. Thus we could find little evidence for SMD driven by 3′ UTR– 
bound Stau1, either over the entire mRNA population or for previously identified 
SMD targets. Instead, higher Stau1 levels led to a preferential increase in 
ribosome density on high-GC-content mRNAs.  
We propose a model (Fig. 8) based on these findings, wherein ribosome-bound 
Stau1 molecules transiently interact with short dsRNA helices throughout the 
CDS and 3′ UTR. In the CDS, such interactions somehow serve to increase 
ribosome density. Because Stau1 interacts with actively translating ribosomes, 
the increase in ribosome density may reflect increased translation efficiency. One 
possibility is that Stau1 helps ribosomes elongate through otherwise inhibitory 
secondary structures by recruiting factors such as RNA helicase A (RHA or 
DHX9) to disrupt them. RHA is a positive regulator of translation on mRNAs 
containing 5′-UTR secondary structures(Hartman et al., 2006) and is known to 
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copurify with Stau1 (ref. (Villacé et al., 2004) and E.P.R., unpublished data). 
Another abundant translational-regulatory protein that binds ribosomes and 
cross-links throughout CDS regions is the fragile X protein, FMRP(Comery et al., 
1997). FMRP, however, is a negative regulator of translation. Whereas deletion 
of either FMRP or Stau1 causes neurological defects, the phenotypes are 
opposite: absence of FMRP leads to dendritic spine overgrowth (Gruber et al., 
2008), whereas absence of Stau1 results in fewer spines(Vessey et al., 2008). 
Thus it is possible that FMRP and Stau1 have opposing roles in synaptic protein 
production, with FMRP inhibiting translation and Stau1 promoting it.  
Finally, mRNAs encoding transcription-regulatory proteins were recently reported 
as being enriched in Drosophila Staufen RIP samples(Laver et al., 2013). 
Consistently with this, we found that mRNAs encoding transcription factors of the 
C2H2 zinc-finger, HMG and homeobox families were highly enriched among 
mRNAs exhibiting the highest preferential 3′-UTR and CDS Stau1-WT 
occupancy. Transcription factors and zinc-binding proteins were also highly 
enriched among the mRNAs whose ribosome density was most positively 
affected by Stau1 protein levels. Thus Stau1 may have a previously 
unrecognized role in the translational regulation of transcription-regulatory 
proteins.  
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APPENDIX C: Alterations in mRNA 3′UTR isoform abundance 
accompany gene expression changes in human Huntington’s 
disease brains 
 
 
 
Appendix C was taken verbatim from the following manuscript, which is 
preparation during the time of this thesis submission.  
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Introduction 
 
Huntington’s disease (HD) is a neurodegenerative disorder caused by 
expansion of the CAG repeat in huntingtin (HTT) exon 1 (MACDONALD, 1993). 
The expansion is dominantly inherited and fully penetrant. Individuals usually 
develop symptoms in their mid-thirties, and death occurs within two decades 
(reviewed in {Suchowersky:k4GDVAry}). Neurodegeneration starts in the 
striatum and motor cortex, but spreads to other brain regions by the time of death 
(Vonsattel et al., 1985). Neuronal toxicity is largely due to the effect of mutant 
HTT protein during aging, although mutant messenger RNA (mRNA) may also be 
toxic. Many emerging therapies aim to decrease mutant HTT mRNA (Hu et al., 
2010) (Pfister et al., 2009). 
 
There are three known isoforms of HTT mRNA. A truncated (7.9 kb) 
isoform is generated via termination at a cryptic polyadenylation (polyA) signal in 
the first intron (Sathasivam et al., 2013). This isoform is of low abundance. Its 
presence in HD patients and mouse models, but not controls, suggests it may be 
associated with disease (Sathasivam et al., 2013).  The two predominant HTT 
mRNA isoforms are generated by alternative polyadenylation in the 3′ 
untranslated region (3′UTR) (Lin et al., 1993). The short (10.3kb) 3′UTR isoform 
predominates in dividing cells such as lymphoblasts, whereas the long (13.7kb) 
isoform predominates in nondividing cells such as neurons(Lin et al., 1993) . It 
has not been established whether HTT mRNA 3′UTR isoforms are metabolized 
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differently, or whether their relative abundance changes in HD. Although many 
genes exhibit expression and splicing differences in HD, 3′UTR isoform 
expression changes have not been investigated (Hodges et al., 2006) (Labadorf 
et al., 2015) (Lin et al., 2016) (Mykowska et al., 2011). 
 
3′UTR length is important for mRNA localization, stability, and translation 
(Di Giammartino et al., 2011). Many mRNAs use 3′UTR alternative 
polyadenylation to achieve tissue-specific expression and function (Lianoglou et 
al., 2013; Smibert et al., 2012; Zhang et al., 2005). Long mRNA isoforms contain 
binding sites for trans-acting factors such as microRNAs that exert dynamic 
changes in steady-state mRNA levels (Sandberg et al., 2008). Ubiquitously 
expressed genes, like HTT, are the most likely to use alternative polyadenylation 
to alter mRNA expression in the brain (Lianoglou et al., 2013; Lin et al., 1993). 
Changes in mRNA 3′UTR length occur in Parkinson’s disease and cancer (Mayr 
and Bartel, 2009; Rhinn et al., 2012). We sought to determine if alterations in 
3′UTR length are a feature of HD. 
 
We provide evidence that the abundance of HTT mRNA 3′UTR isoforms 
differs between HD patients and non-HD controls, including a novel mid-length 
3′UTR isoform. We show that HTT mRNA 3′UTR isoforms have different 
localizations, half-lives, polyA tail lengths, and microRNA sites. Isoform 
alterations in HD are not unique to HTT. There are widespread changes in 
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mRNA 3′UTR isoform expression in human HD motor cortex. Genes with isoform 
changes are associated with pathways dysfunctional in HD. We demonstrate that 
knockdown of the CNOT6 RNA binding protein leads to isoform shifts similar to 
those in HD motor cortex. Our findings indicate that altered 3′UTR isoform 
expression of HTT and a subset of other genes is a feature of molecular 
pathology in HD motor cortex.  
 
Results 
The abundance of HTT mRNA 3′UTR isoforms changes in 
Huntington’s disease 
We identified two abundant HTT mRNA 3′UTR isoforms in public 3′ sequencing 
data (Figure C.1.A) (Lianoglou et al., 2013). As in previous studies, we found 
HTT mRNA isoform abundance varies across normal tissues: the longer isoform 
predominates in the brain, neuronal precursor (NTERA2) cells, breast, and ovary, 
whereas the shorter isoform predominates in testes, B-cells, muscle, and human 
embryonic kidney (HEK293) cells (Figure C.1B). (Lin et al., 1993).  
 
To determine whether HTT mRNA isoform abundance changes in HD, we 
performed qRT-PCR of the HTT long isoform normalized to total HTT expression 
on patient cerebellum, motor cortex, fibroblasts, and neural stem cells. HD 
cerebellum samples were from grade 2, 3, or 4 brains, whereas motor cortex 
samples were from grade 1 and 2 brains (Table S1 online). HD brain grades are 
based on the degree of striatal degeneration and gliosis. Grades range from 1 
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(50% neuronal loss) to 4 (95% neuronal loss) (Vonsattel et al., 1985). There is 
limited involvement of the cerebellum in all grades (Rüb et al., 2013; Vonsattel, 
2008; Vonsattel et al., 1985). Cortical pathology is variable between samples, but 
typically 10% of neurons are lost in grade 1 with minimal gliosis, and up to 40% 
are lost in grade 2 with evident gliosis (Thu et al., 2010; Vonsattel et al., 1985). 
Neuronal loss can confound gene expression studies. We chose to analyze HTT 
isoform expression in cortex and cerebellum rather than in the striatum because 
neuronal loss is more limited in these regions. 
 
We found a 1.6-fold increase in the long 3′UTR isoform relative to total HTT 
mRNA in HD patient cerebellum. Conversely, there is a 2.5-fold decrease in the 
long isoform in patient motor cortex (Figure C.1. C). Patient fibroblasts and 
neural stem cells also exhibit a decrease in the long isoform (Figure 1D, 2-fold 
and 3.3-fold respectively). These results demonstrate the abundance of HTT 
mRNA 3′UTR isoforms changes in HD in a tissue and cell-specific manner.  
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Figure C.1 HTT 3'UTR isoforms change their relative amounts in HD 
 
(A) NTERA2 cell 3′seq reads mapping to the HTT 3′UTR. (B) Quantification of HTT 
3′UTR isoform 3′seq reads relative to total HTT 3′UTR reads across several human 
tissues and cell lines. (C) qPCR of the HTT mRNA long 3′UTR isoform (long) normalized 
to total HTT expression (total, via ΔΔCt method) in HD patient and control cerebellum 
(CB) and motor cortex (MCx). *, **, and *** signify p<0.05, 0.005, and 0.0005. (D) qPCR 
as in C, using patient or control fibroblasts or neural stem cells (NSCs) differentiated 
from fibroblasts. 
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HTT mRNA isoform changes extend to liver and muscle and arise 
from both alleles 
We used HD model mice to determine if disease-associated isoform changes 
extend beyond brain. We bred mice that lack murine Htt, but harbor full length 
human HTT with either 18 or 128 CAG repeats on a yeast artificial chromosome 
(Yac18, Yac128) (Slow et al., 2003; Zeitlin et al., 1995). Like patients, Yac128 
cerebellum exhibits an increase (1.7-fold) in the long HTT 3′UTR isoform 
compared to yac18 mouse cerebellum. Isoform differences extend to muscle 
(quadriceps) and liver, with a 2.2-fold increase and a 1.6-fold decrease in the 
HTT long mRNA isoform respectively (Figure C.2.A). These findings indicate that 
at least two non-brain tissues exhibit tissue-specific HTT mRNA isoform 
changes. 
Altered HTT mRNA isoform abundance in patient brains could arise from the 
wild-type allele, the mutant allele, or both. To determine which allele is 
responsible for the changes, we performed allele-specific qPCR on human 
cerebellum and motor cortex samples heterozygous for single nucleotide 
polymorphism (SNP) rs362267 in the HTT long, but not short, 3′UTR. This SNP 
heterozygosity is not linked to the CAG repeat; in some patients, the C allele is 
expanded, whereas in others the T allele is expanded. The long isoform qPCR 
probe matched either the C or the T SNP. These probes efficiently and 
specifically amplify the matching but not the nonmatching allele. The amounts of 
both the mutant and wild-type HTT long 3′UTR isoform are changed in HD 
cerebellum and motor cortex compared to controls (Figure C.2 B, C). The 
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direction of isoform changes is consistent between alleles in each patient (Figure 
C.2.D, correlation coefficient 0.83). Thus the disease-associated change in HTT 
mRNA isoforms arises from both alleles. 
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Figure C.2 HTT isoform changes extend to muscle and liver and both HTT 
alleles change 3'UTR isoform amounts in HD 
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(A) qPCR of the HTT long 3′UTR isoform (long) normalized to total HTT 
expression (total, via ΔΔCt method) across Yac128 and Yac18 mouse tissues. 
CB=cerebellum. *, **, and *** signify p<0.05, 0.005, and 0.0005. (B) Allele-
specific qPCR using SNP rs362267C/T in the HTT long 3′UTR isoform (long) 
normalized to total HTT expression in patient and control cerebellum. (C) Allele-
specific qPCR in patient and control motor cortex, as in C. (D) Correlation of HTT 
allele abundance within each HD or control (con) cerebellum (CB) or motor 
cortex (MCx) sample; r=0.83. 
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PolyA site sequencing identified a novel conserved mid-3′UTR 
isoform of HTT mRNA 
To identify unknown 3′UTR isoforms of HTT, we used a new polyA site 
sequencing method, PAS-Seq (Figure C.3.A) (Ashar-Patel et al., 2017). PAS-
Seq requires minimal RNA input to produce high quality sequences, or reads. 
The PAS-Seq reverse transcription primer can anneal to mRNA polyA tails and 
polyA sequences encoded in the genome. We excluded genomically-primed 
reads from our analysis (Figure C.3.B, see Experimental Procedures). PAS-Seq 
confirmed there is a decrease in the long isoform (1.4-fold) in HD motor cortex, 
whereas there is a decrease in the short isoform (1.8-fold) in HD cerebellum 
(Figure C.3.G-H,J). 
 
Using PAS-Seq, we identified a novel 12.5kb isoform of HTT expressed in both 
control and HD human cerebellum and motor cortex with abundance similar to 
the short 3′UTR isoform (Figure C.3.C, top). We performed PAS-Seq on mice to 
test if the mid 3′UTR isoform is conserved. We used wild-type and Q140 HD 
mice, which harbor 140 CAG repeats knocked into the mouse HTT genomic 
locus (Menalled et al., 2003). The mid-3′UTR isoform, and the short and long 
3′UTR isoforms, are present in wild-type and Q140 mice (Figure C.3.C, bottom). 
A polyA signal is required for mRNA cleavage and polyadenylation. There is a 
putative polyA signal (AAUGAA) located twenty nucleotides upstream of the mid-
3′UTR isoform polyA site (Sheets et al., 1990; Tian et al., 2005). This polyA 
signal and site are conserved between mice and humans (Figure C.3.D). The 
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regions up and downstream of the isoform polyA sites are also conserved (Figure 
C.3.E). The abundance of the mid-3′UTR isoform varies across tissues and 
increases 2.8-fold in HD motor cortex compared to control (Figure C.3.F-H). 
Isoform changes can’t be explained by gene expression alterations: total HTT 
expression is decreased by 1.4-fold in HD motor cortex but unchanged in 
cerebellum compared to controls (Figure C.3.I). In addition, isoform changes are 
still significant after normalizing to total HTT expression (Figure C.3.J). 
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Figure C.3 PAS-Seq revealed a third HTT 3'UTR isoform whose relative 
abundance also changes in HD 
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(A) Schematic of PAS-seq library preparation. (B) Schematic of the PAS-seq 
data analysis pipeline on Tbr1, an exemplary gene with two 3′UTR isoforms. See 
also Figure S1. (C) PAS-seq peak coordinates mapping to the HTT 3′UTR from 
HD patient and control cerebellum (CB) and motor cortex (MCx), and Q140 and 
wild-type (WT) mouse striatum (Str). (D) Needleman-Wunsch alignment of the 
human (top) and murine (bottom) HTT 3′UTR around the short, mid, and long 
3′UTR isoform polyA signals (blue) and sites (yellow). (E) NCBI BLAST alignment 
score of the human and mouse HTT 3′UTR; arrows indicate the three polyA sites 
at 600, 2763, and 3903 bases into the human 3′UTR. (F) HTT mid 3′UTR isoform 
3′seq reads relative to total HTT 3′UTR reads across several human tissues and 
cell lines. (G) Reads corresponding to HTT isoforms in HD motor cortex 
compared to controls, normalized to sequencing depth. * signifies p<0.05. (H) 
Reads counts as in (G), in HD and conrol cerebellum. (H) Total HTT expression 
in HD motor cortex or cerebellum compared to controls, as in (G). (I) Reads 
corresponding to HTT isoforms in HD motor cortex (left) or cerebellum (right) 
compared to controls, normalized to sequencing depth (top) or total HTT 
expression (bottom).  
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The HTT mRNA 3′UTR isoforms have different localization and half-
lives 
3′UTR length affects mRNA stability, translation, and localization (Di 
Giammartino et al., 2011). To determine how shifts in HTT isoform abundance 
affect HTT mRNA metabolism, we assessed the localization and stability of HTT 
isoforms in SH-SY5Y (human neuroblastoma) cells. These cells have neuronal 
characteristics and express all three HTT 3′UTR isoforms, making them a model 
of HTT mRNA stability in human brain (Datta et al., 2013). To assay the 
localization of HTT isoforms, we performed isoform specific qRT-PCR on nuclear 
or cytoplasmic RNA from SH-SY5Y cells. Over three times as much of the short 
and long isoform is localized in the cytoplasm than in the nucleus, whereas the 
mid isoform is more abundant in the nucleus (Figure C.4.A). To determine if 
isoform localization changes in disease, we assayed RNA from HD and wild-type 
fibroblasts. As in SH-SY5Y cells, we found little difference between the 
localization of the long and short isoforms; however, in wild-type fibroblasts, the 
mid isoform was significantly more abundant in the cytoplasm than the other 
isoforms. The ratio of cytoplasmic to nuclear transcripts is lower in HD fibroblasts 
than in wild-type fibroblasts for all three isoforms, indicating HTT mRNA shifts to 
the nucleus in HD, as has been reported (de Mezer et al., 2011).  
 
To test isoform stability, we incubated SH-SY5Y cells with labeled uridine, and 
collected labeled mRNA 0, 3, 6, 9, and 12 hours after washing away the modified 
nucleotide. We performed isoform specific qRT-PCR on the RNA to determine 
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the relative stability of the HTT short and long isoforms. We found all HTT 
isoforms have significantly different half-lives; the short isoform is most stable, 
whereas the mid isoform is least stable (Figure C.4.B). This finding suggests the 
altered relative abundance of HTT isoforms in HD brains is accompanied by a 
change in total HTT half-life.  
 
The different localization and stability of the HTT 3′UTR isoforms could be due to 
different polyA tail lengths, microRNA sites, or RNA binding protein sites (Di 
Giammartino et al., 2011; Norbury, 2013). To determine the polyA tail length of 
the HTT 3′UTR isoforms, we added a universal sequence to the 3′ end of the 
mRNA polyA tail that was used as a priming site during isoform-specific PCR. 
PCR products were resolved on a gel, enabling quantification of poly-A tail length 
(Figure C.4.C). We found the HTT short isoform has a poly-A tail length of about 
sixty in both SH-SY5Y cells and in patient and control fibroblasts, whereas the 
HTT mid and long isoforms have poly-A tail lengths of about five and ten (Figure 
C.4.). Recent studies found mRNA stability and rate of translation drops as the 
polyA tail length decreases below twenty nucleotides (Chang et al., 2014; Park et 
al., 2016). The very short polyA tail length of the mid and long HTT isoforms may 
explain their low half-lives compared to the short HTT isoform. 
 
To identify microRNA sites exclusive to the HTT long isoform, we used 
TargetScan. This program predicts microRNA target sites based on several local 
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factors known to affect microRNA binding strength and specificity (Lewis et al., 
2003). We found several microRNAs expressed in human brain with sites 
exclusive to the mid and long HTT 3′UTR (Figure C.4.E). To test if these 
microRNAs affect HTT isoform abundance, we transfected SH-SY5Y cells with 
mimics of microRNAs 221, 137, or both.  MicroRNA 137 exclusively binds the 
long isoform, while microRNA 221 has an 8-mer binding site in the long isoform 
and a 6-mer binding site common to the mid and long isoform. We found the 
microRNA 137 mimic had no effect on isoform abundance, but transfection of the 
microRNA 221 or microRNA 221 and 137 mimics reduced the abundance of the 
long and mid but not short isoform relative to total HTT (Figure C.4.F) or to 
GAPDH (Figure C.4.G). These results show at least one microRNA exclusively 
degrades the long and mid HTT transcripts, potentially contributing to the lower 
stability of these isoforms compared to the short isoform. 
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Figure C.4 HTT 3'UTR isoforms are metabolized differently 
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(A) Cytoplasmic versus nuclear abundance of HTT 3′UTR isoforms across cell 
lines. Data points are the average of triplicates with standard deviation. *, **, and 
*** signify p<0.05, 0.005, and 0.0005. (B) Abundance of labeled HTT 3′UTR 
isoforms in SH-SY5Y cells at various times after a 12-hour eithinyl-uridine pulse. 
Data points are the average of triplicates with standard deviation. (C) The polyA 
Tail Length Assay adds a universal sequence to the 3′ end of the polyA tail. HTT 
isoform-specific PCR is then performed. The polyA tail length is the PCR product 
length after subtraction of the universal primer length and the distance from the 
forward primer to the polyA site. (D) Gel of PCR products from the polyA tail 
length assay. (E) Brain-expressed microRNA target sites in the HTT 3′UTR 
predicted by TargetScan. (F-G) Quantitative PCR of HTT 3′UTR isoforms 
normalized to total HTT (F) or GAPDH (G) expression in SH-SY5Y cells after 
transfection of microRNA mimics (miRs) with targets exclusive to the HTT long or 
mid and long 3′UTR isoforms. NT (non-targeting) miR is a C. Elegans microRNA 
mimic 
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To identify RNA binding protein sites exclusive to the long isoform, we used the 
CLIPdb and starBase CLIP-Seq databases (Li et al., 2014; Yang et al., 2015). 
We found several brain-expressed RNA binding proteins adhere to the HTT 
3′UTR. These RNA binding proteins may differentially affect the stability and 
localization of HTT isoforms. Based on these results, we expect the short isoform 
is more translationally efficient than the mid and long isoform due to its longer 
polyA tail and increased stability. Indeed, a study published during preparation of 
this manuscript found the short HTT 3′UTR isoform may be translated more 
efficiently than the long isoform (Xu et al., 2017). 
Many other genes exhibit changes in isoform abundance 
We studied whether alterations in mRNA isoform expression are unique to HTT, 
or features of many genes in HD. To assay transcriptome-wide isoform 
expression, we performed PAS-Seq on motor cortex from grade 1 HD brains 
(n=6) versus controls (n=5), and cerebellum from grade 2-4 patient brains (n=9) 
versus controls (n=7). We identified genes with multiple 3′UTR isoforms, and 
normalized isoform expression to gene expression (see Experimental 
Procedures). We compared the normalized isoform expression between HD and 
control samples using two thresholds for significance: false discovery rate less 
than 10%, or p-value less than 0.01. The false discovery rate threshold corrects 
for false-positives due to multiple testing, but may reject true positives. We 
included the more sensitive p-value threshold to compare HD motor cortex, 
where mRNA expression changes are substantial, to HD cerebellum, where 
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changes are smaller and less likely to pass a stringent threshold (Hodges et al., 
2006). 
 PAS-Seq uses oligo(dT) to capture polyA tails during reverse transcription. 
Oligo(dT) also anneals to genomic polyA stretches. These genomic sites are 
artefacts that can lead to overestimation of the number of alternatively 
polyadenylated genes (Sheppard et al., 2013). We found 33% of genes in the 
motor cortex and 30% in the cerebellum display alternative polyadenylation. This 
percentage is similar to that obtained via the 3Pseq 3′ sequencing method, which 
avoids oligo(dT) priming (Jan et al., 2011). Consistency with 3Pseq data 
indicates PAS-seq accurately captured reads primed from mRNA polyA tails 
while excluding reads primed from genomic polyA regions. As reported, we found 
long isoforms are more abundant than short isoforms in cerebellum and motor 
cortex (Miura et al., 2013). 
 
In the motor cortex, 11% of alternatively polyadenylated genes showed a 
significant (false discovery rate<10%) change in abundance of at least one 
3′UTR isoform in HD, while an additional 2% passed the p-value threshold 
(p<0.01) (Figure C.5.A, red and orange). Many isoform relative abundances 
changed over 25% in HD motor cortex versus controls, indicating a major shift in 
isoform expression for the corresponding gene (Figure C.5.B). In the cerebellum, 
none of the alternatively polyadenylated genes showed a significant (false 
discovery rate <10%) change in abundance of at least one isoform, and just 5% 
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passed the p-value threshold (p<0.01) (Figure 5C, green). Isoform abundance 
changes in the cerebellum were not as large as in the motor cortex (Figure 
C.5.D). These results indicate that there are widespread isoform changes in HD 
motor cortex that alter the 3’UTR isoform abundances for many genes, whereas 
changes in the cerebellum are more modest. 
 
Neurons die and glia proliferate in the HD brain (Vonsattel and DiFiglia, 1998). 
Neuronal loss and gliosis are limited in motor cortex from grade 1 brains (Thu et 
al., 2010). However, it is possible some or all isoform changes we see are due to 
changes in cell populations. We found isoform abundance is highly correlated 
(r=0.87) between the motor cortex and cerebellum despite the different cell milieu 
and trace neuronal loss in the cerebellum. Previous studies that used HD 
caudate, which suffers extensive neuronal loss (50-95%), have demonstrated 
mRNA expression is similar in HD caudate tissue and HD caudate neurons 
(Hodges et al., 2006). These results suggest the isoform changes we observe in 
HD motor cortex are not solely due to neuronal loss. 
 
To determine whether genes with significant (p<0.01) isoform changes shifted 
towards longer or shorter mRNA 3′UTR isoforms, we calculated a weighted 
change (see Experimental Procedures). If the weighted change is positive, the 
gene shifts towards longer mRNA isoforms in HD patients, whereas if it is 
negative, the gene shifts towards shorter isoforms. We found 129 genes shift 
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towards longer isoforms in HD motor cortex, whereas 110 genes shift towards 
shorter isoforms (Figure C.5.E). In the cerebellum, we found 31 genes shifted to 
the longer isoform, whereas 83 shifted to the shorter isoform (Figure C.5.F). Thus 
isoform shifts are gene-specific, and there is no generalized shift towards longer 
or shorter 3′UTR isoforms in HD.  
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Figure C.5 Transcriptome-wide PAS-Seq analysis identifies a large subset 
of genes with 3'UTR isoform changes in HD motor cortex 
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(A) Scatter plot of PAS-seq reads from control (n=5) and HD (n=6) motor cortex. Each 
dot represents a unique 3’UTR isoform expressed in at least five HD and control 
samples. Shown is the number of reads mapping to the isoform divided by the total 
reads mapping to the gene 3′UTR (isoform fraction). Orange dots indicate isoforms with 
p<0.01, whereas red dots indicate isoforms with adjusted p<0.1 (false discovery 
rate<10%). (B) Volcano plot of reads from control and HD motor cortex, colors as in A. 
The percent change is calculated as the difference in the isoform fraction between HD 
and control samples multiplied by 100. (C) Scatter plot of PAS-seq reads from control 
(n=7) and HD (n=9) cerebellum, as in A. Green dots indicate isoforms with p<0.01. (D) 
Volcano plot of reads from control and HD cerebellum, colors as in C. (E) Heat map of 
the weighted change (see methods) of genes with one or more isoform differentially 
expressed in patient motor cortex (p<0.01). A positive number indicates the gene shifts 
towards longer isoforms in HD, whereas a negative number indicates the gene shifts 
towards shorter isoforms in HD. (F) Heat map of genes with one or more isoform 
significantly differentially expressed in patient cerebellum, as in E. (G) Comparison of 
gene weighted changes between patient versus control motor cortex (MCx) and 
cerebellum (CB). Green dots have significant changes in HD cerebellum, orange dots 
have significant changes in HD motor cortex, and purple dots have both (p<0.01). (H) 
Gene ontology analysis of genes exhibiting significant (p<0.01) shifts to longer (long) or 
shorter (short) isoforms in HD motor cortex (MCx) and cerebellum (CB). 
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We compared significant (p<0.01) isoform shifts in the motor cortex and 
cerebellum to look for common changes. Only 11 genes exhibit mRNA 3′UTR 
isoform shifts in both the motor cortex and cerebellum (Figure C.5.G, purple). Of  
these, 9 showed opposite changes in the motor cortex, with 7 of the 9 shifting 
towards shorter isoforms in the cerebellum and longer isoforms in the motor 
cortex. This finding indicates that isoform changes are region-specific. 
To identify affected pathways, we performed gene ontology analysis on genes 
with significant (p<0.01) isoform shifts (Figure C.5.H). We found several 
pathways that have been reported to be enriched among genes differentially 
expressed in HD, including cytokine signaling and production, RNA pol2 
transcription, translation, calcium signaling, vesicle-mediated transport, 
microtubule organization, and DNA binding (Hodges et al., 2006; Labadorf et al., 
2015). Some enriched pathways are thought to be involved in HD pathogenesis, 
including calcium signaling, cytokine signaling, histone acetylation, transcription 
factor binding, axonal transport, synaptic vesicle localization, dendritic spine 
morphogenesis, microtubule organizing, and phagocytic vesicles (Ellrichmann et 
al., 2013; Martinez-Vicente et al., 2010; Moumné et al., 2013; Trushina et al., 
2003; Zuccato et al., 2010). These results suggest aberrant 3′UTR isoform 
expression may influence pathogenesis in these disease pathways.  
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Figure C.6 Gene expression analysis shows most genes with 3'UTR 
isoform changes do not exhibit expression changes in HD 
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(A) Scatter plot of PAS-seq reads from control (n=5) and HD (n=6) motor cortex. Each 
dot represents the normalized expression of a gene. Orange dots indicate isoforms with 
p<0.01, whereas red dots indicate isoforms with adjusted p<0.1 (false discovery 
rate<10%). (B) Scatter plot of PAS-seq reads from control (n=7) and HD (n=9) 
cerebellum, as in A. Green dots indicate isoforms with p<0.01, whereas blue dots 
indicate isoforms with adjusted p<0.1 (false discovery rate<10%). (C) Heat map of genes 
significantly differentially expressed in patient motor cortex (false discovery rate<10%). 
Shown are fold changes in normalized gene expression. (D) Heat map of genes 
significantly differentially expressed in HD cerebellum (false discovery rate<10%), as in 
C. (E) Comparison of gene isoform weighted changes (see methods) and differential 
expression (DE) log 2 fold changes in HD versus control motor cortex. Green dots have 
significant isoform changes in HD, orange dots have significant expression changes in 
HD, and red dots have both (p<0.01). (F) Comparison of gene isoform weighted 
changes and expression log 2 fold changes in HD versus control cerebellum, as in E. 
(G) Comparison of gene expression log 2 fold changes (in motor cortex (MCx) and 
cerebellum (CB). Red dots have significant expression changes in HD motor cortex, blue 
dots have significant changes in HD cerebellum, and light blue have both (false 
discovery rate<10%). (H) Gene ontology analysis of genes exhibiting significant (false 
discovery rate<10%) expression changes in HD motor cortex (MCx) and cerebellum 
(CB). 
 
 
 
 249 
Most genes with isoform changes in HD are not differentially 
expressed 
Widespread gene expression changes are reported in the cortex of late-stage 
Huntington’s disease patients (Hodges et al., 2006; Labadorf et al., 2015). We 
sought to determine if the extensive 3′UTR isoform changes in HD motor cortex 
co-occur with gene expression changes. To measure steady-state gene 
expression, we combined all PAS-seq reads from each gene (see Experimental 
Procedures). Consistent with previous studies, many genes were differentially 
expressed in HD patient motor cortex relative to control motor cortex (false 
discovery rate<10%) (Figure C.6.A) (Hodges et al., 2006; Labadorf et al., 2015). 
Quantitative PCR confirmed differential expression of three genes (Figure S5). Of 
differentially expressed genes, 700 exhibited increased expression in HD motor 
cortex, whereas 1008 exhibited decreased expression (Figure C.6.C). 
Interestingly, the percent of detected genes exhibiting expression changes is 
identical to the percent of alternatively polyadenylated genes exhibiting isoform 
changes (11%). In contrast, only 1% of genes are differentially expressed (false 
discovery rate<10%) in patient cerebellum, with 2.5% making the p-value cutoff 
(Figure C.6.B). Of differentially expressed genes (false discovery rate<10%), 89 
increased expression in HD patient cerebellum whereas 64 decreased (Figure 
C.6.D). Thus, isoform changes are proportional to gene expression changes in 
the HD motor cortex, whereas isoform and gene expression changes are minimal 
in the cerebellum. 
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To determine if genes with isoform changes also exhibit expression changes, we 
compared gene expression to isoform expression for all alternatively 
polyadenylated genes in the motor cortex and cerebellum using a significance 
cutoff of p<0.01 (Figure C.6.E-F). In the motor cortex, only 17% of genes with 
isoform shifts also exhibit gene expression changes (Figure C.6.E, red). Of 
genes exhibiting isoform and gene expression changes, we found no association 
between isoform shift and gene expression direction. This dissociation of isoform 
and gene expression is consistent with studies showing the association between 
3′UTR length and isoform stability is gene-specific (Spies et al., 2013). In the 
cerebellum, only 4% of genes with significant isoform changes are also 
differentially expressed (Figure C.6.F, red). Of these, all are shifted towards 
shorter isoforms, with two exhibiting increased expression and two exhibiting 
decreased expression. These results indicate that most genes with isoform 
changes are not expressed differently in HD motor cortex and cerebellum.  
We compared gene expression between the motor cortex and cerebellum to see 
if there is overlap in differentially expressed genes. We found sixteen (11%) of 
the genes expressed differently in HD cerebellum are also expressed differently 
in HD motor cortex (Figure C.6.G, light blue). We performed gene ontology 
analysis to identify pathways enriched (p<0.01) among genes with increased or 
decrease expression in HD motor cortex, cerebellum, or both (Figure C.6.H). Our 
analysis identified several pathways previously reported to be enriched among 
genes differentially expressed in HD motor cortex: CNS development, protein 
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localization, extracellular exosome, fatty acid biosynthesis, and regulation of TNF 
signaling (Hodges et al., 2006; Labadorf et al., 2015). Unlike previous studies, we 
separated genes into categories based on region and direction of change. We 
found many pathways are enriched between genes with decreased expression 
exclusively in motor cortex, and genes with increased expression exclusively in 
cerebellum. Some of these pathways, including protein folding and ubiquitination, 
are vital for clearance of the mutant HTT protein. Region-specific regulation of 
these processes may be related to region-specific pathology.  
We sought to determine if isoform and gene expression changes are associated 
with common cell pathways. We found several ontology categories enriched 
among genes with isoform changes and genes with expression changes 
including mRNA 3′UTR binding, cell junction, ubiquitination, mRNA binding, and 
protein transport (Figure C.5.H, Figure C.6.H). Within each category, genes with 
isoform differences and genes with expression changes do not overlap; i.e., the 
same gene does not exhibit aberrant isoform and gene expression. These results 
indicate that isoform alterations and gene expression changes are separate, but 
they may affect common processes in HD brains. 
Decreasing expression of the RNA binding protein CNOT6 leads 
some genes to change isoform abundance 
A change in the expression of an RNA binding protein may lead to changes in 
isoform abundance by either altering isoform production rates during alternative 
polyadenylation, or by affecting isoform decay rates post-transcriptionally. To 
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identify candidate RNA binding proteins, we searched for genes differently 
expressed in HD motor cortex with the RNA binding protein GO-term (Figure 
C.7.A). Of those, twenty were involved in mRNA alternative polyadenylation or 
stability. We reasoned an RNA binding protein responsible for HTT isoform shifts 
would show opposite expression changes in HD motor cortex and cerebellum. Of 
nine fitting that description, two (CNOT6 and CNOT7) are subunits of the Ccr4-
not complex that plays a widespread role in mRNA metabolism (Mittal et al., 
2011; Shirai et al., 2014). CNOT6, the subunit that catalyzes deadenylation of 
mRNAs, is most differently expressed in HD motor cortex and cerebellum 
(Yamashita et al., 2005).  
 
To determine if changes in CNOT6 expression exert changes in isoform 
expression, we transfected control human fibroblasts with siRNAs targeting 
CNOT6 or an off-target control (MAP4K4). The CNOT6 siRNAs reduced CNOT6 
mRNA expression over 80% but did not affect total HTT mRNA levels (Figure 
C.7.B-C). We chose HTT and SECISBP2L (SECIS Binding Protein 2 Like) as 
candidate CNOT6 targets. HTT and SECISBP2L shift to longer 3′UTR isoforms in 
HD cerebellum and shorter isoforms in HD motor cortex. We collected RNA from 
transfected cells for qPCR analysis of the HTT long 3′UTR isoform versus total 
HTT, and of the SECISBP2L long 3′UTR isoform versus total SECISBP2L. We 
found knock down of CNOT6 resulted in a decrease in the HTT and SECISBP2L 
long isoforms similar to that seen in HD patient motor cortex and in HD 
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fibroblasts (Figure C.7.D). HTT isoform-specific qPCR revealed that the 
abundance of the short isoform didn’t change while abundance of the long 
isoform decreased by almost two-fold, as in HD patient motor cortex (Figure 
C.7.E). These results suggest changes in the expression of CNOT6 may 
influence the abundance of some 3′UTR isoforms in HD patient motor cortex and 
cerebellum. 
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Figure C.7 Changes in the expression of RNA binding proteins may 
influence alterations in isoform abundances 
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(A) Algorithm to identify proteins that might cause 3′UTR isoform changes in HD patient 
brains identified CNOT6 and CNOT7, members of the multi-functional Ccr4-not complex. 
Numbers are fold changes (FC) in mRNA expression between HD and control motor 
cortex (MCx) or cerebellum (CB). (B) qRT-PCR quantification CNOT6 mRNA compared 
to GAPDH mRNA after transfection of CNOT6 siRNA (gray), no siRNA (white), or non-
targeting (NT) MAP4K4 control siRNA (black) into wild-type fibroblasts. *, **, and *** 
signify p<0.05, 0.005, and 0.0005. Shown is the average of at least three transfections 
with standard deviation. (C) qRT-PCR quantification HTT (HTT) mRNA compared to 
GAPDH mRNA after transfection as in (B). (C) qRT-PCR quantification of the HTT long 
isoform (long) compared to total HTT expression (total) or of the SECISBP2L long 
isoform (long) compared to total SECISBP2L expression (total) after transfection as in 
(B). Red and blue bars are untreated fibroblasts, as in Figure 1D. (D) Isoform-specific 
qRT-PCR quantification of each HTT long isoform (long) compared to total HTT 
expression after transfection of CNOT6 siRNA (colored), no siRNA (white), or non-
targeting (NT) MAP4K4 control siRNA (black) into wild-type fibroblasts. 
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Methods 
Samples 
Human samples were supplied by the New York and Neurological Foundation of 
New Zealand Brain Banks. Fibroblast lines were obtained from the Coriell 
Repository. The M. DiFiglia lab (Massachusetts General Hospital) supplied 
neural stem cell pellets. For mouse experiments, 7-9 month male and female 
mice were sacrificed, and brain regions were dissected and stored in RNAlater 
(Sigma Aldrich) prior to RNA extraction. 
 
Public 3′Seq data analysis 
Raw 3′ sequencing data was downloaded from the NCBI short sequence read 
archive, accession SRP029953 (Lianoglou et al., 2013), and analyzed as below. 
 
RNA extraction 
Total RNA was extracted with Trizol (Ambion), cleaned on Clean and 
Concentrator columns (Zymo), analyzed via Bioanalyzer (Agilent), and treated 
with TurboDNAse (Ambion). 
qRT-PCR 
RNA was reverse transcribed by SuperScript IV (Invitrogen). Quantitative PCR 
was performed by Qiagen QuantiFast SYBR green master mix (non allele-
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specific), or Qiagen 1x Type-it Fast SNP PCR master mix (allele-specific). 
Product amounts were calculated using the ΔΔCt method. We compared group 
averages with unpaired two-tailed t-tests and considered p<0.05 significant. 
Primer and probe sequences are listed in Table S2.  
 
Nuclear and cytoplasmic isoform abundance 
SH-SY5Y nuclear and cytoplasmic RNA fractions were collected as described in 
Supplemental Experimental Procedures, and RNA was submitted to qRT-PCr as 
above. 
 
In vitro transcription of ethinyl-uridine (EU) pulse chase spike-in 
Firefly luciferase with the T7 promoter was in vitro transcribed as described in the 
Supplemental Experimental Procedures. In vitro transcripts were purified on 
Centrispin 20 columns (VWR), precipitated by phenol extraction and ethanol 
precipitation, and Bioanalyzed (Agilent) to ensure a single product. 
 
EU pulse chase and isoform-specific qRT-PCR 
SH-SY5Y cells (ATCC) were pulsed in 200µM EU for 14 hours, washed in PBS, 
and chased with unmodified media. We isolated labeled RNA using the Click-iT 
Nascent RNA Capture Kit (Life Technologies) as detailed in the Supplemental 
Experimental Procedures. SuperScript IV (Invitrogen) reverse transcribed labeled 
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RNA. qPCR of the HTT short and long isoforms was performed as above, and 
Isoform amounts were normalized to those of a firefly luciferase spike-in. 
 
PolyA tail length assay 
RNA was extracted as above. The HTT short and long isoform polyA tails were 
reverse transcribed and amplified by the Affymetrix PolyA Tail Length Assay 
(primers are listed in Table S2). PCR products were resolved on a 2% agarose, 
1x TAE gel.  
 
MicroRNA and RNA binding protein target site prediction 
We used the CLIPdb and starBase v2.0 browsers to identify RNA binding 
proteins that interact with the HTT 3′UTR (Li et al., 2014; Yang et al., 2015). 
Brain expression was confirmed with the human protein atlas, 
www.proteinatlas.org (Uhlen et al., 2015). We included binding sites represented 
by more than five reads. To identify predicted microRNA binding sites, we used 
TargetScanHuman version 7.0 (Lewis et al., 2003). We identified microRNAs 
with predicted 7mer-1A, 7mer-m8, 8mer binding sites. Brain expression was 
confirmed with miRmine Human miRNA Expression Database (Panwar et al., 
2017). 
 
MicroRNA transfection 
SH-SY5Y cells were transfected with microRNA mimics 137, 221, or both 
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(Dharmacon) using Lipofectamine RNAimax transfection reagent (Invitrogen) per 
manufacturer’s instructions. After 72 hours, RNA was extracted and submitted to 
qRT-PCR as above. 
 
PAS-seq library preparation 
For the detailed PAS-seq method, see Supplemental Experimental Procedures. 
Briefly, extracted RNA was fragmented and reverse-transcribed by Superscript III 
(Invitrogen) from the PAS-seq oligo d(T) primer. cDNA fragments 160-200 
nucleotides long were circularized by incubation with CircLigase II (Epicentre), 
and Phusion polymerase (NEB) amplified the cDNA and adaptors with PE 1.0 
and PE 2.0 primers (Illumina). The 215-254 nucleotide library was size-selected 
via gel electrophoresis and subjected to single-end 100 base-pair sequencing. 
 
PAS-Seq analysis 
For the detailed PAS-Seq analysis and bioinformatics pipeline, see the 
supplemental methods.  Briefly, high-quality reads were mapped to gene ORFs 
or 3′UTRs in the hg19 or mm10 genome, and reads corresponding to the same 
isoform were combined. We removed genomically-primed reads and normalized 
isoform expression to gene expression. Normalized isoform abundance was 
compared between HD and control samples using two-tailed t-tests with or 
without correction for multiple-hypothesis testing. We considered an adjusted p-
value <0.1 to be significant unless otherwise stated (false discovery rate<10%). 
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Only isoforms represented in at least five disease and control samples were 
considered.  
 
PAS-seq analysis: isoform weighted change 
We weighed each isoform ratio by the isoform number multiplied by ten. For 
instance, for a gene transcribed into two isoforms of equal abundance (isoform 
ratios of 0.5), the shorter isoform weighted ratio is 5 (0.5 x 10 x 1) whereas the 
longer isoform weighted ratio is 10 (0.5 x 10 x 2). We then calculated the 
difference in the average weighted isoform ratios between HD and control 
samples for the gene. A positive value indicates a shift towards longer isoforms 
in HD samples, whereas a negative value indicates a shift towards shorter 
isoforms in HD samples. 
 
PAS-seq analysis: HD versus control gene expression comparison 
The total reads mapping to each gene were compared between patients and 
controls using DESeq2 (Love et al., 2014a). We considered genes with a change 
greater than 50% and false discovery rate <10% significantly differently 
expressed.  
 
Gene ontology analysis 
The list of genes with significant changes in total expression (false discovery 
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rate<10%) or 3′UTR isoform expression (p<0.01) in HD motor cortex or 
cerebellum were compared to the background total or alternatively 
polyadenylated expressed genes in each region using Panther gene ontology 
analysis (Mi et al., 2013). We considered categories enriched if they had five or 
more genes, enrichment greater than 1.5 fold, and p<0.01.  
 
CNOT6 siRNA transfection 
Wild-type fibroblasts were transfected with three siRNAs targeting CNOT6 
(Qiagen FlexiTube) via Lipofectamine RNAimax (Invitrogen). After 72 hours, RNA 
was extracted and submitted to qRT-PCR as above.  
 
 
Discussion 
 
Widespread changes in isoform abundance may lead to aberrant mRNA 
metabolism in HD. Some tandem 3′UTR isoforms exhibit unique localization and 
function. The long but not short 3′UTR isoform of brain-derived neurotrophic 
factor mRNA is translated in dendrites, where the protein is vital for pruning and 
spine enlargement (An et al., 2008). The long isoform of CD47 mRNA acts as a 
scaffold for proteins that translocate the CD47 protein to the cell membrane, 
whereas the short isoform localizes the protein to the endoplasmic reticulum 
(Berkovits and Mayr, 2015). Loss of normal mRNA isoform abundance can 
contribute to disease. The alpha synuclein long 3′UTR isoform is preferentially 
localized to mitochondria; increased abundance of the extended alpha synuclein 
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mRNA may contribute to mitochondrial dysfunction in Parkinson’s disease (Rhinn 
et al., 2012). Many genes in cancer cells shift towards more stable short 
isoforms, increasing translation of tumorigenic proteins (Mayr and Bartel, 2009). 
In myotonic dystrophy, triplet repleat RNAs sequester muscleblind, a regulator of 
3′UTR length, resulting in an altered polyadenylation profile (Batra et al., 2014). 
We demonstrate that genes with isoform changes in HD motor cortex are 
associated with pathways disrupted in HD including calcium signaling, cytokine 
signaling, histone acetylation, transcription factor binding, axonal transport, 
synaptic vesicle localization, dendritic spine morphogenesis, microtubule 
organizing, and phagocytic vesicles. Altered metabolism of mRNAs in disease 
pathways could result in aberrant localization or function of proteins and 
contribute to HD pathogenesis. 
 
Our results point to a model in which changes in the expression of RNA binding 
proteins in the HD brain lead to changes in the expression of mRNA 3′UTR 
isoforms. RNA binding proteins may interact with nascent mRNA during 
transcription and alternative polyadenylation, leading to changes in polyA site 
selection and isoform production. For instance, aberrant expression of 3′ end 
modulatory factors known to correlate to polyA site selection may lead to isoform 
abundance changes (Gruber et al., 2014). We found three 3′ end processing 
factors are differentially expressed in HD grade 1 motor cortex: CPSF2, PCBP2, 
and THOC5. In addition to interacting with transcripts during alternative 
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polyadenylation, RNA binding proteins may adhere to isoforms post-
transcriptionally, affecting the stability and decay of isoforms and leading to 
changes in isoform abundance. We show a decrease in the CNOT6 deadenylase 
is associated with a decrease in the HTT long isoform, suggesting CNOT6 
stabilizes the long isoform or regulates its metabolism via some other 
mechanism.  
 
Further studies are necessary to determine the mechanism of 3′UTR isoform 
changes in HD. We found HTT and SECISBP2L isoform amounts are responsive 
to changes in CNOT6 mRNA levels. However, altered CNOT6 expression in HD 
cannot explain all isoform changes we identified: isoform differences are largely 
limited to the motor cortex, whereas CNOT6 is down-regulated in motor cortex 
and up-regulated in cerebellum. Other RNA binding proteins, such as 3′ end 
processing factors, likely affect isoform abundance in HD. Exploration of the 
causes of isoform changes in HD motor cortex may result in novel therapeutic 
targets. 
 
Our findings have important implications for HD and may apply to other diseases. 
New therapies aim to disrupt the mutant but not wild-type HTT mRNA by 
targeting SNPs heterozygous in patients (Østergaard et al., 2013; Pfister et al., 
2009). Our results suggest therapies targeting SNPs exclusive to the long 
isoform may be less effective, as HTT long isoform abundance is reduced in 
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Huntington’s patient motor cortex. A study published during preparation of this 
manuscript found transfected HTT exon 1-3′UTR constructs are localized 
differently depending on the 3′UTR length, and the short 3′UTR construct forms 
more aggregates (Xu et al., 2017). The short isoform, which increases its relative 
abundance in HD motor cortex, may be the ideal target for allele-specific 
therapies. Further research exploring 3′UTR isoform changes in other diseases is 
necessary to determine if isoform alterations are unique to HD, or if they 
frequently accompany gene expression changes in human disease.  
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